


















aim!is!to!record!in!more!detail!than!is!possible!in!the!main!text!how!the!call!sets!were!generated!and!analyzed.!!!The! 1000! Genomes! Phase! 1! release! is! the! result! of! a! large! number! of! people!working! in! collaboration.! Where! possible,! we! have! identified! individuals!associated!with!each!section!of!the!supplement!in!order!to!provide!the!reader!a!means!of!identifying!individuals!contributing!to!each!area!of!the!project.!
2 Materials+
2.1 Criteria+for+choosing+populations+included+in+the+project+!
Authors:$Aravinda$Chakravarti,$Bartha$Knoppers,$Lisa$Brooks,$and$Jean$McEwen$!The!choices!of! the!specific!populations! to! include! in! the!project!were! informed!by!recommendations!made!by! the!project’s!Samples!and!ELSI!Group,!and!were!based! on! a! mix! of! scientific,! ethical,! and! practical! considerations.! ! The! most!important! scientific! rationale! was! to! expand! the! sampling! of! humans! so! that!within!each!continent!we!had!multiple!yet!distinct!populations.!!The!underlying!objectives! were! to! obtain! genetic! variation! data! that! would! be! broadly!representative! for!the!vast!majority!of! individuals!within!a!continent!(although!we! did! not! attempt! to! cover!most! of! the! diversity! in! Africa,! since! there! is! too!much! for! the! sample! sizes! that! could! be! done! for! this! project).! ! We! are! well!aware! that! this! is! a! great! challenge! since! the! continents! differ! greatly! in! the!amount!and!patterns!of!their!internal!genetic!diversity!!The!criteria!for!inclusion!were:!!
Broad&consent:!!The!participants!had!to!have!provided!consent!for!broad!use!of!the!samples!and!data,!and! for!broad!data! release! in!databases!available!on! the!Internet.!!!!
No&names&or&other&traditional&individual&identifiers:!!To!protect!the!privacy!of!the!research!participants,!no!names!or!other!traditional!individual!identifiers!were!collected.!!For!a!few!of!the!populations,!where!recruitment!was!carried!out!in! conjunction!with! an!ongoing! genetic! study,! names! that! had!previously! been!collected!were!retained!by!the!original!investigators!in!strict!confidence!but!have!not!been!shared!with!this!project.!!
No& phenotype& data:! ! To! protect! the! privacy! of! the! research! participants,! the!project!preferred!that!no!phenotype!or!clinical!data!be!collected.!!For!a!few!of!the!populations,!where!recruitment!was!carried!out!in!conjunction!with!an!ongoing!genetic!study,!such!data!had!previously!been!collected!and!are!available!only!to!the!sample!collectors!and!their!authorized!collaborators,!and!not!to!the!project.!!!!




samples,!to!have!the!cell!lines!stored!in!a!public!repository,!and!to!have!the!cell!lines!and!DNA!from!the!cell!lines!distributed!to!a!broad!range!of!researchers!for!use! in! a! wide! range! of! genetic! and! genomic! studies,! including! studies! of!molecular!phenotypes!such!as!gene!expression!and!response!to!drugs.!!
Trios:! ! The! project!wanted! to! include! samples! from!motherOfatherOadult! child!trios!wherever!possible!since!even!a!few!trios!for!a!population!helps!in!assessing!the! quality! of! the! data,! confirming! rare! variants,! and! inferring! haplotypes.!!However,! at! many! of! the! collection! sites! it! was! impossible! to! obtain! samples!from! all! three! members! of! trios! within! the! project! timeline.! ! For! these!populations,!the!samples!include!a!mix!of!trios,!parentOchild!duos,!and!unrelated!individuals.!!!!
Genomic&data&already&available:!!The!project!wanted!to!include!some!samples!on!which!considerable!data!were!already!available,!such!as!the!HapMap!Project!samples.! ! This! allows! comparisons!with! other! sets! of! genotype,! sequence,! and!array! data! on! these! samples,! for! validation! of! the! project! data! and! efficacy! of!quality!control!procedures.!!
GWAS& studies:! ! Where! possible,! the! project! sought! to! include! samples! from!populations!in!which!GWAS!studies!were!already!being!conducted.!!Sampling!in!most! cases!was! conducted! in! collaboration!with! a! research! center! or! hospital,!where!a!relationship!of!trust!with!the!community!had!already!been!established.!!This!minimized!the!risks!of!misunderstanding!of!the!research!and!increased!the!likelihood! that! the! data!will! eventually! provide! some! scientific! benefit! for! the!studied!populations!through!the!GWAS!studies.!!









• Utah! residents!with! ancestry! from!Northern! and!Western!European,!US!(CEU)!
• Toscani!in!Italia!(TSI)!





• Puerto!Ricans!in!Puerto!Rico!(PUR)!!!More! detail! about! each! population! can! be! found! on! the!website! of! the! NHGRI!Sample! Repository! for! Human! Genetic! Research! at! the! Coriell! Institute1.! This!includes!information!about!how!each!population!was!defined!for!the!project,!the!rationale! for! the! shorthand! label! chosen! for! each! population,! and! other!important!background! information!relating! to!each!population!and! the!specific!sampling!strategy!used!for!that!population.!!!!!The!way! that!a!population! is!named! in! studies!of!genetic!variation!such!as! the!1000!Genomes!Project!has!important!ramifications!scientifically,!culturally,!and!ethically.! ! It! is! thus! important! to! use! care! in! labeling! the! populations! when!publishing!or!presenting!the!findings!of!studies!that!use!project!data.!!Guidelines!on!how!to!refer!to!the!populations!can!be!found!online2.!!!Samples! from! additional! populations! will! be! included! in! later! phases! of! the!project.!!!!
2.2 Sample+collection+and+distribution+!




anticipated! to!arise! in! the! community!and!how! they!would!be!addressed.! !The!research! groups! obtained! all! required! IRB! and! ethics! approvals! from! their!institutions! and! collaborating! institutions,! as! well! as! government! approvals!where!required.!!Few!major!issues!arose!during!the!course!of!sampling!that!the!Samples!and!ELSI!Group!was!asked!to!address,!but!the!group!remained!available!throughout!the!course!of!the!sampling!to!consult!on!any!matters!that!did!arise.!!!!The! samples! are! stored! at! the! NHGRI! Sample! Repository! for! Human! Genetic!Research!at!the!nonOprofit!Coriell!Institute!for!Medical!Research!in!Camden,!New!Jersey! (Coriell).! !When!Coriell! receives!orders! from!researchers! for! samples,! it!screens! the! statements! of! intended! research! use.! ! Coriell! provides! regular!reports!to!each!community!where!sampling!occurred!on!the!use!of!the!samples!from!that!community,!and!has!funds!available!to!support!educational!or!outreach!activities! related! to! biomedical! research! in! the! communities.! ! Coriell! provides!each! research! group! that! collected! samples! in! a! community!with! a! free! set! of!DNA!or!cell! lines! from!those!samples.! !Coriell! charges!researchers! in! resourceOlimited!countries!a!much!reduced!rate!for!sample!DNA.!!!
2.3 Lymphoblastoid+cell+line+establishment+!




the! submitting! group.! ! A! portion! of! each! frozen! culture! stock! is! reserved! for!replenishment!of!cell!culture!stocks!and!DNA.!!Therefore,! for! as! long! as! possible,! replenishment! of! distribution! stocks! of! cell!cultures! and! DNA! goes! back! to! the! original! frozen! cell! culture! stock.! ! If! the!original! cell! culture! stock! is! ultimately! depleted,! the! reserved! amps! of! an!expansion!of! that!original!stock!will!become!the!new!reserve!stock!and!will!be!approximately!5!to!7!population!doublings!beyond!the!original!culture!stock.!!!
3 Data+generation+and+processing+
3.1 Reuse+of+data+from+Pilot+phase+!
Authors:$Laura$Clarke,$Xiangqun$ZhengKBradley,$and$Richard$E.$Smith$!The! pilot! phase! of! the! 1000! Genomes! Project6! consisted! of! three! separate!projects:!!low!coverage!whole!genome!sequencing!of!unrelated!individuals;!deep!coverage! whole! genome! sequencing! of! two! family! trios;! and! exon! targeted!sequencing! for! a! subset! of! approximately! 1000! genes.! ! Phase! 1! of! the! 1000!Genomes! Project! continued! with! the! low! coverage! sequencing! strategy! of! the!Pilot! phase! of! the! project,! and! also! conducted!whole! exome! sequencing! on! all!samples.!Trio!and!exon!targeted!sequence!data!from!the!Pilot!was!not!included!in!Phase!1.!However,! the! low! coverage!Pilot! data!has!been! included! as!part! of!Phase!1.!!For!Phase!1,!we!performed!Quality!Control!(QC)!and!filtering!of!the!input!FASTA!files!available!in!the!Short!Read!Archive!(SRA)7.!This!QC!and!filtering!consists!of!a! series! of! syntax! and! sequence! checks! to! ensure! the! data! meets! minimum!formatting!and!quality!criteria.!!The!Pilot!phase!contained!early!data!from!the!Illumina,!454!and!SOLiD!platforms.!Much!of!the!early!SOLID!data!consisted!of!25!bp!reads!that!showed!substantial!reference! bias.! The! Project! decided! to! remove! this! data,! rather! than! attempt!adjustment!of!analysis!methods!to!correct!for!this!bias.!
3.2 Low+coverage+sequencing+
3.2.1 Broad+Institute+!




For!a!subset!of!samples,!starting!with!3µg!of!genomic!DNA,!library!construction!was! performed! as! described! by! Fisher! et$ al9.! Another! subset! of! samples,!however,! was! prepared! using! the! Fisher! et$ al.! protocol! with! some! slight!modifications.!Initial!genomic!DNA!input!into!shearing!was!reduced!from!3µg!to!100ng!in!50µL!of!solution.!In!addition,!for!adapter!ligation,!Illumina!paired!end!adapters!were! replaced!with! palindromic! forked! adapters! containing! unique!8!base!index!sequences!embedded!within!the!adapter.!!For!a!subset!of!samples,!size!selection!was!performed!using!gel!electrophoresis,!with! a! target! insert! size! of! either! 340bp! or! 370bp! +/O! 10%.!Multiple! gel! cuts!were! used! for! libraries! that! required! high! sequencing! coverage.! For! another!subset!of!samples,!size!selection!was!performed!using!Sage’s!Pippin!Prep.!!Following!sample!preparation,! libraries!were!quantified!using!quantitative!PCR!(kit! purchased! from!KAPA!biosystems)!with! probes! specific! to! the! ends! of! the!adapters.! This! assay! was! automated! using! Agilent’s! Bravo! liquid! handling!platform.!Based!on!qPCR!quantification,! libraries!were!normalized! to!2nM!and!then! denatured! using! 0.1! N! NaOH! using! PerkinOElmer’s! MultiProbe! liquid!handling! platform.! The! subset! of! the! samples! prepared! using! forked,! indexed!adapters! was! quantified! using! qPCR,! normalized! to! 2nM! using! PerkinOElmer’s!MiniOJanus! liquid! handling! platform,! and! pooled! by! equal! volume! using! the!Agilent!Bravo.!Pools!were!then!denatured!using!0.1!N!NaOH.!Denatured!samples!were!diluted!into!strip!tubes!using!the!PerkinOElmer!MultiProbe.!!Cluster! amplification! of! denatured! templates! was! performed! according! to! the!manufacturer’s! protocol! (Illumina)! using! either! Genome! Analyzer! v3,! Genome!Analyzer!v4,!HiSeq!2000!v2,!or!HiSeq!v3!cluster!chemistry!and! flowcells.!For!a!subset!of!samples,!after!cluster!amplification,!SYBR!Green!dye!was!added!to!all!flowcell!lanes,!and!a!portion!of!each!lane!visualized!using!a!light!microscope,!in!order! to! confirm! target! cluster! density.! Flowcells! were! sequenced! either! on!Genome!Analyzer!IIX!using!v3!or!v4!SequencingObyOSynthesis!Kits,!then!analyzed!using!RTA!v1.7.48;!or!on!HiSeq!2000!using!HiSeq!2000!v2!or!v3!SequencingObyOSynthesis!Kits,! then! analyzed!using!RTA!v1.10.15!or!RTA!v.1.12.4.2.! For!whole!genome! sequencing,! 101!bp!pairedOend! reads!were!used.! ! For! pooled! libraries!prepared! using! forked,! indexed! adapters,! Illumina’s! Multiplexing! Sequencing!Primer!Kit!was!used,!and!a!third,!8!base!sequencing!read!was!performed!to!read!molecular!indices.!
3.2.2 Baylor+College+of+Medicine+–+Human+Genome+Sequencing+Center+!
Author:$Donna$Muzny$!




fragments.!!The!fragmented!DNA!was!repaired!using!the!EndOIt!DNA!End!Repair!Kit!(Epicentre)!followed!by!ligation!of!the!LMP!CAP!adaptor.!Size!selection!of!the!ligation!product!was!then!performed!using!1.0%!agarose!gel!electrophoresis!for!resolution! and! 1O2! kb! DNA! fragments! were! excised! from! the! gel! and! purified!using!QIAquick!Gel!Extraction!Kit!(Qiagen).!The!DNA!circularization!reaction!was!catalyzed! using! the! Quick! Ligation! kit! (New! England! Biolabs)! with! SOLiD!biotinylated! Internal! Adaptors! (approximately! 10O15! pmoles,! based! on! the!quantity!of!the!sizeOselected!DNA).!!Following!circularization,!DNA!PlasmidOSafe!ATPODependent!DNase! (Epicentre)!was! used! to! eliminate! unOcircularized!DNA,!resulting! in! 500!ng! –! 1! ug! of! circularized!DNA!product! after! purification.! ! The!circularized! DNA! was! then! nick! translated! using! DNA! Polymerase! I! (New!England! Biolabs)! at! 50O100! units/reaction,! depending! on! the! quantity! of! the!circularized! product.! ! Following! nick! translation! and! purification,! the! DNA!fragments!were!sequentially!digested!with!10O20!units!of!T7!exonuclease!(New!England!Biolabs)! and!S1!nuclease! (Invitrogen).!The!digested!DNA!product!was!endOrepaired!using! the!Epicenter!EndOIt!DNA!End!Repair!Kit!and!was!bound! to!the!Dyna!MyOne!C1!Streptavidin!beads! (Invitrogen)! through! the!biotinOlabeled!internal! adaptor.! P1! and! P2! adaptors! were! ligated! as! specified! by! the! LMP!protocol! to! the! library! fragments,! and! the! ligated! product! was! PCR! amplified!using! SOLiD! Library! PCR! Master! Mix! with! minimum! cycling! (5O7! cycles)! to!maintain!library!complexity.! !The!library!was!size!selected!on!a!4%!agarose!gel!to!obtain!250O350!bp!fragments.! !Final!QC!of!the!library!was!performed!using!a!Picogreen!assay!(Invitrogen)!and!Agilent!Bioanalyzer!2100!trace!with!DNA!7500!Chip.!!






&Base!and!quality!calling!for!the!SOLiD!data!was!performed!onOinstrument!using!standard! vendor! software! and! settings.! ! Upon! completion! of! a! run,! read! and!quality!data!were!copied!into!our!dataOcenter!where!individual!sequence!events!were! split! into! 10M! read! bundles! to! undergo! preliminary! quality! control!mapping! using! BFAST.! ! After! read! group! bundles! were! mapped,! their! results!were!merged!back!into!a!single!sequenceOeventOlevel!BAM,!and!where!necessary,!these!BAMs!were!merged! into! a! sampleOlevel!BAM!using!Picard,! and!duplicate!reads!were!marked!at!the! library! level!using!SAMtools.! !Alignment!metrics!and!uniqueness! were! evaluated! to! confirm! that! the! sequencing! performed! as!expected! and! to! verify! that! each! sample! met! a! minimum! of! 6X! sequencing!coverage.! ! In! addition,! sample! concordance! analysis! was! also! performed! by!comparing! SNP! array! genotypes! to! the! sequencing! data! to! confirm! sample!identity!and!evaluate!contamination.!
3.2.3 BGI+!












sequencing! reads!were! aligned! to! the!human!genome! (hg18,!NCBI! build! 36.1).!The!identity!of!each!sample!was!confirmed!using!HapMap!genotypes.!
3.2.5 Washington+University+!
Author:$Elaine$Mardis$!Genomic! DNA! was! obtained! from! the! Coriell! Institute! for! Medical! Research.!Illumina! libraries! were! constructed! according! to! the! manufacturer's! (Illumina!Inc,!San!Diego,!CA),!recommendations!with!the!following!exceptions:!!1)!500!ng!of!DNA!was!sheared!using!a!Covaris!S220!DNA!Sonicator!(Covaris,!INC.!Woburn,!MA)!to!a!size!range!between!200O500!bp.!!2)!PCR!optimization!was!performed!to!determine! the! optimal! cycle! number! to! prevent! overOamplification,! thus!decreasing!duplication!rates.!!3)!Eight!PCR!reactions!were!amplified!to!enrich!for!proper!adaptor! ligated! fragments.!4)!The! final! size! selection!of! the! library!was!achieved! by! electrophoresis! of! the! enriched! library! on! a! 4O10%!PAGE! gel,! and!isolating!50!to!100!bp!fractions!within!a!window!size!of!350O400!bp,!300O400!bp!or!450O500!bp.! !The!fractions!collected!include!the!Illumina!adaptor!sequences.!!qPCR!was!used!to!determine! library!concentrations.! !Libraries!were!sequenced!on! the! Illumina! GAIIx!with! a! target! of! greater! than! 4X! coverage! of! the! human!genome.! ! Four! lanes!of!2!X!101!bp! read!pairs!were!generated! for! each! sample!with!a!minimum!of!12!Gb!per!sample!as!a!minimum!passing!criterion.!!!
3.2.6 Sanger+Institute+!
Authors:$Thomas$Keane$and$Jim$Stalker$!Genomic! DNA! was! obtained! from! the! Coriell! Institute! for! Medical! Research.!Three!different!types!of!libraries!were!produced:!standard,!highOcomplexity,!and!noPCR.! For! all! libraries! we! began! with! 5! µg! of! genomic! DNA.! The! standard!libraries! were! constructed! according! to! the! manufacturer's! recommendations!(Illumina! Inc,! San!Diego,! CA).! Each! sample!was! fragmented! using! a! disposable!nebulizer!(Invitrogen)!and!purified!using!a!qiaquick!column!(Qiagen).!DNA!was!endOrepaired! and! adaptors! ligated! to! the! ends! of! the! DNA.! Fragments! of!approximately! 300O400! bp!were! gelOpurified! and! PCR! amplified.! For! details! of!the! highOcomplexity! and! noPCR! library! preparation! adaptations,! see! Quail! et$
al.10.!Flow!cells!were!prepared,!clusters!generated,!and!processed!flowcells!were!pairedOend!sequenced!from!each!end!on!either!an!Illumina!Genome!Analyzer!II!(108! bp)! or! HiSeq! 2000! (100! bp).! For! each! lane,! reads! were! aligned! to!hg19/NCBI37!and!HapMap!genotype!validation!was!performed.!
3.2.7 Illumina+!




prepare! pairedOend! sequencing! libraries! with! average! insert! size! of! 303! bp!human!insert!and!a!6%!1xSD.!Libraries!were!denatured!using!NaOH!(0.1!N)!and!diluted!in!cold!(4!°C)!hybridisation!buffer!(5x!SSC!+!0.05!%!Tween!20)!prior!to!seeding! clusters! on! the! surface! of! the! flow! cell.! Cluster! amplification,!linearization,!blocking!and!hybridisation!to!the!Read!1!sequencing!primer!were!carried!out!on!a!Cluster!Station.!Following! the! first! sequencing! read,! flow!cells!were! held! in$ situ! and! clusters! were! prepared! for! Read2! sequencing! using! the!Illumina! PairedOEnd! Module.! PairedOend! sequence! reads! of! 101! bases! were!generated!using!the!Genome!Analyzer!IIX!with!v5!SBS!reagent!kits,!as!described!in!the!Illumina!Genome!Analyzer!operating!manual.!Data!were!processed!using!Real!Time!Analysis!(RTA)!v1.6.47.1.!!We!generated!an!average!of!17Gb!PF!(pass!filter)!data!for!each!sample.!!A!total!of!93%!of!PF!reads!had!a!raw!read!accuracy!of!≥Q30.!
3.3 Whole+exome+sequencing+
3.3.1 Description+of+Exome+consensus+!







DNA!samples!(5ug)!were!constructed!into!SOLiD!precature!libraries!according!to!a! modified! version! of! the! manufacturer’s! protocol! (Applied! Biosystems,! Inc.).!!Briefly,!the!genomic!DNA!was!sheared!into!fragments!of!approximately!120!base!pairs! with! the! Covaris! S2! or! E210! system! as! per! manufacturer! instruction!(Covaris,! Inc.! Woburn,! MA).! ! Fragments! were! processed! through! DNA! EndORepair! (NEBNext!EndORepair!Module;!Cat.!No.!E6050L)!and!AOtailing!(NEBNext!dAOTailing!Module;!Cat.!No.!E6053L).!!The!resulting!fragments!were!ligated!with!BCMOHGSCOdesigned!TruncatedOTA!(TrTA)!P1!and!TAOP2!adapters!with!the!NEB!Quick! Ligation! Kit! (Cat.! No.! M2200L).! ! Solid! Phase! Reversible! Immobilization!(SPRI)! bead! cleanup! (Beckman! Coulter! Genomics,! Inc.;! Cat.! No.! A29152)! was!used!to!purify!the!adapted!fragments,!after!which!nick!translation!and!LigationOMediated! PCR! (LMOPCR)! was! performed! using! Platinum! PCR! Supermix! HIFi!(Invitrogen;! Cat.! No.12532O016)! and! 6! cycles! of! amplification.! After! bead!purification,! PCR! products’! quantification! and! their! size! distribution! were!analyzed!using!the!Agilent!Bioanalyzer!2100!DNA!Chip!7500.!!Primer!sequences!and!a!complete!library!construction!protocol!are!available!on!the!Baylor!Human!Genome!Website13.!
&
SOLiD&Exome&Capture&&The! preOcapture! libraries! (2! ug)!were! hybridized! in! solution! to!NimbleGen! EZ!Exome! 2.0! Solution! Probes! (~44! Mb! of! sequence! targets! from! ~30K! genes)!according! to! the! manufacturer’s! protocol! with! minor! revisions.! ! Specifically,!hybridization!enhancing!oligos!TrTAOA!and!SOLiDOB!replaced!oligos!PEOHE1!and!PEOHE2! and! postOcapture! LMOPCR! was! performed! using! 12! cycles.! ! Capture!libraries! were! quantified! using! PicoGreen! (Cat.! No.! P7589)! and! their! size!distribution!analyzed!using! the!Agilent!Bioanalyzer!2100!DNA!Chip!7500.! !The!efficiency! of! the! capture! was! evaluated! by! performing! a! qPCRObased! quality!check! on! the! builtOin! controls! (qPCR! SYBR! Green! assays,! Applied!Biosystems).!!Four!standardized!oligo!sets,!RUNX2,!PRKG1,!SMG1,!and!NLK,!were!employed!as! internal!quality!controls.! !The!enrichment!of! the!capture! libraries!was!estimated!to!range!from!7!to!9!fold!over!the!background.!!Primer!sequences!and! a! complete! capture! protocol! are! available! on! the! Baylor! Human! Genome!Website13.!!




centrifuge! tubes! and! then! enriched! and! 3’! modified! according! to! the! Life!Technologies!MacroOScale!8!ePCR!reaction!protocol.!!!!The! 3’! modified! template! positive! beads! were! deposited! onto! XD! sequencing!slides,! targeting!approximately!300!K!beads/panel! and! sequenced!using!SOLiD!V4! ToP! reagents.! Both! barcode! fragment! and! paired! end! sequencing!methods!were! used! in! this! project.! For! barcoded! methods,! capture! libraries! were!individually! captured! and! then! pooled! in! sets! of! 4! samples! after! postOcapture!amplification.!The!4! sample!barcode! library!pools!were! sequenced!with! SOLiD!Barcode!Fragment!Sequencing!Kits!(Life!Technologies,!4452697).!!Here!the!first!5! bp! barcode! read! is! utilized! to! deOconvolute! the! individual! capture! libraries!followed!by!a!50!bp!forward!read.!!Individual!capture!libraries!were!sequenced!with!SOLiD!Paired!End!Sequencing!Kits!(Life!Technologies,!4459179)!using!a!35!bp!reverse!read! followed!by!a!50!bp! forward!read.!Base!and!quality!calling! for!the! SOLiD! data!was! performed! onOinstrument! using! standard! vendor! software!and!settings.!!!
3.3.3 Broad+Institute+!
Author:$Namrata$Gupta$!Whole! exome! library! preparation! was! conducted! using! the! same! procedure!described!in!the!Low!Coverage!sequencing!section.!In!place!of!size!selection,!inOsolution! hybrid! selection! was! performed! as! described! by! Fisher! et$ al9.!Sequencing! procedures! were! the! same! as! described! for! the! Low! Coverage!sequencing!methods,!with!the!exception!that!76!bp!pairedOend!reads!were!used.!!
3.3.4 Washington+University+!






!DNA! samples! were! sent! to! the! Broad! Institute! Genetic! Analysis! Platform!for!genotyping.! Initially! all! samples! were! typed! using!a! Sequenom! MassArray!SNP!Genotyping!panel!of!23!SNPs!and!one!gender!determining!assay!to!establish!a! genetic! fingerprint.! !After! gender! concordance! was! verified! the! samples! are!then! placed! on! 96Owell! plates! using! the! Illumina! HumanOmni2.5OQuad! v1O0!B!SNP!array.!Omni!genotypes!were!called!using!GenomeStudio!v2010.3!with!the!calling!algorithm/genotyping!module!version!1.8.4!using!the!default!cluster! file!HumanOmni2.5O4v1OMulti_B.egt.!!Called!genotypes!were!run!through!a!standard!QC!pipeline!and!only!samples!passing!a!call! rate! threshold!of!97%!and!passing!genetic! fingerprint! and! gender! concordance! were! passed.! The! Broad! Institute!did! not! filter! any! SNPs! based! on! of! technical! quality! control! metrics.! Only!samples!passing!an!overall!call!rate!of!97%!criteria!and!standard!identity!check!were!released.!!
3.5 Lane+level+identity+checks+!
Authors:$ Laura$ Clarke,$ Xiangqun$ ZhengKBradley,$ Richard$ E.$ Smith,$ and$ Petr$
Danecek$!Each! run!was! subsampled! (typically! 250O500Mb)! and! aligned! to! the! reference!genome.! GLFtools14! checkGenotype! was! then! used! to! calculate! genotype!likelihoods!for!all!the!sites!and!these!are!compared!to!the!known!genotypes!of!all!the! samples.! A! total! log! likelihood! for! each! possible! sample! is! calculated! and!scaled!according!to!the!number!of!sites!available! for!each!possible!sample.!The!ratio!of!the!second!most!likely!sample!to!the!most!likely!sample!is!calculated!and!provided! it! is! greater! than!1.2! then! the!most! likely! sample! is! considered! to!be!correct.!If!the!most!likely!sample!does!not!match!expectations,!or!the!ratio!is!less!than!1.2,!then!the!lane!was!withdrawn!from!further!analysis!and!the!production!center!responsible!informed!for!further!investigation.!Many!sample!swaps!could!be! resolved!using! this!process,!with! the! lane! reassigned!and! reintroduced! into!the!analysis!process.!
3.6 PostKalignment+identity+and+contamination+checks+!
Authors:$Laura$Clarke,$Xiangqun$ZhengKBradley,$Richard$E.$Smith,$and$Hyun$Min$















Low!coverage!Illumina!data!was!aligned!to!the!reference!using!bwa!v0.5.517.!First!indexing!the!genome!reference!sequence!was!indexed!using!the!command!“bwa!index!Oa!bwtsw”.!To!align,!the!command!“bwa!aln!Oq!15”!was!used!to!find!suffix!array! coordinates! of! good! hits! for! each! individual! read.! A! chromosomal!coordinate!sorted!BAM!file!was!then!generated!using!the!bwa!sampe!option!for!pairedOend!reads!or!the!bwa!samse!option!for!unpaired!reads.!!Low!coverage!LS454!data!was!aligned!to!the!reference!using!ssaha!v2.518!by!first!precomputing!the!hash!index!using!the!command!“ssaha2Build!Oskip!3!Osave!$ref!
$ref”,!where!$ref! is!the!reference!fasta!file.!Reads!were!filtered!to!remove!those!shorter!than!30!bp,!then!mapped!independently!using!“ssaha2!Odisk!O454!Ooutput!cigar!Odiff!10!Osave!$ref”.!The!top!10!hits!for!each!read!were!recorded.!The!cigar!output!was!then!converted!to!BAM!format,!taking!into!account!whether!the!reads!were!paired!and!the!expected! library! insert!size.!For!paired!reads,! if!both!ends!aligned! uniquely,! then! the! reads! were! assigned! to! these! positions.! If! one! end!mapped!uniquely!and!the!other!end!had!multiple!hits,!then!the!multiple!hit!read!was! placed! at! the! position! closest! to! the! expected! insert! size.! If! both! ends!mapped!with!multiple!hits,!then!the!reads!were!placed!at!the!location!closest!to!the!expected!insert!size!and!the!mapping!quality!set!to!zero.!!The! laneOlevel! alignment! BAMs!were! further! processed! to! increase! the! quality!and!speed!of!subsequent!SNP!calling!using!tools!from!GATK19,20!and!samtools21.!Reads! underwent! local! realignment! around! known! indels! from! the! 1000!Genomes! Pilot6! using! the! GATK! IndelRealigner! command.! Next,! mate!information! in! the! resulting! BAMs! was! fixed! and! coordinate! sorted! using! the!Picard! package! FixMateInformation! command8.! Read! qualities! were! then!recalibrated! using! the! GATK! TableRecalibration! package,! masking! SNPs! from!dbSNP! release! 129.! Finally,! the! command! “samtools! calmd! –r”! was! used! to!introduce!BQ!tags22!which!could!be!used!during!SNP!calling.!!The!processed!BAMs!were!merged!to!create!the!release!BAM!files!available! for!download.!This!process!began!by!removing!extraneous!tags!(OQ,!XM,!XG,!and!XO)!to!reduce!total!file!size!by!around!30%.!Next,! lanes!from!the!same!library!were!merged! using! the! Picard! MergeSamFiles! command,! with! PCR! duplicates!subsequently! marked! in! these! libraryOlevel! BAMs! (Picard! MarkDuplicates).!LibraryOlevel!BAMs!were!merged!(Picard!MergeSamFiles)! to! the!platform!level,!to! produce! a! single! BAM! file! for! each! of! the! sequencing! platforms! used! to!sequence! each! sample.! Finally,! the! platform! level! BAMs! were! split! into! two!separate!BAM!files!O!one!containing!all!reads!that!mapped!to!the!reference!and!one!containing!reads!which!did!not!map.!
4.2 Low+coverage+SOLiD+read+mapping+!




using! BFAST23! version! 0.64e! with! the! following! settings:! maxKeyMatches=8,!maxNumMatches=384,! queueLength=25000,! local! align! offset=20,!minMappingQuality=10,! minNormalizedScore=36,! and! algorithm=3.! ! SRR/ERR!level! outputs!were! realigned!with! GATK’s! indel! realigner! tool! (V:1.0.04418)20,!followed! by! FixMateInformation! within! Picard8.! Following! realignment,! lane!level! BAM! files! were! recalibrated! with! GATK! (V:1.0.4705).! After! recalibration!BAM!files!had!certain!fields!removed!to!only!include!RG,!X1,!NM,!XT,!MD,!CS,!CQ!in!order!to!reduce!file!size.!These!BAMs!were!then!ready!to!be!merged!to!sample!level.!After!merging!they!went!through!Picard’s!mark!duplicates!tool.! !All!BAMs!were!split!by!chromosome.!Finally!BAI,!BAS,!and!md5sum!files!were!generated!for!each!BAM!before!they!were!transferred!back!to!DCC.!
4.3 Exome+Illumina+read+mapping+!















*$Corresponding$Author$!Low! coverage! SNP! calling! was! performed! on! the! project! official! lowOcoverage!BAM!files.!Exome!SNP!calling!was!carried!out!using!Illumina!data!only!on!BAM!files!produced! locally!at! the!Broad! Institute!using!an!equivalent!pipeline! to! the!official! low!coverage!BAMs.!These!BAMs!are!available! in!a!separate! location!on!the!project!FTP!site26.!!The!Broad!Institute!produced!a!SNP!callset!for!both!the!low!coverage!and!exome!samples!using!the!GATK’s!Unified!Genotyper.!This!multipleOsample,!technologyOaware! SNP! and! indel! caller! uses! a! Bayesian! genotype! likelihood! model! to!estimate! simultaneously! the! most! likely! genotypes! and! allele! frequency! in! a!population! of! N! samples,! emitting! an! accurate! posterior! probability! of! there!being!a!segregating!variant!allele!at!each!locus!as!well!as!for!the!genotype!of!each!sample.!Mathematical!details!are!given!in!DePristo!et$al19.!





• QualByDepth.! The! variant! quality! score! (the! confidence! assigned! by! the!unified!genotyper!in! the! site!being! a! variant! site)!divided!by! the!number!of!reads! in! the! pileup.! This! statistic! captures! the! intuition! that! as! sequencing!depth! increases! the!confidence! in! the!site!should!also! increase! if! it! is!a!real!variant.!
• DepthOfCoverage.!The!number!of!passing!reads!which!cover!this!site.!
• HaplotypeScore.!A!measure! for!how!well! the!data! from!a!10!base!window!around! the!SNP!can! be! explained! by! at! most! two!haplotypes.! In! the! case!of!mismapped!reads,!the!pattern!of!mismatches!around!the!SNP!would!seem!to!imply!many!more!than!two!haplotypes!and!is!indicative!of!error.!!
• MappingQualityRankSum.! A! Wilcoxon!rank! sum! test! that! tests! the!hypothesis! that! the! reads! carrying! the! alternate! base! have! a! consistently!lower!mapping!quality!than!the!reads!with!the!reference!base.!
• ReadPositionRankSum.! A! Wilcoxon!rank! sum! test! which! tests! the!hypothesis! that! the! alternate! base! is! consistently! found! more! often! at! the!beginning!or!ending!of!the!read!instead!of!randomly!distributed!throughout.!A!bias!would!indicate!that!the!reads!are!mismapped.!
• FisherStrand.! The! pOvalue! from! a! Fisher’s! exact! test! of! the! strandedness!(positive! or! negative)! of! reads!which! hold! the! alternate! allele! versus! those!that!hold!the!reference!allele.!
• RMSMappingQuality.& The! root!mean! square! of! the!mapping! quality! of! all!reads!covering!this!site.!








SNPTools!applies!a!variance!ratio!statistic28! to!discover!SNP!sites.!This!statistic!compares!the!difference!in!variation!contributed!from!the!variant!read!coverage!(in! case! that! they! are! true! positives),! and! the! variation! that! would! be! due! to!sequencing!and!mapping!errors!(in!case!that!they!are!false!positives).!The!larger!the!variance!ratio!statistic!is,!the!more!likely!the!site!is!a!true!polymorphic!site.!!We!identified!34.14!million!SNPs!from!the!Phase!I!samples,!the!overall!Ti/Tv!rate!was!2.14.!The!novel!sites!were!~88.2%!of!our!discoveries,!and!their!Ti/Tv!was!2.13,!indicating!high!quality.!!!The!next!stage!is!to!estimate!the!genotype!likelihoods!by!clustering!all!candidate!sites! within! each! particular! BAM! file! to! overcome! data! heterogeneity! using! a!binomial!mixture!model!–! this! is!named!as! the! ‘BAMOspecific!Binomial!Mixture!Model’!(BBMM).! !BBMM!normalizes!the!heterogeneity!within!each!sample!BAM!by! estimating!BAM/sample! specific! parameters.! ! It! takes! into! consideration! all!the! variant! sites! identified! from! the! sample! collection! (30O40! million! sites! in!~1000!individuals),!and!clusters!across!sites! in!one!particular!BAM!to!estimate!the!genotype!likelihoods.!By!clustering!the!scaled!read!coverage!across!millions!of! sites,! it! substantially! reduces! the!variance!and! improves! the!accuracy! in! the!genotype! likelihood! estimation.! The! BBMM! can! effectively! overcome! the!heterogeneity!in!the!low!coverage!data.!The!genotype!likelihoods!are!passed!to!an! imputation! engine! to! refine! the! individual! genotypes! and! produce! phased!haplotypes.!!
5.3 Low+coverage+SNP+calling:+University+of+Michigan+!
Authors:$Hyun$Min$Kang,$Mary$Kate$Trost,$and$Goncalo$Abecasis$!The!UMAKE!SNP!calling!pipeline29!was!used!to!produce!low!coverage!SNP!calls!contributed! by! University! of! Michigan.! The! pipeline! first! computes! genotype!likelihood! for! each! platform! using! the! default! samtools! genotype! likelihood!model,! after! adjusting! by! perObase! alignment! quality! (BAQ)22.! Genotype!likelihoods! are! merged! across! platforms! if! needed.! This! strategy! effectively!assumes! dependency! between! base! calling! errors! within! a! platform,! but! no!dependency!across!platforms.!!!To! detect! polymorphic! sites,! we! used! Brent’s! algorithm30! to! obtain! maximum!likelihood! estimates! of! allele! frequency! at! each! locus.! We! compared!




correlation! between!machine! cycle! and! allele! (cycle! bias),! and! (5)! distance! to!nearby! 1000! Genomes! pilot! 1! indels.! For! each! of! these! features,! a! manually!chosen! threshold! based! on! the! empirical! distribution! of! feature! statistics,!transition!to!transversion!ratio,!and!overlap!with!HapMap!SNPs!was!determined!and! filtered! out! the! variants! beyond! the! threshold.! Each! feature! was!independently!considered!during!the!filtering,!and!the!sites!that!did!not!pass!at!least!one!criterion!were!filtered!out!from!the!call!set.!!!From!the!procedure!described!above!a!total!of!34,515,663!SNPs!were!identified.!The! transition! to! transversion! ratio! (Ts/Tv)! for! the! variants! overlapping!with!dbSNP! build! 129! was! 2.14,! and! 2.16! for! the! rest! of! the! variants.! 98.63%! of!HapMap3!SNPs!were!rediscovered!in!this!call!set.!!
5.4 Low+coverage+SNP+and+indel+calling:+Sanger+!
Author:$Petr$Danecek$!The! Sanger! low! coverage! SNP! and! indel! calls! were! made! by! samtools! and!bcftools!version!0.1.17!(r973:277)21.!Samtools!was!used!to!generate!allOsite!allOsample!BCF!files!(samtools!mpileup!OC50!Om2!OF0.0005!Od!10000!–P!ILLUMINA)!with!bcftools! subsequently!used! to! call! variants! (bcftools! view! Op!0.99! Obvcgs).!Calling!was!conducted!separately!within!the!four!continental!groups,!AMR,!AFR,!ASN,! and! EUR.! The! calls! were! then! merged! and! filtered! (StrandBias! 1eO5;!EndDistBias!1eO7;!MaxDP!10000;!MinDP!2;!Qual!3;!SnpCluster!5,10;!MinAltBases!2;! MinMQ! 10;! SnpGap! 3).! The! pseudoautosomal! regions! on! chrX! (60001O2699520!and!154931044O155270560)!were!treated!as!diploid!in!male!samples.!
5.5 Low+coverage+SNP+calling:+NCBI+!
Authors:$Chunlin$Xiao,$Tom$Blackwell,$Alistair$Ward,$Erik$Garrison,$WanKPing$Lee,$
Hyun$ Min$ Kang,$ Mary$ Kate$ Trost,$ Gabor$ Marth,$ Goncalo$ Abecasis,$ and$ Stephen$
Sherry$







*$Corresponding$Author$!For! the! Phase! 1! Exomes,! two! different! capture! platforms! were! applied! (see!above).!The!BCMOHGSC!and!BGI!used!the!SeqCap!EZ!Human!Exome!Library!(v2.0!and! v1.0! respectively)! from! Nimblegen,! whereas! the! BI! and! WUGSC! used!SureSelect! All! Exon! V2! Target! Enrichment! kit! from!Agilent.!We! first! defined! a!consensus!capture!target!region31!by!intersecting!the!two!different!target!design!files!(the!.bed!files)!with!the!NCBI!CCDS!database.!!!SNPs!and!indels!were!called!using!the!Atlas2!Suite32,33.!Atlas2!has!capabilities!for!calling! variants! in! high! coverage! nextOgeneration! sequencing! data! on!multiple!sequencing!platforms! (i.e.! Illumina,!Roche!454)! for! both! SNPs! and! shortOrange!(within! tens! of! bps)! indels.! ! The! Atlas2! Suite!makes! use! of! logistic! regression!models!trained!on!whole!exome!capture!sequencing!(WECS)!data!to!identify!SNP!and! indel! sites!with! high! sensitivity! and! specificity,! and! subsequently! produce!accurate!genotypes.!
5.7 Exome+SNP+calling:+University+of+Michigan+!









with!the!addition!of!highOconfidence!sites!identified!by!the!SVM!filter!in!another!call!set!(BC,!UMich,!BCM,!or!Broad).!The!SVM!consensus!site!list!includes!597,687!SNPs.! No! minimum! quality! score! filtering! was! applied! to! this! call! set,! and! all!observed! alternate! alleles!were! kept.! The! combined! call! set! summary! VCF! file!includes! all! alternate! alleles! observed! (in! order! of! decreasing! frequency),! the!minimum!quality!score!for!a!population!where!the!variant!was!observed,!and!the!combined! depth! and! allele! count! across! all! populations.! PopulationOspecific!information! in! the!VCF! file! includes! the!number!of!populations!where! the!SNP!was!observed!(NPOP),!and!the!alternate!allele!count!observed!in!each!population!(POPAC).!For!sites!where!multiple!alternate!alleles!were!observed,!the!alternate!alleles! in! each! population! are! listed! (POPALT).! The! Ts:Tv! ratio! for! the! major!alternate! allele! was! 2.8! (436,186! transitions! and! 155,281! transversions),!excluding! 6,220! sites! in! the! SVM! consensus! site! list! where! no! SNPs! were!observed!in!this!call!set.!
5.9 Variant+calling+from+MOSAIK+alignments+!





















(QualByDepth,! DepthOfCoverage,! HaplotypeScore,! MappingQualityRankSum,!ReadPositionRankSum,! FisherStrand,! RMSMappingQuality,! and!InbreedingCoefficient).!Each! input!variant! is!assigned!a!VQSLOD!score,!which! is!the!log!odds!ratio!between!the!probability!that!the!SNP!is!true!or!false!given!the!model.!In!addition!to!using!the!error!covariate!statistics!the!model!incorporates!a!prior! probability! of! being! a! true! variant! which! is! based! on! the! number!of!callsets!that! the! original! variant! is! found! in.! This! captures! the! intuition! that!variants!called!independently!by!multiple!callers!are!more!likely!to!be!real.!The!prior!used!here!is!Q<10X>,!where!X!is!number!of!callsets!the!variants!was!found!in.!5)!Partition!the! list!of!variants! into!those!that!are!PASSing!and!those!which!are!filtered!out!by!choosing!the!VQSLOD!value!which!gives!99.8%!sensitivity! to! the!accessible!HapMap3!variants.!!!This!procedure!produces!a!high!quality!and!statistically!principled!consensus!set!of!sites.!
5.11 Generation+of+consensus+Exome+SNP+call+set+!








*$Corresponding$Author$!As!for!SNP!calling!at!the!Broad,!low!coverage!indel!calling!was!performed!on!the!project!official!lowOcoverage!BAM!files.!However,!exome!indel!calling!was!carried!out!using!Illumina!data!only!on!BAM!files!produced!locally!at!the!Broad!Institute!using!an!equivalent!pipeline!to!the!official!low!coverage!BAMs.!These!BAMs!are!available!in!a!separate!location!on!the!project!FTP!site26.!!!The!Broad! Institute! produced! an! indel! dataset! consisting! of! genomic! sites! and!genotype!likelihoods!for!all!low!coverage!samples,!as!well!as!for!the!822!exome!samples! sequenced!with! Illumina! technology.! The! production! of! both! datasets!followed!the!same!procedure:!!
1.&Realignment&around&Indels&in&reads&The!purpose!of! this!step! is! to!create!consensus! indels! in!the!reads!so!that!base!mismatches! are! minimized.! Each! sample! was! realigned! independently,!considering! as! candidate! sites! known! indels,! as! well! as! sites! where! the! read!mapping!software!introduced!insertions!or!deletions.!!




3.&Genotype&candidate&alleles&on&each&sample&For! each! candidate! site,! the! genotype! likelihoods! were! computed! for! each!sample.! Likelihood! computation! involved! forming! 2! candidate! haplotypes! per!site,! one! containing! only! the! reference! allele! and! the! other! containing! the!alternate! allele,! and! then! scoring! each! sample’s! read! against! each! of! these! 2!haplotypes.! The! likelihood! of! each! read! scored! against! each! haplotype! was!computed!using!a!Pair!Hidden!Markov!Model40!using!affine!gap!penalties.!!
















The! Dindel2! algorithm! realigns! reads! to! candidate! haplotypes! using! a!probabilistic! approach! based! on! the! readOhaplotype! alignment! probabilistic!model!described!in!Albers!et$al.41.!The!main!differences!are!that!Dindel2!uses!a!multiOsample!haplotype!caller!based!on!a!model!selection!approach!rather!than!a!pooled!Bayesian!EM!algorithm,! and! that! it! uses! a! banded! gapped! alignment! of!the!read!to!two!seed!positions!in!the!candidate!alignment.!!Individuals! in!the!same!population!group!were!analyzed!jointly.!First,!all! indels!identified!by!the!read!mapper!(BWA)!were!extracted!from!the!alignments.!All!of!these! indels!were! tested! by! realigning! the! reads! against! candidate! haplotypes!consisting! of! the! reference! haplotype! and! the! alternative! haplotype! resulting!from!the!indel.!Second,!all!indels!called!in!the!first!step!were!retested,!however,!allowing!for!at!most!two!nearby!SNPs,!thus!potentially!realigning!all!reads!to!at!most! 8! candidate! haplotypes! consisting! of! candidate! SNPs! and! one! candidate!indel.!Third,!all!indels!called!in!the!second!step!were!subjected!to!a!postOanalysis!filter! step.! All! indel! calls! satisfying! at! least! one! of! the! following! criteria! were!filtered:! Bayes! factor! for! strand! bias!was! >4.0,! called! from! only! one! fragment,!indel! is! in! a! homopolymer! run! longer! than! 10! nucleotides,!more! than! 90%! of!reads!have!mapping!quality!below!Q30,!or!more!than!90%!of!the!reads!have!the!indel!positioned!in!the!first!or!last!10!bases.!!
5.15 Low+coverage+indel+calling:+Oxford+!
























*$Corresponding$Author$!The! set!of! structural! variants! included! in! the! integrated! call! set!was! limited! to!large! (greater! than! 50bp)! biOallelic! deletions.! Site! selection! of! these! structural!variants!was!done! in! three! steps:! First,! a! list! of! candidate! sites!was! chosen!by!combining!deletion!calls! from!five!deletion!discovery!algorithms!(BreakDancer,!CNVnator,!Delly,!Genome!STRiP,! and!Pindel)!plus! the! set!of!deletion!calls! from!the! 1000! Genomes! pilot! that! had! assembled! breakpoints.! Second,! a! subset! of!these!candidate!sites!was!selected!for!genotyping!based!on!estimating!the!overall!false!discovery!rate!using!the!Omni!2.5!SNP!array!intensity!data.!Third,!the!set!of!sites!contributed! to! the! integrated!call! set!was!selected!after!genotyping!based!on! (a)!whether! there!was! sufficient!data! available! at! the! site! to! generate!wellOcalibrated! genotype! likelihoods! (b)! removal! of! redundant! overlapping! calls! of!the!same!underlying!polymorphism!and!(c)!removal!of!sites!that!were!classified!as!false!discoveries!based!on!the!genotyping!results.!!Five!deletion!discovery!algorithms!were!used!to!make!independent!calls!of!large!deletions!(longer!than!50!base!pairs).!These!were!combined!with!a!site!list!from!the! 1000! Genomes! pilot! consisting! of! 10,855! deletions! that! had! assembled!breakpoints! in! the! pilot! to! yield! a! (potentially! redundant)! set! of! 113,649!candidate! sites.! The! five! computational! methods! used! for! selecting! the! list! of!candidate!sites!are!described!below.!
5.17.1 BreakDancer+(run+at+WTSI)+!




size!distribution,!(2)!the!median!plus!four!times!the!standard!deviation,!(3)!the!median!plus!five!times!the!median!absolute!deviation!(MAD),!then!the!maximum!of! those! three! types!was!used.! In!a! few!cases!when!the!median! insert!size!was!zero,! the! cutOoff! 1,000! was! chosen,! and! if! the! third! quantile! of! the! insert!distribution!was!zero,!the!cutOoff!10,000!was!chosen.!The!raw!BreakDancer!calls!were!filtered!for!deletion!size!(≤!50!bp!and!>!1!Mb),!for!estimated!copy!number!(<! 0! and! ≥! 2),! for! number! of! spanning! read! pairs! (≥! 20),! for! regions! around!centromeres! (+/O!1!kb),! for! regions! around!assembly! gaps! (+/O!50!bp)! and! for!alpha!satellite!regions.!Deletions!were!then!merged!across!samples!if!there!was!a!50%! reciprocal! overlap! with! connected! components.! The! merging! process!generates! confidence! intervals! for! the! start! and! for! the! end! position! of! the!deletion!that!were!used!for!further!filtering,!i.e.!if!the!upper!confidence!limit!for!the!end!position!was!lower!than!the!lower!confidence!limit!for!the!start!position,!or!if!the!confidence!interval!was!larger!than!10!kb.!To!improve!the!specificity!of!the! call! set,! the! deletion! set! of! the! 1000! Genomes! Pilot! Project! was! used! as!training!set6.!A!likelihood!ratio!was!computed!using!the!attributes!deletion!size,!BreakDancer!score,!number!of!samples,!estimated!copy!number!and!number!of!libraries.!The!breakpoints!were!estimated!by! centering! the!deletion!within! the!outer! confidence! limits! and! by! using! the! deletion! size! estimate! from!BreakDancer.!
5.17.2 CNVnator+!
Author:$Alexej$Abyzov$!To! call! CNVs!with! CNVnator,! data! from! all! individuals! within! each! population!were! pooled! together.! The! data! were! processed! with! CNVnator! software45!(version!0.2.2)!with!standard!settings!and!100!bp!and!50!bp!bins.!Additionally,!CNVs! were! called! with! relaxed! parameters! to! call! for! lower! allele! frequency!CNVs.! For! each! population,! overlapping! calls! were! merged! by! selecting! the!largest!call!of!all!overlapping!ones.!Merged!calls!were!filtered.!A!CNV!call!passes!the! filter! if:! i)! it!does!not!overlap!a!gap! in! the!reference!genome!for!a!deletion,!and!it!is!not!within!0.5!Mb!from!a!gap!in!the!reference!genome!for!a!duplication;!ii)!a!deletion!must!have!at!least!two!pairedOend!reads!supporting!the!predictions!(overlapping!by!50%!reciprocally)!or!read!depth!in!the!middle!part!(1!kb!away!from! breakpoints)! of! the! called! region! should! be! statistically! different! from!average! read!depth.! Statistical! testing!was!done! the! same!way!as!when! calling!CNV!regions.!
5.17.3 Delly+!








*$Corresponding$Author$!We!used! the!Genome! STRiP! algorithm48! (Version! v1.04.683)! for! large! deletion!discovery! using! information! from! read! pairs! with! unexpected! alignments! and!analysis!of!sequencing!read!depth.!Low!coverage!Illumina!sequencing!data!from!946! samples!was!analyzed! together! to!perform!discovery.!We! ran! the!Genome!STRiP!algorithm!with!default!parameters!plus!two!more!stringent!filters!for!this!phase!of!the!1000!Genomes!project:!a) (alpha! satellite! repeat)! Sites! were! removed! if! at! least! 90%! of! the!deletion! site! was! annotated! as! alphaOsatellite! repeat! (based! on! the!UCSC!hg19!RepeatMasker!annotations).!b) (multiple! read! pairs! per! genome)! Sites! were! required! to! have! an!average! of! at! least! 1.1! aberrantly! aligned! read! pairs! per! genome!having! any! observed! aberrant! read! pairs! at! this! site.! This! removed!sites! that! were! supported! predominantly! by! observing! only! one!aberrant!read!pair! in!each!putative!carrier! individual!(usually!across!only!two!or!three!putative!carrier!individuals).!
5.17.5 Pindel+!
Author:$Kai$Ye$!An! improved! version! of! Pindel49! (version! 0.2.0)! was! used! to! call! insertions,!deletions,! inversions,! and! tandem! duplications! from! Phase! 1! Illumina! low!coverage!sequence!data.!All! samples!were!processed!at! the!same!time! for! joint!variant!discovery!of! all! variant! types! simultaneously.!All! reads!with! suspicious!mapping!status!such!as!softOclip!and!>5%!mismatches!were!subjected!to!Pindel!reOalignment! and!up! to!3%!of! the! read! length!was!allowed! for!mismatch.! !The!new! version! of! Pindel! can! find! deletions,! inversions! and! tandem! duplications!even! in! the! presence! of! nonOtemplate! bases! inserted! at! the! edges! of! the!structural! variation,! and! also! reports! the!nonOtemplate!bases.! The! variants! are!selected! if! larger! than! 100! bp,! appear! in!more! than! 3! samples! and!with!more!than!10!supporting!reads!in!total!among!all!samples.!
5.17.6 Merging+candidate+deletion+calls+to+create+sensitive+set+
&




First,!we!determined!the!confidence! intervals!of!each!computational!call!set!by!comparing!deletion!calls!with!calls!from!the!1000!Genomes!Pilot!Phase!that!had!assembled!breakpoints.!We!required!80%!reciprocal!overlap! to!match!deletion!calls!with!the!pilot!phase!assembled!deletions!as!a!filter!to!avoid!comparing!calls!that! correspond! to! different! deletions.! Start! and! end! position! residuals! were!obtained!from!each!matched!call,!resulting!in!the!distributions!of!deviations!from!the!actual!event.!The!95th!percentile!of!the!observed!deviations!was!assigned!as!the!confidence!interval!of!each!call!in!the!deletion!call!set.!!Next,! the! calls! from!5!deletion! call! sets,! plus! the! calls! from! the!1000!Genomes!Pilot! with! assembled! breakpoints,! were! merged! using! hierarchical! clustering!with!complete!linkage!with!a!decreasing!reciprocal!overlap!from!100%!to!80%.!We! allowed! deletion! calls! to! be! merged! together! only! when! the! confidence!intervals!intersected.!!!If!the!predicted!breakpoints!of!the!merged!calls!were!outside!of!the!intersection!of!the!confidence!intervals,!the!midpoint!of!the!intersection!was!assigned!as!the!most!likely!breakpoint!of!the!merged!call,!pending!breakpoint!assembly,!and!the!upper!and! lower!bounds!of! the! intersecting!confidence! intervals!were!assigned!as! the! merged! confidence! intervals! (CIIPOS/CIIEND).! ! If! there! were! any!predicted! breakpoints! within! the! intersection,! then! the!midpoint! between! the!predicted!breakpoints!was!used! as! the!most! likely! breakpoint.! If! deletion! calls!were!merged!with!a!call!from!the!pilot!set,!the!assembled!breakpoints!were!used!as!breakpoints!of!the!merged!call,!and!the!intersecting!confidence!intervals!were!set!to!zero.!We!did!not!allow!calls!from!the!pilot!set!to!be!merged!together!since!they! were! assumed! to! correspond! to! different! deletions.! The! most! distal!confidence!intervals!of!the!merged!calls!were!kept!as!the!maximum!values!of!the!CIPOS/CIEND!intervals.!
5.17.7 Assembly+of+deletion+breakpoints+!







Breakpoint!assembly!was!performed!using!TIGRAOSV!(version!v0.3.0)!on&a!set!of!113,649!merged!candidate!deletion!calls.!For!each!call,!TIGRAOSV53!first!obtained!reads! surrounding! the! predicted! breakpoints! (+O500! bp)! from! the! set! of! bam!files! that!were!predicted!as!deletion!containing.! It! then!ran!a!de$Bruijn! graphic!assembly!algorithm!to!decode! the!set!of!nonOreference!alleles! that!best!explain!the!set!of!reads.!!111,353!calls!were!successfully!assembled!(i.e.,!obtained!at!least!one!contig).!An!assembly!score!was!calculated!to!summarize!both!the! length!of!the! contigs! and! the! amount! of! reads! that! contributed! to! the! results.! ! The!assembled! contigs! were! aligned! with! CROSSMATCH51! and! AGE52! as! described!below!to!yield!breakpoints!for!each!deletion!call.!
5.17.9 Deriving+breakpoints+from+CROSSMATCH+alignments+
&
Author:$Ken$Chen$!Contigs! locally! assembled!with!TIGRAOSV50!were!aligned!using!CROSSMATCH51!(version! 1.080721)! against! corresponding! 1000! Genomes! v37! reference!sequences! that! span! the! putative! deletions! with! 700! bp! flanking! sequence! on!either!end.!!A!deletion!is!called!“validated”!and!is!passed!to!the!next!stage!if!the!associated! pairOwise! alignments! indicate! the! existence! of! the! same! deletion! as!was!predicted!by!the!original!callers.!!A!deletion!is!not!validated!if!the!alignment!was! ambiguous,! i.e.,! contain! more! than! 2! high! scoring! pairs! and! have! an!assembly! score! <! 200,! or! if! the! size! differed! by! more! than! 50%! from! the!expectation.! !In!total,!61,265!deletions!had!some!evidence!of!assembly!support.!38,020!were!called!“validated”!by!CROSSMATCH.!!For!each!validated!deletion,!its!precise!boundary!as!well!as!patterns!of!target!site!duplication! and! nonOtemplate! insertion!were! deduced! from! the! alignment! and!recorded!in!the!VCF!files.!
5.17.10 Deriving+breakpoints+from+AGE+alignments+!








*$Corresponding$Author$!Using! BreakSeq! (version! v1.3),! SVs! were! classified! according! to! their! likely!mechanism!of! formation54.! In! particular,! SVs!were! classified! into! the! following!formation!mechanisms:! (1)!nonOallelic!homologous! recombination! (NAHR);! (2)!nonOhomologous!rearrangements!(NHR),!including!nonOhomologous!endOjoining!(NHEJ)! or! microhomologyOmediated! breakOinduced! replication! (MMBIR);! (3)!variable!number!of! tandem!repeats! (VNTR);!and!(4)!mobile!element! insertions!(MEI).! The! fraction! of! deletions! classified! as! NAHR! and! NHR! are! roughly!consistent! for!deletions!with! lengths!above!500!bp,! the!size!range! in!which!we!had!good!power!to!genotype!these!events!(Table!S9).!
5.17.12 Creation+of+the+specific+SV+discovery+set+and+FDR+estimation+!

















*$Corresponding$Author$ $!In! addition! to! the! 14,422! deletions! genotyped! on! the! autosome! and! X,! an!additional!36!sites!were!genotyped!on!chromosome!Y.!The!site!selection!criteria!and!genotyping!methods!employed!were!the!same!as!for!the!autosome!with!the!following!differences:!! a) (YOspecific! read! depth! normalization)! Read! depth! normalization! was!performed!relative!to!the!region!Y:1O28780000!rather!than!relative!to!the!whole!reference!genome.!This!was!done! to!address!problem!with!some!samples!that!appear!to!be!deficient!in!Y!relative!to!the!rest!of!the!genome!(perhaps! due! to! mosaicism! within! the! cell! lines)! and! to! avoid! the!repetitive!region!Yq12.!b) (genotype!in!males!only)!Samples!labeled!as!being!female!were!not!used!in!the!genotyping.!c) (remove!highly!repetitive!sites)!Sites!<!1%!uniquely!alignable!sequence!were!not!included.!Uniquely!alignable!sequence!is!defined!as!the!number!of!base!positions!where!a!36!bp!window!centered!over!the!base!position!is!unique!within!the!reference!genome.!!The!structural!variation!genotypes! for!chromosome!Y!were!not! included! in! the!integrated!call!set,!but!are!available!as!a!separate!data!file.!
5.18 Integration+of+SNPs,+short+indels,+and+SVs+into+a+single+call+set+
+




section.! Indel! likelihoods! were! calculated! as! described! in! the! Broad! Low!coverage! Indel! calling! section.! The! calculation!of! deletion! genotype! likelihoods!was! performed! using! Genome! STRiP! as! described! in! the! earlier! description! of!structural!variant!detection.!!The! merged! genotype! likelihoods! were! used! as! the! input! to! run! the! BEAGLE!software55! with! 50! iterations! across! all! samples! together.! The! resulting!haplotypes!were! refined! using! a!modified! version! of! the! THUNDER! software56!with! 300! states! chosen! by! longest! matching! haplotypes! at! each! iteration! in!addition! to! 100! randomly! chosen! states.! The! approach! of! using! BEAGLEOestimated! haplotypes! to! initialize! methods! such! as! THUNDER! and! IMPUTE2!produces! higher! quality! haplotypes! than! any! of! these! methods! alone! (Bryan!Howie,! personal! communication).! Processing! all! samples! together! facilitates!downstream!analysis,!and!work! in!the!related! field!of!genotype! imputation!has!shown!that!these!methods!perform!well!in!multiOethnic!datasets57,58.!!For! chromosome! X! calling! in! the! non! pseudoOautosomal! regions,! the! male!genotype! likelihoods! for! heterozygous! allele! were! assigned! as! the! minimum!possible!value!under!the!diploid!model.!!
5.19 PostKhoc+short+indel+filtering+!
Authors:$Adrian$Tan,$Hyun$Min$Kang,$Goo$Jun,$Adam$Auton,$Scott$Devine,$Heng$Li,$









*$Corresponding$Author$!Calls! were! made! on! the! 525! male! samples! in! the! Phase! I! release,! plus! an!additional!sample!belonging!to!Haplogoup!A!(NA21313).!Calls!were!made!using!samtools21! and! bcftools! 0.1.17! (r973:277).! Samtools!was! used! to! generate! allOsite,! allOsample! BCFs! (samtools! mpileup! ODS! OC50! Om2! OF0.0005! Od! 10000! OP!ILLUMINA).! Sites! were! identified! by! calling! the! four! continental! groups,! AMR,!AFR,!ASN!and!EUR,!separately!with!bcftools!(bcftools!view!Op!0.99!Obvcgs),!then!combining! and! recalling! at! the! sites! discovered! in! these! four! groups.! The! Os!option! in!bcftools!was!used! to! identify! the! samples!as!haploid! for! calling.!Calls!were! then! merged! and! filtered! (StrandBias! 1eO5;! EndDistBias! 1eO7;! MaxDP!10000;!MinDP!2;!Qual!3;!SnpCluster!5,10;!MinAltBases!2;!MinMQ!10;!SnpGap!3).!!A! revised! version! of! Yfitter6! was! used! to! assign! a! haplogroup! to! each! sample!based!on!the!variable!sites!called.!!
Site&filtering&and&site&QC&matrix&





Using!the!haplogroup!assigned!to!each!sample,!we!carried!out!the!filtering!steps!described!below.!! 1. For! sites! that! appeared! multiple! times! in! one! haplogroup! but!as!singletons! in! other! haplogroups! inconsistent! with! the! phylogeny,!we!treated!the!singletons!as!missing!data!(bad!calls).!2. We!treated!sites!that!were!found!in!two!or!more!haplogroups!with!two!or!more! calls! each,! but!were! inconsistent!with! the!phylogeny,! as!recurrent!sites!and!filtered!them!out!when!the!phylogenetic!tree!was!constructed.!3. We!used!the!overlap!with!Complete!Genomics!data!to!set!read!depth!and!genotype!quality!cut!off!filters!for!bad!calls,!and!treated!these!as!missing!data.!4. Two! individuals! were! outliers! in! the! tree,! NA12413! with! the!highest!proportion!of!missing!data,!and!NA18603!which!for!unclear!reasons!was!placed!far!from!the!position!expected!from!its!HapMap3!genotype.!These!individuals!were!both!filtered!out.!!286! individuals!overlapped!with!HapMap3!and! therefore!have!YOSNP!genotype!data! available.! Genotype! data! were! obtained! with! the! Affymetrix! Human! SNP!array! 6.0! (interrogating! 1,852,600! genomic! sites)! and! the! Illumina!Human!1M!single! beadchip! (1,199,187! genomic! sites)61,! and! were! used! to! assess! the!genotype!accuracy.!!
Results:&!In!total,!18,699!unique!region!YOSNPs!were!called!in!the!raw!VCF!file.!Only!seven!sites!were! filtered! out! using! the! quality! cutoff! determined! using! the! literature!sites,!suggesting!that!the!site!calling!quality!is!good.!The!site!false!negative!rate!was!17.2%!(25/145)!based!on!the!literature!sites,!and!17.3%!(393/2661)!based!on! the! Complete! Genomics! calls.! The! proportion! of! sites! called! in! the! 1000!Genomes! analysis! but! not! by! Complete! Genomics! in! the! overlapping! samples!(maximum!false!positive!rate)!was!1.72%!(142/8,269).!!Among!the! filtered!18,692!YOSNP!sites,!an!ancestral!state!could!be!assigned!for!16,679!(the!allele!matching!the!Ensembl!release!66!chimpanzee!Y!chromosome!sequence).! We! identified! 720! recurrent! sites,! which! were! not! included! in! the!phylogenetic! tree,! and! assigned! 3,263!genotypes! (0.03%)! as!missing! data.! The!genotype!accuracy!was!estimated!at!97.4%!(20,687/21,235)!by!comparison!with!the!HapMap3!Y!genotype!calls.!
7 Variant+calling+for+mtDNA+!







For!calling!variants!in!the!mitochondrion,!a!custom!java!script!was!used!to!filter!reads! based! on! the! NM! (number! of! mismatch)! information! in! the! SAM! files,!removing!reads!with!>10%!mismatch!(typically!1~5%!of!initial!reads).!Duplicate!reads! were! removed! by! MarkDuplicates,! implemented! in! Picard! v1.368.! For!subsequent! analyses,!we!used! the! SAMtools! package21! to! generate! pileup! files.!Consensus! sequences! were! then! generated! based! on! the! pileup! files! by! using!SAMtools! mpileup,! bcftools! view! and! vcfutils.pl! vcf2fq! commands! from! the!SAMtools! package.! Indels!were! checked!manually! later.! For! all! samples! in! this!analysis,! positions!where! the! nonOreference! allele! (compared!with! the! revised!Cambridge! Reference! Sequence! (rCRS62)! was! covered! by! less! than! two! reads!were!considered!as!‘N’!(missing!site!and!ambiguous!site).!!!We!excluded!samples! that!had!more! than!1%!Ns,!or!Ns! in!positions!critical! for!haplogroup! assignment,! leaving! 1074! samples.! Mean! coverage! for! each!individual!ranged!from!53x!to!7,555x!and!mean!coverage!for!mtDNA!sites!ranged!from!201x!to!2,205x.!!Heteroplasmy!was!called!conservatively,!with!a!mean!MAF!of!33%.!The!pattern!of!heteroplasmy!is!mostly!even!along!the!mtDNA!molecule,!with!peaks!within!the!control!region!as!noted!before6.!
8 Variant+annotation+
8.1 Functional+annotation+!
Authors:$ Suganthi$ Balasubramanian,$ Ekta$ Khurana,$ Lukas$ Habegger,$ Arif$





Author:$Laura$Clarke$!The! SNP! ancestral! alleles! were! derived! from! the! Ensembl! 59! comparative! 32!species! alignment69.! The! VCF! files! were! annotated! using! the! VCFtools! ‘fillOaa’!script37,!with!the!ancestral!allele!recorded!using!the!‘AA’!INFO!tag.!The!ancestral!allele!FASTA!files!used!for!this!annotation!are!available!for!download70.!
9 Validation+and+data+quality+!In! order! to! assess! the! quality! of! the! Phase! 1! SNP! calls,! a! series! of! validation!experiments! were! performed! for! both! the! low! coverage! and! exome! call! sets.!!Multiple! independent! technologies! including! PCRORoche! 454! and! PacBio! RS!sequencers! and! Sequenom! MassARRAY! were! used! so! as! to! ensure! that! the!results!were!not!skewed!by!error!modes!from!just!a!single!platform.!
9.1 Low+Coverage+SNP+validations+!
Authors:$Danny$Challis,$Jin$Yu,$Fuli$Yu,$and$Eric$Banks$!All! three! technologies! were! applied! to! a! selection! of! 300! SNP! loci! from!Chromosome! 20! that! were! potentially! polymorphic! in! at! least! one! of! eight!samples! (HG00321,! HG00577,! HG01101,! NA20800,! NA19313,! NA20296,!NA19740,!NA18861).!!These!samples!were!randomly!chosen!from!the!collection!of! samples! available! at! different! production! centers.! ! A! locus! was! eligible! for!validation!only!if!it!had!evidence!of!the!alternate!allele!in!at!least!one!sequencing!read!among!the!eight!samples.!This!however!does!not!necessarily!mean!that!the!site! was! called! polymorphic! in! any! of! the! eight! samples.! ! The! SNP! loci! were!randomly!selected! from!eligible!sites! from!the!Chr20!of! the! initial!Phase!1!SNP!call!set.!
9.1.1 Sequenom+and+Pacific+Biosciences+validation+!We! used! the! Mass! Spectrometry! genotyping! technology! and! utilized!AssayDesigner! v.3.1! software! to! design! PCR! and! extension! primers! for! low!multiplex!SNP!assays.!Two!sets!of!validation!designs!were!created,!one!using!100!base! pair! PCR! amplicons! and! another! set! of! complementary! 600! base! pair!amplicons.! SNPs! were! amplified! in! multiplex! PCR! reactions! consisting! of! a!maximum!of!12!loci!each.!The!volume!of!the!PCR!reaction!was!used!in!both!the!Sequenom!MassArray! protocol! and! pooled! together! for! the! Pacific! Biosciences!sequencing!aspect!of!the!validation.!!Sequenom:! Following! amplification,! the$ Single! Base! Extension! (SBE)! reaction!was! performed! on! Shrimp! Alkaline! Phosphatase! treated! PCR! product! using!




analyzed!in!automated!mode!by!a!MassArray!MALDIOTOF!Compact!system!with!a!solid! phase! laser!mass! spectrometer.! The! resulting! spectra!were! called! by! the!realOtime!SpectroCaller!algorithm!and!analyzed!by!SpectroTyper!v.4.0!software!that!combines!a!base!caller!with!the!clustering!algorithm.! !246!sites!had!usable!Sequenom! genotyping! data! after! excluding! those! assays! that! failed! the! design!phase!as!well!as!those!with!call!rates!of!less!than!75%.!!The!Sequenom!validation!was!applied!to!383!samples!(including!the!8!validation!target!samples).!!Pacific! Biosciences:! The! RS! sequencer! output! was! processed! using! the! Broad!InstituteOGATK! PacBio! Processing! Pipeline! (manuscript! in! review71).! ! 30! sites!could!not!be!genotyped!because!the!sequencing!read!coverage!was!less!than!20x!over! all! eight! samples;! the! average! coverage! for! the! remaining! 270! sites! was!over!500x.!!Sites!were!called!and!genotyped!using!the!GATK!Unified!Genotyper20.!!Pacific! Biosciences! sequencing! was! performed! just! for! the! 8! validation! target!samples.!




with! a! variant! read! ratio! above! a! defined! cutoff! (10%! for! single! sample!validation,! 3%! for! pooled! samples! validation)! it! was! considered! confirmed,!otherwise! the!SNP!was!considered!a! false!positive.! !Of! the!273!SNPs! for!which!primers!were! successfully! designed,! 260! produced! good! results! (that! is,! 95%)!and!13!were!PCR!failures!in!the!first!experiment.!!In!the!second!experiment,!264!produced!good!results!(97%)!and!9!were!PCR!failures.!
9.1.3 Consolidation+of+validation+genotypes+!Once! all! three! validation! experiments! were! completed,! the! results! were!combined!to!minimize!any!ambiguity.! !Any!locus!that! failed!to!produce!reliable!results! in!one!of!three!experiments!was!usually!reliable! in!another!experiment.!All!but!6!of! the!300! loci!had! reliable! results! in!at! least!one!of! the!experiments!(Table!S4).!!!!Although! the! validation! experiment! was! designed! using! a! preliminary! chr20!Phase!1!SNP!call!set,!the!results!have!been!applied!to!the!whole!genome!call!set.!!Due! to!adaptations! in!parameters!and! filtering!used! in! the!SNP!calling!process!between! whole! genome! and! chr20! data,! 3! of! the! 300! validated! SNPs! are! not!included!in!the!final!call!set.!!In!addition,!there!are!10!SNPs,!which!while!they!had!direct!evidence! in!at! least!one!of! the!eight! samples,!were!not!actually!called! in!any!of!the!eight!samples!in!the!final!call!set.!!!!When! combining! the! validation! results,! 15! of! the! 300! loci! had! contradictory!results! where! one! experiment! identified! the! locus! as! a! true! SNP! and! another!identified!it!as!an!error.!!8!of!these!contradictions!were!caused!by!the!locus!being!confirmed! in! one! sample! in! one! experiment,! and! not! confirmed! in! a! different!sample!in!a!different!experiment.!!These!8!SNP!loci!were!accepted!as!true!SNPs.!!The! other! 7! contradictions! are! due! to! apparent! errors! in! the! validation!experiments.! !These!7!loci!were!resolved!by!simple!voting,!with!each!validation!experiment! giving! a! single! vote! on! the! correct! classification.! ! To! give! a! more!accurate! estimate! of! the! final! call! set’s! quality! the! 10! SNPs! not! called! in! a!validated!sample!and!the!3!sites!not!in!the!final!call!set!have!been!excluded!from!the!results.!






9.2.1 Exome+SNP+validation+!Three! series! of! exome! SNP! validation! experiments! were! carried! out! at! BCMOHGSC!on!both!the!consensus!and!unique!SNPs!calls!of!the!three!different!centers!using! single! sample! PCRORoche! 454! validation! as! described! above! in! the! low!coverage!SNP!validation.!A!total!of!417!SNPs!on!chromosome!20!were!selected!from!these!validation!experiments!and!submitted!for!primer!design.!412!of!those!were! designed! successfully.! The! amplicons! had! an! average! length! of! 302! base!pairs.!The!amplified!DNA!were!then!divided!in!five!pools!and!sequenced!on!the!Roche! 454! sequencing! platform,! generating! a! total! of! 1419k! reads! with! an!average!length!of!287!base!pairs.!After!excluding!amplicons!that!failed!PCR,!the!average! read! depth! of! coverage! for! each! amplicon! is! 1625.! After!mapping! the!reads! to! the! human! genome! and! applying! the! same! quality! control! steps! and!cutoff!as!in!low!coverage!single!sample!PCRORoche!454!validation,!a!total!of!354!sites!were!genotyped!confidently.!!!!The!detailed!exome!SNP!validation!are!available!for!download74.!
9.2.2 Exome+consensus+SNPs+stratified+by+allele+frequency+!100!singleton!SNPs,!50!of!allele!frequency!(AF)!<1%,!and!50!of!allele!frequency!(AF)! >=1%!were! randomly! selected! in! this! validation! experiment! to! represent!the!SNP!allele!frequency!distribution!of!the!Phase1!integrated!genotypes!call!set.!At! least! one! and! at! most! 5! samples! were! chosen! for! each! site! to! prepare! the!sequencing!library!pools!and!a!total!of!188!sites!were!genotyped!confidently.!For!this!set!of!SNPs,!the!overall!FDR!is!estimated!to!be!1.6%!(Table!S5).!All!SNPs!in!AF>1%!are! validated! as! true! positives! and! the! FDR!of! singleton! SNPs! is! 1.1%.!The!SNPs!in!<1%!bins!has!a!higher!FDR!of!4.1%.!This!may!be!explained!by!the!fact! that! only! a! small! subset! of! samples! for! each! SNP! were! selected! in! this!validation!and!imputation!errors!are!more!likely!to!be!concentrated!in!this!bin.!






Authors:$Jin$Yu,$Mike$Jin,$and$Fuli$Yu$!To! assess! the! quality! of! LoF! SNPs! in! the! Phase! 1! integration! release,! we! first!applied!several!filters!to!remove!possible!annotation!artifacts,!excluded!the!sites!that! were! included! in! previous! experiments! and! then! selected! the! remaining!ones!for!single!sample!PCRORoche!454!sequencing!experiment.!
9.3.1 LoF+SNP+selection+!To!produce!a!set!of!high!confidence!LoF!SNPs,!a!series!of!fairly!stringent!filters!were!applied!to!all!SNP!sites!predicted!to!create!a!nonsense!codon!or!to!disrupt!a!splice!site! in! the!Phase1! integrated!release75.!These! filters! included:!1)!remove!all! SNPs! with! estimated! AC=0;! 2)! remove! splice! SNPs! in! nonOcanonical! splice!sites!or!in!introns!shorter!than!10bp;!3)!remove!SNPs!where!the!LoF!allele!is!the!same!as!the!inferred!ancestral!allele;!4)!remove!SNPs!that!effect!only!a!subset!of!known! transcripts! and! 5)! remove! nonsense! SNPs! found! in! the! last! 5%! of! the!coding! region! of! the! longest! affected! transcript.! After! applying! above! filters,! a!total!of!3,697!LoF!SNPs!of!the!whole!genome!were!selected,!which!we!identify!as!a! high! confidence! LoF! SNP! set.! This! set! consists! of! 2,535! nonsense! and! 1,162!spliceOdisrupting!SNPs.!We!further!excluded!the!sites!that!had!been!selected!for!validation!in!the!1000!Genomes!Pilot!LoF!validation!experiments,!sites!in!exome!chip! design,! and! those! in! dbSNP! release! 129.! The! 2,003! remaining! LoF! SNPs!consisted!of!1296!nonsense!and!707!spliceOdisrupting!sites.!




1,352! produced! good! results! with! an! average! read! coverage! depth! of! 1088!reads/site.!
9.3.3 Results+!The!overall!FDR!of!these!1,352!SNPs!is!5.2%.!Stratified!by!allele!frequency,!most!of!the!LoF!SNPs!are!singletons!and!doubletons,!which!also!have!the!lowest!FDRs!of!3.1%!and!4.8%!respectively.!With! increasing!allele! frequency,!the!number!of!LoF!SNPs!decreases!significantly,!while!both!the!FDR!and!‘No!call’!rate!increase.!There!are!only!8!LoF!SNPs!with!allele! frequency!>!5%,! although! the!FDR! is! as!high!as!80.0%!(Table!S8).!This! is! in!contrast! to! the!results! in!exome!validation!experiments,! in!which! the! SNPs!with! allele! frequency!>!1%!have! an! estimated!0%!FDR!(Table!S5).!!We!propose!several!reasons!for!this!phenomenon:!1)!The!LoF!variants!tend!to!be!rare!due!to!negative!selection,!the!high!frequency!LoF!SNPs!are!more!likely!to!be!artifacts.!The!high!no!call!rate!of!the!SNPs!in!this!category!also!suggests!many!of!them! are! in! regions!with! low!mappability;! 2)! Common! LoF! variants! are!more!likely! to! be! included! in! exome! chip! design! and! dbSNP129.! These! sites! were!excluded!in!this!validation!experiment,!and!hence!the!remaining!sites!are!more!likely! to! contain! false! positives;! 3)! As! SNPs! with! allele! frequency! >=1%!were!only!validated!in!one!sample,!conflation!with!genotyping!error!would!lead!to!an!increased!false!positive!rate!estimate.!!!The!validation!results!are!available!for!download74.!!
9.4 Short+indel+Validation+!
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9.4.1 Sequenom+and+PacBio+validation+!Sequenom! and! PacBio! indel! validation! was! carried! out! at! the! Broad! Institute.!!AssayDesigner!v.3.1!software!was!used!to!design!PCR!and!extension!primers!for!low! multiplex! Sequenom! indel! assays.! Two! sets! of! validation! designs! were!created,!one!set!using!100!base!pair!PCR!amplicons!and!the!other!set!using!600!base!pair!amplicons.!!Each!set!of!indel!amplicons!was!amplified!in!multiplex!PCR!reactions!consisting!of!a!maximum!of!12!loci.!The!600!bp!amplicon!PCR!reaction!was!used!not!only!in!the!Sequenom!MassArray!protocol!but!also!was!used!for!the!PacBio!sequencing!aspect!of!the!validation.!Sequenom!assays!were!then!analyzed!by!SpectroTyper!v.4.0!software.!The!600!bp!amplicons!also!were!used!for!PacBio!reOsequencing,!using!target!coverage!of!120x!at!each!site.!
9.4.2 454+validation+!454! indel! validation! was! carried! out! at! the! Institute! for! Genome! Sciences,!University!of!Maryland!School!of!Medicine.!An! independent!set!of!primers!was!designed! using! Primer! 3! software76! with! target!melting! temperatures! of! 63°C!and!a!target!PCR!amplicon!size!of!400!to!600!bp.!!The!93!sites!were!amplified!in!the!eight!samples!plus!a!negative!control! that! lacked!DNA.! !PCR!products!were!evaluated!on!2%!agarose!gels!to!ensure!accurate!amplicon!sizes!and!to!confirm!that! the! negative! controls! lacked! products.! A! total! of! 77/93! (80.5%)! of! the!attempted! PCR! assays! were! successful! and! yielded! robust! products! of! the!expected!sizes.!The!PCR!products!were! labeled!with!sampleOspecific!bar!codes,!pooled,! and! sequenced! with! 454! Titanium! chemistry.! Sequencing! yielded! an!average!depth!of!194!reads!per!indel!allele!and!these!were!mapped!to!a!library!of!all!possible!alleles!to!determine!the!genotype!of!each!indel!in!the!eight!samples.!Alignments!were!manually!inspected!to!evaluate!mapping!and!allele!calling.!
9.4.3 Results+of+PCRKbased+validation+!Data! from! the! Sequenom,! PacBio,! and! 454! validation! experiments! were!integrated!and!used!to!calculate!a!combined!FDR!of!35%!for!the!exercise!(Table!S6).!Despite!the! fact! that!three! independent!platforms!were!used!for!validating!indel!calls,!17! indels!remained!uncalled!by!any!platform.! !These!sites!generally!fell!within!simple!repetitive!regions!that!were!difficult!to!analyze!and/or!did!not!amplify!well!in!the!PCR!assays.!!On!the!basis!of!these!data,!we!noted!that!indels!generally!fell!into!two!broad!categories!in!humans:!!1)!variants!in!“wellObehaved”!regions!of!the!genome!(regions!containing!complex!sequences)!with!high!quality!mapping,! sequencing,! and! alignment! data! underlying! the! variant! calls,! and! 2)!variants!in!more!challenging!regions!of!the!genome!(often!within!simple!repeats)!where! lower! quality! mapping,! sequencing,! and/or! alignment! data! may!contribute!to!incorrect!variant!calls.!!!




synonymous! coding! SNPs! from! the! Axiom™! Genomic! Database.! ! A! total! of!260,889!of! these!variants!(including!~17,524! indels! in!exons!and!CDS!regions)!are! expected! to! cause! nonsynonymous! changes! in! protein! sequences.! ! An!additional! 13,328! variants! are! predicted! to! cause! synonymous! changes.! ! An!additional!17,610! indels!were! identified! in! the!50!–!100!bp! flanking!regions!of!exons! that! were! captured! for! exome! sequencing.! ! ! Additional! variants! were!selected! for! significance! in! previous! GWA! studies,! usefulness! as! ancestry!informative! markers! or! for! calculation! of! identity! by! descent,! and! for! other!purposes!described!on!the!above!website.!!A! total! of! 1,249! individuals! from!14!populations!were! genotyped! on! the! array!using! the! Axiom! 2.0! assay,! which! employs! a! ligationObased! approach! to!interrogate!whole!genomeOamplified!DNA.!Genomic!DNA!from!the!HapMap!and!1000!Genomes! collections!was! purchased! from!Coriell! (population/DNA!plate:!CEU/T01,! CHB+JPT/T02,! CHS/MPG00002,! CLM/MPG00005,! FIN/MPG00001,!GBR/MPG00003,! IBS/MPG00010,! JPT/MPG00009,! LWK/MPG00008,!MXL/MPG00006,! PEL/MPG00011,! PUR/MPG00004,! TSI/MPG00007,! YRI/T03).!!Genotyping! analysis! was! performed! with! Affymetrix! Power! Tools! software!version! 1.14.4.! ! Genotype! calls! are! available! on! the! Affymetrix! and! 1000!Genomes!websites.!In!order!to!evaluate!the!FDR!of!the!indels!on!the!array!that!were!derived!solely!from!1000!Genomes!Phase!I!data!sets,!we!limited!our!analysis!to!the!genotyping!data!that!was!generated!from!865!samples!(exclusively!Phase!I!data!setOderived!samples).! ! Our! analyses! revealed! an! FDR! of! 33%! O! similar! to! the! 35%! FDR!obtained!with!the!PCRObased!validations.!!
9.4.5 Short+indel+filtering+!The! indel! validation! experiment! revealed! a! subset! of! indels! contributing! the!majority!of!falseOpositive!calls.!In!order!to!produce!a!final!high!quality!indel!call!set,! the! calls! were! filtered! as! described! in! Section! 5.19.! After! filtering,! the!estimated!FDR!for!the!final!integrated!low!coverage!indel!call!set!was!5.4%!(with!the!caveat!of!underestimation!due!to!potential!model!overfitting).!
9.5 SV+validation+









called! by! different! calling! methods.! Although! arrays! (and! individual! array!probes)!can!vary!in!their!quantitative!response!to!variation!in!copy!number,!the!validation!method!employed!is!based!on!the!simple!idea!that!samples!with!lower!copy!number!should,!on!average,!exhibit!lower!signal!intensities!at!a!given!probe!than! samples! with! higher! copy! number.! Each! deletion! (or! duplication)! site! is!specified! by! chromosome! and! start! and! end! coordinate! and! a! set! of! samples!thought! to! carry! the! deletion! (duplication)! at! that! site.! The! normalized! probe!intensities!for!each!SNP!were!summed!to!create!a!single!intensity!value!at!each!SNP! position.!We! performed! a! nonOparametric! test! that! computes! a!Wilcoxon!rankOsum!POvalue!across!all!array!SNP!positions!that!underlie!a!given!deletion!or!duplication! site.! The! samples! are! first! ranked! separately! at! each! position! in!intensity! space!and! then! the! ranks!across! all!positions!underlying! the!putative!deletion! or! duplication! are! used! to! calculate! the! Wilcoxon! POvalue! that! the!samples! carrying! the! deletion! (duplication)! have! ranks! below! (above)! the!remaining! samples.! The! FDR! for! a! set! of! deletion! or! duplication! calls! was!estimated!as!two!times!the!fraction!of!putative!deletion!or!duplication!sites! for!which!we!measured!a!Wilcoxon!rankOsum!POvalue!P$>$0.5.!!!In! addition! to! using! the! SNP! genotyping! arrays! to! estimate! FDR! for! sets! of!deletion!calls,!we!also!used!a!threshold!of!P$<$0.01!for!selection!of!individual!sites!for!genotyping.!
9.5.2 SV+validation+using+PCR+
&
Authors:$Adrian$Stütz,$Sarah$Lindsay,$Matthew$Hurles,$and$Jan$Korbel$!PCR!validation!experiments!for!deletions!were!designed!using!a!spanning!primer!strategy! where! both! primers! hybridize! to! regions! flanking! the! predicted! SV.!PCRs! resulted! in! either! a! band! size! corresponding! to! the! reference! allele,! or! a!shorter!amplicon!corresponding!to!the!reference!allele!band!size!reduced!by!the!inferred! SV! size.! Each! PCR!was! carried! out! along!with! two! controls:!NA12892!genomic!DNA!(control!1)!and!a!pool!of!five!DNAs,!corresponding!to!four!human!samples! (HG00407! +! HG00689! +! NA18507! +! NA19314! (Coriell)! and! a!chimpanzee!sample!EB176!(JC)!(HPA!Culture!Collections)!(control!2).!
9.5.2.1 Design,of,PCR,validation,experiments,
!
Random$ locus$ selection:! To! enable! the! calculation! of! FDRs! for! independent! SV!callsets,!we! randomly!picked!96! loci! from!each!deletion! callset! for! subsequent!PCR! validation! experiments.! The! randomization! was! carried! out! by! randomly!picking,!without!replacement,!from!the!entire!list!of!generated!calls!for!each!SV!discovery! callset.! Duplicate! primers! between! different! callsets! were! removed,!yielding!91O96!loci!tested!per!callset.!!




of! alternative! amplicons!with! similar,! or! smaller! size.! Primer! pairs! generating!unique! amplicons!were! kept! and!used! in! the!PCR! experiments.! If! primer!pairs!generated!more! than! one! amplicon! at! the! given! size! (or! at! a! smaller! size),! as!judged! by! inOsilico! PCR,! the! primer! positions! were! masked! with! ‘N’s,! and! the!primer! design! pipeline! was! reOinitiated.! If! primer3! failed! to! identify! suitable!primers,!the!windows!for!primer!design!were!iteratively!increased!by!150!bp!on!either!side!of!the!inferred!SV.!
9.5.2.2 PCR,experimental,conditions,
!PCR! primers!were! synthesized! by! Sigma.! PCR!was! carried! out!with! JumpStart!REDAccuTaq! LA! DNA! polymerase! (SigmaOAldrich)! on! a! PTCO225! DNA! Engine!Tetrad!Cycler!(BioORad)!in!25!ul!reaction!volumes.!A!first!PCR!experiment!used!the! following! parameters! with! 10! ng! genomic! DNA! as! template.! Initial!denaturation!at!96°C!for!30!sec;!then!28!cycles!of!94°C!5!sec,!58°C!30!sec,!68°C!8!min;!followed!by!an!additional!cycle!of!68°C!for!30!min.!A!second,! independent!PCR! experiment! used! these! modified! conditions,! with! 20! ng! genomic! DNA! as!template.!Initial!denaturation!at!96°C!for!1min;!5!cycles!of!94°C!15!sec,!64°C!30!sec,!68°C!8!min;!5!cycles!of!94°C!15!sec,!62°C!30!sec,!68°C!8!min;!followed!by!22!cycles!of!94°C!15!sec,!60°C!30!sec,!68°C!8!min!and!an!additional!cycle!of!68°C!for!10!min.!All!PCR!products!were!run!on!1%!agarose!gels!for!2h!at!150V!for!band!visualization! and! compared! against! the! DNA! ladders! Hyperladder! I! and! IV!(Biolane).! Selected! PCR! reactions!were! repeated! and! capillary! sequenced!with!PCR!primers!from!both!ends.!
9.5.2.3 Analysis,of,PCR,validation,data,








reference! genome! at!more! than! 10! positions!were! discarded,! as!well! as! those!that!fell!below!an!arbitrary!minimum!score.!The!remaining!best!scoring!probes!for!each!region!were!then!utilized!up!to!the!maximum!considered.!!Custom! Agilent! 2x1M! arrayOCGH! DNA! microarrays! were! used! to! validate!deletions! in!25!selected!samples.!The!highOresolution!probe!design!allowed! for!the!direct!interrogation!of!probes!falling!into!predicted!SV!candidate!regions.!All!probeOlevel! data! from! the! array!were! normalized! using! the! default! settings! of!Agilent’s! Feature! Extraction! 10.10! software.! Probes! with! saturated! or! varied!reference! signal! intensity! across! arrayOCGH! experiments! were! masked! out! as!potentially!nonOspecific! or!noisy.! Such!probes!were! identified! if! the!mean! log2!reference! signal! intensity! was! >16! or! if! the! standard! deviation! of! these! log2!values! was! >0.6.! Additionally,! we! excluded! probes! with! high! reference! signal!intensity! and! low! log2Oratios! across! all! samples,! since! such!probes!were! likely!also!saturated!and!nonOspecific.!The!cutOoffs!used!for!the!identification!of!these!probes!were!derived!empirically!and!are!as! follow:!mean! log2!reference!signal!intensity!>10,!absolute!mean!log2Oratio!<0.4,!and!standard!deviation!of!the!log2Oratios!<0.25.!Log2Oratios!values!of!nonOmaskedOout!probes!were!normalized!by!GCOcontent!and!each!chromosome's!medianOshift.!Deletion!calls!containing!only!a!single! probe! postOfiltering! were! omitted! and! did! not! contribute! to! the! FDR!calculation.! For! each! other! deletion,!we! selected! a! subset! of! probes! that!were!deemed! the! most! suitable! to! validate! a! call.! This! step! was! necessary,! as! the!boundaries!of!some!calls!may!have!been!overestimated!resulting!in!the!incorrect!usage! of! distal! probes! that! would! be! inappropriate! for! a! call! validation.! We!estimated!that!optimal!probes!were!those!that!(i)!had!variable!log2O!ratios!across!the!samples,!which!would!reflect!copy!number!differences,!and!(ii)!whose!log2Oratios!were! correlated! in! probe!pairwise! comparisons,!which!would! indicate! a!coherent!signature!of!a!copy!number!variation.!Therefore,!for!each!deletion!call!probes!were!hierarchically! clustered!with! the!goals!of!maximizing!both!58! the!range!of!mean!log2Oratios!between!the!samples!as!well!as!the!average!pairwise!Pearson!correlation!of! the! log2Oratio!values!of!probes!clustered.!The!clustering!score!was!defined!as!the!product!of!the!first!factor!multiplied!by!the!second.!We!considered!a!cluster!of!probes!to!be!representative!for!a!call!if!it!contained!50%!or!more!postOfiltered!probes!and!if!the!average!pairwise!correlation!of!the!log2Oratio!values!was!>0.!If!none!of!the!clusters!met!these!two!requirements,!the!call!was!marked!as! "NA"!and!was!not!used! for! the!FDR!estimation.! If! two!or!more!clusters!of!probes!could!be!considered!as!representative,!all!such!clusters!were!used!independently!in!the!next!step!and!the!final!decision!as!to!which!was!most!optimal!was!determined!at!the!end!of!the!validation!process.!The!validation!was!performed! by! genotyping! each! locus! and! comparing! our! results!with! the! ones!provided!in!discovery!sets.!The!following!rules!were!applied!to!determine!copy!number!variations:!!
• If,!regardless!of!a!cluster!of!probes!used,!the!maximum!of!absolute!mean!log2Oratios!was! <0.5,!we! assigned! two! copies! to! all! samples,! unless! the!next!rule!was!true.!





• If!the!maximum!of!absolute!means!was!≥0.5,!sigmoid!transformations!of!the! means! were! modeled! by! kKmeans$ clustering! (with! k=2)! and! the!means,! within! each! cluster,! were! subjected! to! an! AndersonODarling!normality! test! (using! empirically! derived! alpha=0.01).! The! limited!number! of! samples! (25)! precluded! the!modeling! of! the! probes! at! each!locus!as!a!mixture!of!Gaussian!densities.!The!sigmoid!transformation,!also!known!as!a!hyperbolic!tangent!(tanh),!was!applied!to!reduce!the!influence!of!extreme!means!on!modeling,!while!the!AndersonODarling!test!was!used!to!avoid!the!modeling!of!nonnormal!densities.!Copy!number!states![1,!or!2]!were!assigned!respectively!to!the!samples.!
• If! the!range!of!mean! log2Oratios!was!≥1.0,! then!the!rule!above!was!used!but!with!k=3,!and![0,!1,!or!2]!copy!number!clusters!assignments.!
• If!two!or!more!alternative!models!were!created,!that!were!differed!by!the!
k$value!and/or!set!of!probes!used,!we!chose!as!the!most!likely!the!model!with! the! lowest! clustering! score.! The! clustering! score!was! defined! as! a!root! mean! square! deviation! of! tanh! mean! log2Oratios! from! the! cluster!centers.!!FDRs! were! calculated! perOsample! and! were! defined! as! the! number! of! false!discoveries! over! the! sum! of! false! and! correct! ones.! If! a! deletion! call! was!genotyped! by! us! as! a! homozygous! or! heterozygous! variant,! then! the! call! was!evaluated!as!a!true!discovery;!otherwise!we!marked!it!as!a!false!discovery.!
10 Analysis+
10.1 Quantifying+the+Phase+1+dataset+!




start! and! end! position! on! the! genome! with! any! CNVs! classified! as! human,!germline!SVs!in!dbVAR!(March,!2012).!
10.2 Assessment+of+power+of+variant+discovery+and+genotype+accuracy+!
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$The! assess! the!power! to!detect! variants! in!Phase!1,! individual! genotypes! from!Omni2.5M! SNP! array! are! compared! to! the! Phase! 1! integrated! genotypes.! The!power! is!defined!as! [#!variants!with!positive!1000!Genomes!variant! count]/[#!variants!with!positive!Omni2.5!variant! count],! grouped!by! the!Omni2.5!variant!count!among!1,092!individuals.!Whole!genome!power!was!evaluated!across!the!genome,!and!the!exome!power!was!evaluated!within!consensus!target!among!the!1,092!individuals.!The!resulting!estimates!are!show!in!Figure!1a.!!We! estimated! that! 98.3%! of! SNPs! for! each! individual! are! included! in! the!integrated! callset! by! comparing! with! OMNI2.5! genotypes.! This! estimate! was!obtained!by!first!estimating!the!expected!allele!frequency!spectrum!(AFS)!across!whole!genome!from!the!AFS!of!synonymous!variants!within!the!consensus!target!region,! after! adjusting! for! the! false! negative! rate! evaluated! by! OMNI2.5! (as!shown!in!Figure!1a).!We!then!calculated!the!perOindividual!SNP!discovery!rate!by!comparing! OMNI2.5! SNP! genotypes!with!whole! genome! integrated! genotypes,!weighted! by! the! ratio! of! expected! to! observed! wholeOgenome! AFS! across! all!possible!variant!count.!!To!estimate!genotype!accuracy,!the!squared!Pearson's!correlation!coefficient!(r2)!between!Omni2.5!array!genotypes! (observed!variant!count!per! individual)!and!the!genotype!dosages!(expected!variant!count!per!individual)!was!calculated!for!each! SNP! across! the! 1,092! individuals.! The! average! r2! value! (among! 1,092!individuals)!was!calculated!across!the!genome!(WGS),!and!within!the!consensus!target! (Exome).! The! genotype! dosages! were! calculated! from! the! posterior!probability! of! the! MaCH/Thunder! haplotyping! software! (with! LD),! or! from!posterior! probability! computed! from! genotype! likelihood! and! estimated! allele!frequency!(without!LD).!The!resulting!estimates!are!shown!in!Figure!1b.!
10.3 Variant+discovery+by+low+coverage+and+exome+sequencing+!
















mapping!quality!of!zero,!and! that! the!average!mapping!quality! for! the!position!should! be! 56! or! greater.! This! definition! is! quite! stringent! and! focuses! on! the!most!unique!regions!of!the!genome.!In!the!regions!that!are!marked!as!passed!by!this!mask,!only!~2%!of!sites!called!in!an!initial!analysis!are!marked!as!likely!false!positives!by!VQSR.!The!average!total!depth!of!coverage!across!Phase!I!samples!is!5132.!Thus,!sites!with!a!depth!of!coverage!of!<2566!or!>7698!were!excluded.!!Overall,!this!strict!mask!results!in!about!6.6%!of!bases!marked!N,!1.4%!marked!L,!0.9%!marked!H,!22.1%!marked!Z,!and!1.6%!marked!Q.!The!remaining!67.5%!of!passed!are!marked!passed!(P)!O!corresponding!to!72.2%!of!the!nonON!bases.!!Each!mask!is!summarized!in!both!a!FASTAOstyle!file!and!a!BEDOstyle!file,!which!are!available!for!download79.!!
10.5 Haplotype+estimation+from+OMNI+data+!






!To! evaluate! the! utility! of! the! Phase! 1! haplotypes! as! a! genotype! imputation!resource,! we! performed! crossOvalidations! in! external! datasets! genotyped!with!different! technologies.! We! measured! imputation! accuracy! at! SNPs,! short!insertion/deletion! polymorphisms! (indels),! and! large! deletions! from! the!reference!sequence!(structural!variants,!or!SVs).!




those! that! fall! within! consensus! target! regions! of! the! capture! arrays! used! for!Phase!1!exome!sequencing.!We!excluded!83!exome!SNPs!from!this!analysis!due!to!excess!heterozygosity! (inbreeding!statistic! less! than! O0.95!across!all!Phase!1!individuals),! which! is! a! hallmark! of! spurious! variants! caused! by! segmental!duplications!that!are!not!present!in!the!reference!sequence.!!Our! initial! results!showed!that! the!apparent! imputation!accuracy!of! indels!was!consistently! lower! than! that! of! SNPs.! Comparisons! with! arrayObased! indel!genotypes! suggest! that! this! effect! is! driven! by! the! difficulty! of! calling! indel!genotypes!from!short!sequence!reads!in!both!the!Phase!1!and!CGI!datasets!(data!not!shown).!To!generate!a!comparison!set!enriched!for!variants!that!were!called!well! in!both!datasets,!we!restricted!the! indel!results! to!sites!not! located!within!the!Phase!1!sequence!mask.!










Authors:$Adam$Auton$and$Gil$McVean!!To!generate!Figure!2b,!we!extracted!the!alternative!allele!counts!for!all!variants!in!the!Phase!1!release.!For!each!variant,!we!also!calculated!the!alternative!allele!count! in! each! population! or! continental! grouping! (AFR:!ASW,! LWK,! YRI;! AMR:!CLM,!MCL,!PUR;!ASN:!CHB,!CHS,! JPT;!EUR:!CEU,!FIN,!GBR,!TSI).!Using!this!data,!we! determined! if! the! alternative! allele! was! private! to! a! specific! population! /!continent,!or!shared!across!multiple!populations!or!continents!(‘cosmopolitan’).!!Figure!2b!shows!the!fraction!of!sites!restricted!to!single!populations/groups!and!the!fraction!shared!across!each!group/population.!!Because!rare!variants!will!(whatever!the!true!degree!of!differentiation)!typically!be! found!in!only!one!or!a! few!populations,!we!also!calculated!a!metric!of!allele!sharing! within! and! between! populations! that! can! detect! the! excess! of!differentiation! relative! to! chance.! ! Specifically,! we! compute,! for! each! group! of!populations,! the! probability! of! sampling! (without! replacement)! two!chromosomes!carrying!the!variant!allele!if!the!chromosomes!are!drawn!from!the!same! population! (weighted! by! the! number! of! sampleOpairs! within! each!population).! ! This! is! divided! by! the! probability! of! sampling! (without!replacement)! two!chromosomes!carrying!the!variant!allele! if! the!chromosomes!are! drawn! from! the! entire! pool! of! populations.! ! If! the! number! of! copies! of! an!allele!in!population!i$is!ai,!the!number!of!haploid!genomes!in!that!population!is!ni,!the!total!number!of!copies!of!the!allele!across!the!group!is!a!and!the!total!number!of!haploid!genomes!is!n,!then!the!statistic!is!! ! = !!(!!!!)!!!(!!!!)! / !(!!!)!(!!!) .!For!a!given!value!of!a,! the!statistic! is!averaged!over!all!sites! in!which!the!allele!count! in! the!group! is!a.! !This! statistic!was!used! to! calculate! the!excess! sharing!shown! in! Figure! S6a.! ! The! statistic! can! also! be! computed! between! groups! (by!pooling! all! sampling!within! a! group),! to! give! the!black! line! in!Figure!S6a.! !The!statistic!can!also!be!computed!for!a!single!population:!! !! = !!(!!!!)!!(!!!!) / !(!!!)!(!!!) .!Again,! the! statistic! can!be!averaged!over! all! sites!where! the!allele! count! in! the!wider!group!is!a.!!These!plots!are!shown!in!Figure!S6b.!
10.8 Density+of+variants+as+a+function+of+derived+allele+frequency+!






Authors:$ Vincenza$ Colonna,$ Yali$ Xue,$ Yuan$ Chen,$ Qasim$ Ayub,$ and$ Chris$ TylerK
Smith*$
$
*$Corresponding$Author$!Derived! allele! frequencies! (DAF)! were! calculated! for! each! population! or!continent! using! data! from! the! final! integrated! call! set.! Continents! were! AFR:!ASW,! LWK,! YRI;! ASN:! CHB,! CHS,! JPT;! EUR:! CEU,! FIN,! GBR,! TSI.! We! excluded!populations!with! small! sample! size! (IBS)! and! extensive! admixture! (CLM,!MXL,!PUR).!For!each!pair!of!populations!or!continents!ΔDAF!was!calculated! for!each!SNP!as!the!absolute!difference!between!DAFs!in!each!population!or!continent.!!!!Highly! differentiated! (HD)! sites! tend! to! cluster! in! the! genome.!However,!most!likely!only!one!or!a!few!SNPs!in!each!cluster!have!functional!consequences!that!have! driven! the! observed! extreme! differentiation.! Therefore,! from! the! highest!1%! of! each! ΔDAF! distribution! a! subset! of! sites! was! chosen! according! to! two!criteria:!each!SNP!is!the!most!highly!differentiated!SNP!in!every!1000!SNPs!from!nonOoverlapping!chromosome! intervals,!and! it!must!have!ΔDAF!≥!0.7!or!≥!0.25!for! continental! and! population! comparisons,! respectively.! The! filtered! subset!should!be!enriched!for!sites!with!functional!consequences,!and!depleted!of!sites!that!do!not!contribute!directly!to!the!phenotype.!








$In!Figure!3a,!we!investigated!patterns!of!allele!sharing!for!variants!with!very!low!frequencies.! Specifically,!we! identified! all! variants!with! a!minor! allele! count! of!exactly! 2! across! the! entire! Phase! 1! sample,! corresponding! to! a! frequency!estimate! of! 0.09%.! We! refer! to! these! as! f2! variants.! For! each! f2! variant,! we!tabulated!the!populations!in!which!the!two!copies!of!the!variant!were!contained,!allowing! estimation! of! the! relative! proportion! of! rare! allele! sharing! between!populations.!!Figure!3a!summarises!the!results!in!a!graphical!form.!
10.11 Shared+haplotype+length+as+a+function+of+allele+frequency+!














sites!(therefore,!the!children!of!each!trio!had!nonOnegligible!quantity!of!missing!data).! Finally,! local! ancestry! tracts! were! called! by! each! method! for! both!haplotypes! of! each! chromosome! per! admixed! individual! using! default!parameters!except!where! indicated;! (i)!LAMPOLD86!using!S=25!and!W=100,! (ii)!HAPMIX87!with!two!reference!panels!for!ASW!individuals!and!a!extended!version!of! HAPMIX! with! three! reference! panels! for! MXL,! PUR! and! CLM! (iii)! RFMIX! a!discriminative!model!based!on!conditional!random!fields!using!windows!of!100!SNPs!and!(iv)!MULTIMIX.!!!In!order!to!generate!the!set!of!consensus!calls,!the!perOchromosome!haplotypes!were! collapsed! at! each! genotyped! site! (Affy6! or! OMNI! 2.5M)! to! give! single!diploid! call!per! site! (probabilistic! calls!were! rounded! to!0!or!1)! in!all! admixed!individuals!across!all!four!methods.!Diploid!calls!were!generated!to!avoid!errors!in!haploid!calls!due!to!switch!errors!in!phasing.!Calls!across!four!methods!were!compared!at!every!site!to!generate!the!‘high!accuracy’!consensus!calls;!where!3!or! 4! of! the!methods! agreed,! the!majority! call!was! set! as! the! consensus! call,! if!there!was!a!tie,!3O!or!4Oway!disagreement!between!methods,!the!site!was!set!to!‘unknown’.! Sequential! diploid! calls! along! chromosomes!were! collapsed! to! give!diploid!call!tracts!of!base!pair!length!the!distance!between!the!first!and!last!SNP!in!the!tract.!Base!pairs!between!the!SNP!at!the!end!of!one!tract!and!the!first!SNP!at! the! beginning! of! the! next! tract!were! labeled! ‘undetermined’.! Regions! at! the!start!and!end!of!each!chromosome! flanking! the! first!and! last!SNP!sites!used! in!the! calling! are! also! listed! as! ‘undetermined’.! Global! proportions! of! European,!African,! or! Native! American! ancestry! in! ASW,! MXL,! PUR! and! CLM! admixed!individuals!and!the!proportion!called!as!‘unknown’!were!calculated!by!averaging!over! all! diploid! ancestry! called! tracts! (excluding! ‘undetermined’! tracts;! Figure!S9a).!!Once! local! ancestry! assignments! have! been! performed,! we! obtained! the!proportion! of! novel! SNPs,! heterozygous! sites,! and! nonsynonymousOtoOsynonymous! ratio! at! nonOreference! sites! as! a! function! of! the! diploid! ancestry!(AFR/AFR,! AFR/EUR,! NAT/NAT! etc.).! The! proportion! of! heterozygous! sites! in!each!ancestry!category! (Figure!S9b)!was!calculated!among!sites!with!sufficient!data!and!passed!quality!filters!(specifically!using!the!PilotOstyle!mask!described!in!section!10.4)79.!The!proportion!of!novel!SNPs! in!each!population!(Figure!3c)!was!calculated!with!respect!to!the!list!of!SNPs!in!dbSNP!version!135!but!pruned!for! SNPs! that!were! previously! discovered! and! reported! by! the! 1000! Genomes!Project.! Finally,! the! rate! of! nonsynonymousOtoOsynonymous! SNPs! in! each!ancestry! category! (Figure! S9c)! was! calculated! over! all! sites! that! were! not!homozygous!for!the!reference!allele.!





Author:$Adam$Auton$!We!estimated!FST!for!each!pairwise!population!comparison!for!both!the!Weir!and!Cockerham90! and! the! HapMap91! estimators.! This! was! achieved! by! using!VCFtools37! for! each! autosome! separately.! For! a! given! estimator,! the! estimates!were!very!similar!for!each!chromosome,!and!we!therefore!calculated!a!combined!estimate! by! averaging! the! perOchromosome! values.! The! results! are! shown! in!Supplementary! Table! S11.! Although! the! two! estimators! provide! different!estimates,! the! relative! ordering! of! pairwise! comparisons! is! largely! consistent,!with!the!exception!of!the!IBS!population,!which!has!a!small!sample!size!in!Phase!1.!These!estiamtes!can!be!demonstrated!by!the!removal!variants!with!MAF!<!5%!in!the!combined!sample!resulting!in!significantly!different!estimates!(also!shown!in!Table!S11).!
10.13.2 Hudson+ratio+of+averages+!
Authors:$Gaurav$Bhatia,$Nick$Patterson,$Alkes$L.$Price$!We!computed!FST!estimates!using!the!definition!of!Hudson!et!al.92,!equivalent!to!an!earlier!definition!of!Nei93.!!Estimates!were!computed!using!a!ratio!of!averages,!as! opposed! to! an! average! of! ratios94.! ! Results! are! displayed! in! Table! S11.! In!sequencing!data!with!many!rare!variants,!discrepancy!between!approaches! for!calculating!FST!can!become!very!large,!as!rare!populationOprivate!SNPs!with!low!FST! will! cause! large! decreases! in! FST.!We! recommend! that! estimates! of! FST! be!computed!using! the! ratio!of!averages!approach94,! as! this!approach! is! robust! to!the!inclusion!of!rare!variants.!!
10.14 Quantifying+potentially+functional+variants+in+the+Phase+1+dataset+!For! the! analysis! presented! in! Table! 2,! we! calculated! the! average! number! per!individual! of! variant! sites! belonging! to! different! potentially! functional! classes!(detailed! in! the! following! sections),! based! on! sites! discovered! in! the! low!coverage! genomeOwide! sequence! data.! These! numbers! are! expressed! as! the!mean! per! population,! and! the! population! range! is! given.! Numbers! are! broken!down!into!rare!(<0.5%),!low!frequency!(0.5O5%),!and!common!(>5%)!according!to!global!derived!allele!frequency!in!the!Phase!1!samples.!
10.14.1 Coding+variant+classes+!
Authors:$Yali$Xue,$Yuan$Chen,$Suganthi$Balasubramanian,$Lukas$Habegger,$Mark$




Two!sets!of!numbers!were!calculated:!one!for!all!sites,!and!a!second!for!sites!with!GERP!score!>2,!except!for!indels!where!GERP!scores!are!not!available!and!lossOofOfunction! (LoF)!variants!which!were!considered!damaging! irrespective!of! the!GERP! score! of! the! variant! nucleotide(s).! Potential! LoF! variants! received!additional!annotation!and!curation,!described!below.!
10.14.2 Identification+and+filtering+of+lossKofKfunction+variants+!
Authors:$Daniel$MacArthur,$Suganthi$Balasubramanian,$Mike$Jin,$Adam$Frankish,$




In!addition!to!applying!these!criteria!to!all!candidate!LoF!variants,!we!manually!inspected! the! annotation! evidence! supporting! all! novel! LoF! variants! with! a!global! allele! frequency! above! 5%,! and! removed! those! with! poor! transcript!support,! or! for! which! other! criteria! supporting! an! annotation! artifact! were!observed!(manual_annot).!
10.14.3 HGMDKDM+and+COSMIC+SNPs+!
Authors:$Yali$Xue,$Yuan$Chen,$Qasim$Ayub,$Edward$V.$Ball,$Peter$D.$Stenson,$David$
N.$Cooper,$and$Chris$TylerKSmith$!The!set!of!SNPs!overlapping!between!1000!Genomes!Phase!1!and!the!HGMD!DM!(Damaging! Mutation)! class! (HGMD96! version! 2010.4)! or! the! COSMIC97! base!substitutions! (v56)! were! picked! based! on! correspondence! between! the!chromosome!coordinate!and!allele.!The!overlapping! sets!of! variants!were! then!filtered!by!GERP!score!>2.!!!
10.14.4 NonKcoding+variant+classes+!
Authors:$Xinmeng$Jasmine$Mu,$Ekta$Khurana,$Yali$Xue,$Yuan$Chen,$Arif$Harmanci,$
Cristina$Sisu,$Chris$TylerKSmith,$and$Mark$Gerstein!!The! following! nonOcoding! variant! categories! were! included:! UTRs! (5’! and! 3’),!nonOcoding!RNAs!(lincRNA,!miRNA,!miscRNA,!rRNA,!snoRNA,!snRNA),!motif!gain!in!TF!peak,!and!motif!loss!in!TF!peak.!The!categories!are!based!on!the!nonOcoding!annotations! derived! from! the! GENCODE65! v7! and! ENCODE! Integrative! paper!release66,67.!The!counts!are!redundant!O!i.e.!no!hierarchy!was!used!and!a!variant!was!counted!multiple!times!if!it!received!multiple!annotations.!!!The! motif! gain! and! loss! analysis! investigated! SNPs! that! fall! into! TFObinding!motifs!for!the!121!TFs!assayed!by!ChIPOseq!experiments!in!the!ENCODE!project.!Data! from! all! cell! types! were! used! for! this! analysis.! The! motif! gain! variant!category!is!defined!as!a!SNP!whose!derived!allele!has!a!higher!frequency!in!the!Position!Weight!Matrix!(PWM)!of!the!bound!motif!than!the!ancestral!allele;!the!motif!loss!variant!category!is!defined!as!a!SNP!whose!derived!allele!has!a!lower!frequency!in!the!PWM!of!the!bound!motif!than!the!ancestral!allele.!!!All!nonOcoding!variant!numbers!were!calculated!for!all!variants!and!for!variants!with!GERP!>2.!
10.14.5 Other+conserved+variants+!
Authors:$Yali$Xue,$Yuan$Chen,$Xinmeng$Jasmine$Mu,$Ekta$Khurana,$Mark$Gerstein,$





Author:$Tuuli$Lappalainen$!Figure! 4a! shows! the! correlation! between! evolutionary! conservation! and! allele!frequency! in!different! functional!annotation!categories.!This!analysis!was!done!on! SNPs! found! in! the! low! coverage!data! to!have! comparable!data! from!coding!and! nonOcoding! variants.! Conservation! of! the! SNP! sites! was! measured! by! the!mammalian! GERP! score98.! Derived! allele! frequency! was! calculated! across! the!entire!sample,!and!the!plot!shows!the!proportion!of!sites!with!frequency!<!0.5%.!Sites! without! GERP! score! or! ancestral! allele! information! were! excluded.! The!functional!annotation!is!described!in!Section!8.1;!additionally,! the!null!category!consists!of!2!million! random! low!coverage!SNP!sites! that!do!not!belong! to!any!annotation! category.! In! the! figure,! the! lines! represent!medians! of! bins! of! size!adjusted!according!to!the!number!of!SNPs!in!each!annotation!category,!with!75%!overlap!between!adjacent!bins.!The!crosses!adjacent!to!the!axes!show!the!overall!medians!of!the!annotation!categories.!
10.16 Estimation+of+excess+nonsynonymous+variants+in+KEGG+pathways+!
Author:$Adam$Auton$!Gene!pathways!were!obtained!from!the!KEGG!database99.!We!selected!pathways!with!more! than!5!genes,! giving!a! total!of!186!pathways.!For!each!pathway,!we!estimated!the!number!nonsynonymous!(NSyn)!SNPs!to!synonymous!(Syn)!SNPs,!separately! for! SNPs!with!minor! allele! frequency! >! 0.5%! and! <! 0.5%.! For! each!pathway,! we! estimated! the! excess! of! NSyn! SNPs! at! low! frequencies! by!calculating:!!Excess!rare!NSyn!=!#NSynMAF<0.5%!O!(#SynMAF<0.5%!x!#NSynMAF>0.5%!/!#SynMAF>0.5%)!!This!formula!provides!an!estimate!of!the!excess!number!of!rare!nonsynonymous!SNPs!on!the!basis!of!the!number!expected!from!the!NSyn/Syn!ratio!of!common!SNPs.!!The!resulting!estimates!are!compared!to!the!conservation!GERP!score98!in!Figure!S11,!and!Table!S13.!
10.17 Nucleotide+diversity+around+CTCF+binding+motifs+!




identify!an!identical!motif!outside!of!a!peak!(without!replacement).!This!could!be!achieved!for!17,485!motifs!(97.3%).!!We! identified! the! SNPs! at! every! base! in! each! motif,! and! summed! across! all!motifs,!with!the!resulting!plot!shown!in!Figure!4c,!partitioned!by!SNP!frequency.!Motifs!contained!within!CTCFObound!regions!show!lower!levels!of!polymorphism!than!those!outside!of!these!regions,!and!the!SNPs!within!CTCFObound!motifs!tend!to!be!less!common!than!those!outside!binding!sites,!indicating!an!increased!level!of!constraint!on!CTCFObound!loci.!!!
10.18 Population+differentiation+of+functional+SNPs+!
Authors:$Adam$Auton$and$Gil$McVean$!To!produce!Figure!S13,!we! first!partitioned!variants!on!the!basis!of! their!allele!count!within!each!population.!!For!each!alleleOcount!within!each!population,!we!estimated!FST! to! all! other!populations!using! just! nonsynonymous!variants,! and!separately!using! just! synonymous!variants.! !We! then!plotted! the!proportion!of!estimates!with!a!larger!nonsynonymous!estimate!as!a!function!of!allele!count!in!the!target!population.!!Although!estimates!of!FST!are!sensitive!to!allele!frequency,!we! do! not! expect! nonsynonymous! and! synonymous! sites! (which! are! also!interleaved)!to!show!systematic!differences!in!differentiation!unless!selection!is!operating! differently! on! the! different! variant! types.! ! The! systematically! higher!differentiation! of! nonsynonymous! variants! at! low! frequencies! is! therefore!consistent! with! the! effects! of! purifying! selection.! ! At! higher! frequencies! the!difference! between! nonsynonymous! and! synonymous! variants! decreases,!perhaps!because!higherOfrequency!nonsynonymous!variants!are!less!likely!to!be!under!strong!purifying!selection!than!rarer!ones.!
10.19 Variants+in+linkage+disequilibrium+with+focal+GWAS+SNPs+!





Author:$Klaudia$Walter$!The!UK10K!project,!a!collaboration!between!the!Wellcome!Trust!Sanger!Institute!and! multiple! research! centres! in! the! UK! and! Finland,! aims! to! research! the!relationship!between!genetic!variants!of!a!broad!frequency!range!and!measures!of!health!and!disease!status!in!a!variety!of!study!designs!using!4,000!whole!lowOcoverage!genomes!and!6,000!highOcoverage!exomes.!!The! December! 2011! UK10K! release! (RELO2011O12O01)! contains! 2432! lowOcoverage!genomes.!The!percentage!of!variable!sites!shared!between!this!UK10K!release!and!the!Phase!1!release!of!the!1000!Genomes!Project!is!46.0%!at!a!minor!allele! frequency! (MAF)!of! 0.1%,!95.8%!at!1%!and!97.7%!at!5%.!The!MAF!was!estimated! from! the! allele! counts! in! the! UK10K! data,! and! the! percentage! was!computed!for!each!reported!MAF!allowing!a!small!range!of!+/O!10%.!!
10.21 Comparison+of+1000+Genomes+Phase+1+to+SardiNIA+study+!
Author:$Goncalo$Abecasis!!The!SardiNIA!Medical!Sequencing!Discovery!Project!is!a!study!of!the!genetics!of!ageOrelated! traits! including! blood! lipid! levels! and! personality! in! a! Sardinian!population!cohort.!As!of! June!2012,! the!genomes!of!2120! individuals!had!been!sequenced!to!3.5X!coverage!by!this!project!at!the!CSR4!research!institute,!in!Pula,!Sardinia,!and!at!the!University!of!Michigan.!Samples!have!been!sequenced!using!Illumina!GAII!and!HiSeq!2000!instruments!with!100!O!120!bp!pairedOend!reads.!!We! performed! a! comparison! of! the! SardiNIA! dataset! to! the! 1000! Genomes!Project!Phase!1!release.!Sites!within!the!‘populationOgenetics!mask’!(see!Section!10.4:! chosen! so! as! to! minimize! the! effects! of! betweenOproject! differences! in!variant!detection!algorithms)!with!variants!at!minor!allele!frequency!of!0.1%!in!the!SardiNIA!study!were!also!variable!in!the!1000!Genomes!dataset!23.7%!of!the!time,! rising! to! 76.9%! and! 99.3%! for! variants! with! MAF! of! 1.0%! and! 5.0%!respectively.!!!
11 Accessing+1000+Genomes+data+!






A!description!of!the!FTP!structure!can!be!found!in!the!README!file!contained!in!the!topOlevel!directory.!!Tutorials! explaining! recommended! methods! for! accessing! and! using! the! data!have! been! made! available! at:! http://www.1000genomes.org/usingO1000OgenomesOdata!!!Finally,! support! for! using! the! 1000! Genomes! Project! data! can! be! obtained! via!email:!info@1000genomes.org!
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Table S1    Low-coverage sequence coverage
Population Platform Sample Number Total Raw Base Pairs Total Base Pairs Mapped Base Pairs
Estimated Mean 
Coverage (*)
ASW ILLUMINA 50 1,089,813,717,972            968,854,526,076               860,327,970,070               6.07
ASW SOLID 11 500,286,849,800               342,449,243,700               216,331,285,800               6.94
ASW all 61 1,590,100,567,772            1,311,303,769,776            1,076,659,255,870            6.22
CEU ILLUMINA 79 1,502,960,787,784            1,294,604,937,320            1,094,649,530,588            4.89
CEU LS454 13 146,488,692,190               131,480,819,959               98,961,124,472                 2.68
CEU all 85 1,649,449,479,974            1,426,085,757,279            1,193,610,655,060            4.95
CHB ILLUMINA 81 1,265,574,070,165            1,134,008,661,926            984,021,701,292               4.28
CHB SOLID 16 630,769,366,650               417,614,608,100               244,511,888,650               5.39
CHB all 97 1,896,343,436,815            1,551,623,270,026            1,228,533,589,942            4.47
CHS ILLUMINA 92 1,418,189,794,341            1,299,646,744,020            1,071,501,746,928            4.11
CHS SOLID 8 200,584,536,300               128,336,437,000               84,922,544,700                 3.74
CHS all 100 1,618,774,330,641            1,427,983,181,020            1,156,424,291,628            4.08
CLM ILLUMINA 50 1,081,008,434,634            997,880,714,716               809,514,266,283               5.71
CLM SOLID 10 499,995,107,550               326,310,219,800               205,501,075,700               7.25
CLM all 60 1,581,003,542,184            1,324,190,934,516            1,015,015,341,983            5.97
FIN ILLUMINA 75 1,138,524,186,998            1,044,187,677,032            836,323,008,056               3.93
FIN SOLID 18 608,575,692,700               445,003,405,050               293,354,088,000               5.75
FIN all 93 1,747,099,879,698            1,489,191,082,082            1,129,677,096,056            4.28
GBR ILLUMINA 70 1,215,027,872,642            1,101,288,886,042            824,982,280,523               4.16
GBR SOLID 19 746,168,251,800               525,113,156,350               340,810,710,650               6.33
GBR all 89 1,961,196,124,442            1,626,402,042,392            1,165,792,991,173            4.62
IBS ILLUMINA 6 91,768,475,800                 86,301,704,300                 79,602,973,565                 4.68
IBS SOLID 8 365,162,926,050               240,650,750,400               160,414,631,900               7.07
IBS all 14 456,931,401,850               326,952,454,700               240,017,605,465               6.05
JPT ILLUMINA 78 1,934,078,557,132            1,700,345,329,015            1,396,406,178,908            6.31
JPT SOLID 11 469,831,458,750               312,859,319,500               180,345,872,950               5.78
JPT all 89 2,403,910,015,882            2,013,204,648,515            1,576,752,051,858            6.25
LWK ILLUMINA 83 1,618,796,704,250            1,488,826,665,046            1,308,949,191,963            5.56
LWK SOLID 14 632,314,850,250               430,833,584,700               236,644,976,100               5.96
LWK all 97 2,251,111,554,500            1,919,660,249,746            1,545,594,168,063            5.62
MXL ILLUMINA 54 1,092,715,400,556            1,013,311,530,884            863,106,820,709               5.64
MXL SOLID 12 541,920,312,100               372,689,964,700               232,992,623,250               6.85
MXL all 66 1,634,635,712,656            1,386,001,495,584            1,096,099,443,959            5.86
PUR ILLUMINA 52 1,201,929,599,317            1,089,276,083,789            807,903,247,949               5.48
PUR SOLID 3 54,314,001,150                 40,579,894,850                 29,324,996,900                 3.45
PUR all 55 1,256,243,600,467            1,129,855,978,639            837,228,244,849               5.37
TSI ILLUMINA 98 1,432,811,860,807            1,333,997,141,749            1,234,369,684,334            4.44
TSI all 98 1,432,811,860,807            1,333,997,141,749            1,234,369,684,334            4.44
YRI ILLUMINA 76 1,422,168,538,822            1,237,450,311,835            1,060,031,524,163            4.92
YRI SOLID 12 534,037,533,950               349,126,967,950               193,688,013,900               5.69
YRI all 88 1,956,206,072,772            1,586,577,279,785            1,253,719,538,063            5.02
Total ILLUMINA 944 17,505,368,001,220          15,789,980,913,750          13,231,690,125,331          4.94
Total LS454 13 146,488,692,190               131,480,819,959               98,961,124,472                 2.68
Total SOLID 142 5,783,960,887,050            3,931,567,552,100            2,418,842,708,500            6.01
Total all 1092 23,435,817,580,460         19,853,029,285,809         15,749,493,958,303         5.09
* Assuming an accessible genome of 2.84Gb
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Table S2    Exome sequence coverage
Population Platform Sample Number Total Base Pairs Mapped Base Pairs Mapped to Target
Estimated Mean 
Coverage in Target (*)
ASW ILLUMINA 49 481,145,063,324             364,701,630,723             104,015,041,744           72.14
ASW SOLID 9 132,601,206,696             98,844,286,498               12,777,136,555             48.25
ASW all 58 613,746,270,020             463,545,917,221             116,792,178,299           68.43
CEU ILLUMINA 55 781,710,583,271             611,783,336,621             162,444,963,408           100.37
CEU SOLID 26 548,672,944,700             382,456,472,127             50,535,591,941             66.05
CEU all 81 1,330,383,527,971          994,239,808,748             212,980,555,349           89.36
CHB ILLUMINA 70 811,460,564,028             656,573,012,363             208,394,101,425           101.17
CHB SOLID 23 381,992,713,440             280,204,262,734             37,342,955,772             55.18
CHB all 93 1,193,453,277,468          936,777,275,097             245,737,057,197           89.79
CHS ILLUMINA 90 857,138,087,206             714,503,886,102             251,302,974,303           94.89
CHS SOLID 10 156,047,716,700             114,921,715,511             14,521,688,209             49.35
CHS all 100 1,013,185,803,906          829,425,601,613             265,824,662,512           90.34
CLM ILLUMINA 41 431,647,861,041             335,038,858,436             93,040,137,384             77.12
CLM SOLID 19 297,290,521,550             213,373,947,718             27,039,889,718             48.36
CLM all 60 728,938,382,591             548,412,806,154             120,080,027,102           68.01
FIN ILLUMINA 75 716,066,832,301             584,073,449,816             199,492,310,600           90.39
FIN SOLID 17 270,302,462,280             199,112,568,168             25,641,811,876             51.26
FIN all 92 986,369,294,581             783,186,017,984             225,134,122,476           83.16
GBR ILLUMINA 60 771,096,882,996             602,232,267,940             169,836,973,098           96.19
GBR SOLID 26 443,801,705,735             318,174,886,647             44,696,071,194             58.42
GBR all 86 1,214,898,588,731          920,407,154,587             214,533,044,292           84.77
JPT ILLUMINA 68 964,872,725,317             748,071,660,429             237,137,258,342           118.51
JPT SOLID 19 376,101,495,295             274,988,883,452             33,233,029,976             59.44
JPT all 87 1,340,974,220,612          1,023,060,543,881          270,370,288,318           105.61
LWK ILLUMINA 24 303,943,651,024             228,078,920,282             74,710,024,695             105.79
LWK SOLID 62 987,305,907,096             740,239,916,698             91,749,291,260             50.29
LWK all 86 1,291,249,558,120          968,318,836,980             166,459,315,955           65.78
MXL ILLUMINA 54 572,707,204,495             429,456,560,453             114,487,895,932           72.05
MXL SOLID 11 164,258,975,400             123,917,538,096             15,551,396,516             48.04
MXL all 65 736,966,179,895             553,374,098,549             130,039,292,448           67.99
PUR ILLUMINA 48 890,850,110,179             679,446,353,545             161,346,605,090           114.23
PUR all 48 890,850,110,179             679,446,353,545             161,346,605,090           114.23
TSI ILLUMINA 60 701,190,245,690             547,862,286,112             157,297,411,348           89.09
TSI SOLID 35 585,031,422,890             413,598,481,830             62,757,299,612             60.93
TSI all 95 1,286,221,668,580          961,460,767,942             220,054,710,960           78.72
YRI ILLUMINA 71 1,066,578,885,883          826,820,770,280             243,135,647,582           116.37
YRI SOLID 17 304,701,577,167             220,513,527,517             26,860,376,444             53.69
YRI all 88 1,371,280,463,050          1,047,334,297,797          269,996,024,026           104.27
Total ILLUMINA 765 9,350,408,696,755          7,328,642,993,102          2,176,641,344,951       96.69
Total SOLID 274 4,648,108,648,949          3,392,004,935,418          442,706,539,073           54.91
Total all 1039 13,998,517,345,704       10,720,647,928,520       2,619,347,884,024       85.67
* Assuming a exome target size of 29.4Mb
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Table S3    Samples with OMNI 2.5M genotypes available, phased using family data available
POP # duos # trios # unrelateds Total samples
ACB 2 21 31 98
ASW 20 12 21 97
CDX 0 0 100 100
CEU 0 2 98 104
CHB 0 0 100 100
CHD 0 0 1 1
CHS 0 50 0 150
CLM 1 34 3 107
FIN 0 0 100 100
GBR 1 0 99 101
GIH 0 0 93 93
IBS 1 48 1 147
JPT 0 0 100 100
KHV 2 19 57 118
LWK 1 0 98 100
MKK 0 0 31 31
MXL 1 29 11 100
PEL 0 34 2 104
PUR 0 35 6 111
TSI 0 0 100 100
YRI 13 43 6 161
Total 84 981 1058 2123
Note this includes samples beyond Phase1 (and not all Phase 1 samples)




Table S4    Low-coverage SNP validation
Total True SNP False SNP No call FDR (%) No call rate (%)
Total 287 276 5 6 1.8 2.1
Singletons 70 65 3 2 4.4 2.9
MAF<0.01 134 131 2 1 1.5 0.7
0.01<MAF<0.05 33 33 0 0 0 0
MAF>0.05 50 47 0 3 0 6
Results for each SNP can be found at
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/experimental_validation/snps/  
A total of 287 SNP sites were included in the final SNP validation results.  True and false SNPs are those 
confirmed or rejected by the consensus of the four validation experiments.  “No call” SNPs did not 
produce a reliable result in any of the validation experiments.  The false discovery rate (FDR) is calculated 
by dividing the number of false SNPs by the sum of the true and false SNPs.  The no call rate is the no call 
SNPs divided by the total SNPs.  The data has also been split by minor allele frequency (MAF).  The 
MAF<0.01 category does not include singleton SNPs.
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Table S5    Exome SNP validation
Novel exome consensus SNP validation
Total True SNP False SNP No call FDR (%) No call rate (%)
Total 200 185 3 12 1.6 6
singleton 100 92 1 7 1.1 7
AF < 1% 50 47 2 1 4.1 2
AF > 1% 50 46 0 4 0 8
Novel 100 84 2 14 2.3 14
Center-unique exome SNP validation
Illumina
BC Unique 28 74 20 2 4 14 67% 70
BCM Unique 77 157 20 13 5 2 28% 10
UM Unique 175 74 20 13 1 6 7% 30
SOLiD
BC Unique 63 28 17 6 7 4 54% 23.5
BCM Unique 238 200 20 4 14 2 78% 10
UM Unique 83 117 20 0 16 4 100% 20
Results for each SNP can be found at
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/experimental_validation/snps/ 
A total of 417 SNP sites were included in three exome SNP validation experiments. Table S5a shows the validation results of 
exome consensus SNPs stratified by allele frequency and novelty.  The AF<0.01 category does not include singleton SNPs.  SNPs 
are considered novel if they are not found in the low coverage SNP call set or in dbSNP135.  Table S5b shows the results of 
different centers’ unique exome SNP calls that were not included in the exome consensus set. In both tables, true and false 
SNPs are those confirmed or rejected by PCR-Roche 454 validation.  “No call” SNPs did not produce a reliable result in the 
validation experiment.  The false discovery rate (FDR) is calculated by dividing the false SNPs by the sum of the true and false 
SNPs.  The no call rate is the no call SNPs divided by the total SNPs.  








True SNP False SNP No call
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Table S6.  Low-coverage INDEL validation summary
Total True INDEL False INDEL No call FDR (%)






Total 93 49 27 17 35.5 18.3 12.5 5.4
MAF<0.01 15 4 10 1 71.4 7.1 13.8 8.1
0.01<MAF<0.10 36 22 6 8 27.3 22.2 12.1 5.2
MAF>0.10 42 23 11 8 32.4 19 12.2 3.7
Individual results for each indel can be found at
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/experimental_validation/indels/
A list of indel sites excluded in the post-hoc filtering can be found at
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/supporting/excluded_indel_sites/
A total of 93 INDEL sites were included in the INDEL validation study.  True and false SNPs are 
those confirmed or rejected by the consensus of the three validation experiments.  “No call” SNPs 
did not produce a reliable result in any of the validation experiments (some were not amplified by 
PCR, others did not produce reliable sequencing calls).  The false discovery rate (FDR) is calculated 
by dividing the number of false INDELs by the sum of the true and false INDELs.  The no call rate is 
the number of no call INDELs divided by the total number of INDELs.  AFFY-FDR-BEFORE-SVM and 
AFFY-FDR-AFTER-SVM are the estimated false discovery rate before and after applying SVM 
filtering calculated as a proportion of monomorphic sites genotyped in Affymetrix Exome Array. 
The data has also been split by minor allele frequency (MAF).
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Selection criterion for 
promotion to discovery set
Number in 
discovery set
Inferred FDR of discovery 
set
Omni 2.5 PCR Array CGH
BreakDancer 20,388 14.1% 12.0% 13.9% calls validated by Omni 2.5 5,914 1% (assumed)
n=6,959 n=75 n=11,417 (p < 0.01)
CNVnator 20,062 74.1% 29.6% 1 38.2% calls validated by Omni 2.5 2,084 1% (assumed)
n=5,097 n=27 n=58,293 (p < 0.01)
Delly 38,758 57.2%  0.0% 2 15.9% calls validated by Omni 2.5 5,073 1% (assumed)
n=10,822 n=78 n=4,092 (p < 0.01)
Genome STRiP 18,912 1.5% 2.9% 4.2% all calls 18,912
1.5% - 4.2%                
across validation methods
n=10,386 n=70 n=12,187
Pindel 41,370 83.0% 40.0% 1 47.9% calls validated by Omni 2.5 1,294 1% (assumed)
n=6,619 n=10 n=57,504 (p < 0.01)
Non-redundant total 113,649 23,594 1.4% - 3.7%
Genotyped set 3 14,422 1.4% - 3.7%
Summary of implied FDR of discovery set after construction 4
aCGH PCR
Sites attempted 3,305 87
Sites validated 3,186 64
Sites invalidated 70 2
Sites inconclusive or discordant 49 21
Estimated FDR 2.1% 3.0%
Notes
1 For CNVnator and Pindel, the calls for PCR validation were originally selected from a more sensitive superset.
  The reported FDR is based on a more stringent subset used in the other validation experiments and subsequent analyses.
2 For Delly, the calls for PCR validation were selected on a per-observation (frequency weighted) basis sampled disproportionately from sites with high deletion allele frequency.
  The resulting FDR estimate is not comparable to the other call sets where calls were selected on a per-site basis, independent of deletion allele frequency.
3 Sites were genotyped if sufficient data was available to calculate accurate genotype likelihoods; additional non-polymorphic and redundant sites were removed during genotyping.
4 Array CGH and PCR validation sites were selected randomly from the calls in the individual call sets from each method, not the promoted discovery set.
The array CGH and PCR validation results were not available when the promoted discovery set was created.
Omni 2.5 validation uses SNP array probe intensities and is more sensitive for longer deletion events.
Array CGH validation was performed in 25 selected samples and only tests sites discovered in those samples.
Merged discovery sets are available as a supplementary data file.














Table S8    LOF SNPs validation results
Frequency Class Total True SNP False SNP No Call FDR (%) No Call rate (%)
Singleton 1183 1078 34 71 3.1 6
Doubleton 150 129 8 13 5.8 8.7
Tripleton 35 25 3 7 10.7 20
<1% (3Q=0.4%) 88 46 17 25 27 28.4
1% - 5% 17 3 4 10 57.1 58.8
>5% 8 1 4 3 80 37.5
Total 1481 1282 70 129 5.2 8.7
Results for each variant can be found at
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/experimental_validation/snps/
A total of 1,481 SNP sites were included in LOF PCR-Roche 454 validation. True and false SNPs are those confirmed 
or rejected by PCR-Roche 454 validation.  “No call” SNPs did not produce a reliable result.  The false discovery rate 
(FDR) is calculated by dividing the false SNPs by the sum of the true and false SNPs.  The no call rate is the no call 
SNPs divided by the total SNPs.  The data has been split by allele frequency (AF).  The AF<0.01 category does not 
include singleton, doubleton and tripleton SNPs.
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Table S9    Formation mechanisms of large deletions
Mechanism < 500 bp 500 - 1000 bp 1 kb - 10 kb 10 kb + All
NAHR 9 (2.6%) 294 (23.3%) 1420 (22.6%) 255 (24.7%) 1978 (22.1%)
NHR 284 (82.8%) 889 (70.4%) 4642 (73.7%) 748 (72.4%) 6563 (73.5%)
MEI 47 (13.7%) 67 (5.3%) 124 (2.0%) 0 (0%) 238 (2.7%)
VNTR 2 (0.6%) 7 (0.6%) 64 (1.0%) 23 (2.2%) 96 (1.1%)
Undefined 1 (0.3%) 6 (0.5%) 45 (0.7%) 7 (0.7%) 59 (0.7%)
Total 343 (100%) 1263 (100%) 6295 (100%) 1033 (100%) 8934 (100%)
NAHR: Non-allelic homologous recombination
NHR: non-homologous rearrangements (including non-homologous end-joining and microhomology-mediated break-induced replication)
VNTR: variable number of tandem repeats
MEI: mobile element insertion
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Table S10    Cryptic relationships identified by genome-wide SNP analysis
Population Sample 1 Sample 2 Relationship IBD0 IBD1 IBD2
ASW NA19713 NA19985 Sibling 0.3 0.51 0.19
ASW NA20289 NA20341 Sibling 0.23 0.53 0.24
ASW NA20334 NA20336 Sibling 0.24 0.51 0.25
ASW NA19625 NA20414 Second-order 0.43 0.57 0
ASW NA20359 NA20363 Second-order 0.52 0.48 0
MXL NA19660 NA19685 Parent/Child 0 1 0
MXL NA19661 NA19685 Parent/Child 0 1 0
MXL NA19675 NA19678 Parent/Child 0 1 0
MXL NA19675 NA19679 Parent/Child 0 1 0
MXL NA19660 NA19672 Sibling 0.24 0.48 0.28
MXL NA19657 NA19753 Second-order 0.47 0.51 0.02
MXL NA19660 NA19664 Second-order 0.57 0.43 0
MXL NA19664 NA19672 Second-order 0.46 0.54 0
MXL NA19672 NA19685 Second-order 0.44 0.56 0
MXL NA19726 NA19738 Second-order 0.49 0.51 0
CHS HG00656 HG00702 Parent/Child 0 1 0
CHS HG00657 HG00702 Parent/Child 0 1 0
CHS HG00501 HG00512 Sibling 0.28 0.48 0.24
CHS HG00501 HG00524 Sibling 0.24 0.5 0.26
CHS HG00512 HG00524 Sibling 0.2 0.52 0.28
CHS HG00577 HG00584 Sibling 0.21 0.55 0.24
CHS HG00578 HG00581 Sibling 0.19 0.54 0.27
CHS HG00578 HG00635 Sibling 0.22 0.55 0.23
CHS HG00581 HG00635 Sibling 0.26 0.55 0.19
CHS HG00418 HG00427 Second-order 0.49 0.51 0
LWK NA19313 NA19331 Parent/Child 0 1 0
LWK NA19381 NA19382 Parent/Child 0 1 0
LWK NA19445 NA19453 Parent/Child 0 1 0
LWK NA19469 NA19470 Parent/Child 0 1 0
LWK NA19331 NA19334 Sibling 0.29 0.48 0.23
LWK NA19347 NA19352 Sibling 0.23 0.52 0.25
LWK NA19373 NA19374 Sibling 0.24 0.5 0.26
LWK NA19396 NA19397 Sibling 0.23 0.53 0.24
LWK NA19434 NA19444 Sibling 0.27 0.51 0.22
LWK NA19443 NA19470 Sibling 0.26 0.49 0.25
LWK NA19313 NA19334 Second-order 0.51 0.49 0
LWK NA19380 NA19382 Second-order 0.43 0.57 0
LWK NA19434 NA19453 Second-order 0.59 0.41 0
LWK NA19443 NA19469 Second-order 0.54 0.46 0
LWK NA19444 NA19453 Second-order 0.47 0.53 0




Table S11 Pairwise estimates of FST
Weir and Cockerham Estimator
LWK YRI ASW CLM MXL PUR CEU FIN GBR IBS TSI CHB CHS JPT
LWK 0.00% 0.56% 0.65% 4.09% 4.63% 3.77% 5.06% 5.24% 5.08% 4.69% 4.98% 5.78% 5.85% 5.78%
YRI 0.56% 0.00% 0.57% 4.72% 5.30% 4.37% 5.79% 6.00% 5.81% 5.66% 5.69% 6.55% 6.64% 6.55%
ASW 0.65% 0.57% 0.00% 2.93% 3.63% 2.54% 4.23% 4.47% 4.26% 2.82% 4.22% 5.46% 5.56% 5.41%
CLM 4.09% 4.72% 2.93% 0.00% 0.51% 0.34% 0.98% 1.19% 0.99% 0.42% 0.98% 3.51% 3.63% 3.54%
MXL 4.63% 5.30% 3.63% 0.51% 0.00% 0.99% 1.82% 1.86% 1.81% 1.69% 1.83% 3.10% 3.24% 3.15%
PUR 3.77% 4.37% 2.54% 0.34% 0.99% 0.00% 0.90% 1.22% 0.93% 0.25% 0.85% 3.95% 4.06% 3.98%
CEU 5.06% 5.79% 4.23% 0.98% 1.82% 0.90% 0.00% 0.48% 0.06% 0.51% 0.21% 4.77% 4.86% 4.87%
FIN 5.24% 6.00% 4.47% 1.19% 1.86% 1.22% 0.48% 0.00% 0.48% 1.11% 0.77% 4.57% 4.66% 4.67%
GBR 5.08% 5.81% 4.26% 0.99% 1.81% 0.93% 0.06% 0.48% 0.00% 0.38% 0.27% 4.73% 4.82% 4.84%
IBS 4.69% 5.66% 2.82% 0.42% 1.69% 0.25% 0.51% 1.11% 0.38% 0.00% 0.40% 7.53% 7.85% 7.71%
TSI 4.98% 5.69% 4.22% 0.98% 1.83% 0.85% 0.21% 0.77% 0.27% 0.40% 0.00% 4.53% 4.62% 4.64%
CHB 5.78% 6.55% 5.46% 3.51% 3.10% 3.95% 4.77% 4.57% 4.73% 7.53% 4.53% 0.00% 0.12% 0.45%
CHS 5.85% 6.64% 5.56% 3.63% 3.24% 4.06% 4.86% 4.66% 4.82% 7.85% 4.62% 0.12% 0.00% 0.60%
JPT 5.78% 6.55% 5.41% 3.54% 3.15% 3.98% 4.87% 4.67% 4.84% 7.71% 4.64% 0.45% 0.60% 0.00%
Weir and Cockerham Estimator (MAF > 5%)
LWK YRI ASW CLM MXL PUR CEU FIN GBR IBS TSI CHB CHS JPT
LWK 0.00% 0.75% 1.25% 9.60% 10.86% 8.90% 11.48% 11.61% 11.48% 11.76% 11.19% 13.36% 13.56% 13.45%
YRI 0.75% 0.00% 1.31% 10.42% 11.65% 9.71% 12.33% 12.46% 12.34% 12.99% 12.04% 14.12% 14.36% 14.23%
ASW 1.25% 1.31% 0.00% 5.90% 7.35% 5.18% 8.02% 8.26% 8.05% 6.84% 7.91% 11.22% 11.48% 11.26%
CLM 9.60% 10.42% 5.90% 0.00% 0.92% 0.52% 1.58% 1.81% 1.58% 1.07% 1.59% 6.81% 7.09% 6.88%
MXL 10.86% 11.65% 7.35% 0.92% 0.00% 1.79% 3.23% 3.13% 3.23% 2.91% 3.35% 5.75% 6.05% 5.82%
PUR 8.90% 9.71% 5.18% 0.52% 1.79% 0.00% 1.23% 1.65% 1.26% 0.75% 1.15% 7.66% 7.93% 7.73%
CEU 11.48% 12.33% 8.02% 1.58% 3.23% 1.23% 0.00% 0.63% 0.06% 0.42% 0.32% 8.82% 9.07% 8.96%
FIN 11.61% 12.46% 8.26% 1.81% 3.13% 1.65% 0.63% 0.00% 0.64% 1.08% 1.13% 8.14% 8.39% 8.27%
GBR 11.48% 12.34% 8.05% 1.58% 3.23% 1.26% 0.06% 0.64% 0.00% 0.33% 0.39% 8.81% 9.06% 8.96%
IBS 11.76% 12.99% 6.84% 1.07% 2.91% 0.75% 0.42% 1.08% 0.33% 0.00% 0.35% 10.74% 11.26% 11.01%
TSI 11.19% 12.04% 7.91% 1.59% 3.35% 1.15% 0.32% 1.13% 0.39% 0.35% 0.00% 8.71% 8.96% 8.87%
CHB 13.36% 14.12% 11.22% 6.81% 5.75% 7.66% 8.82% 8.14% 8.81% 10.74% 8.71% 0.00% 0.16% 0.62%
CHS 13.56% 14.36% 11.48% 7.09% 6.05% 7.93% 9.07% 8.39% 9.06% 11.26% 8.96% 0.16% 0.00% 0.82%
JPT 13.45% 14.23% 11.26% 6.88% 5.82% 7.73% 8.96% 8.27% 8.96% 11.01% 8.87% 0.62% 0.82% 0.00%
HapMap Estimator
LWK YRI ASW CLM MXL PUR CEU FIN GBR IBS TSI CHB CHS JPT
LWK 0.00% 0.37% 0.37% 2.84% 3.88% 2.19% 5.85% 6.61% 6.19% 0.13% 6.68% 8.18% 8.54% 7.48%
YRI 0.37% 0.00% 0.46% 3.95% 5.12% 3.20% 7.20% 7.92% 7.51% 0.58% 7.93% 9.56% 9.92% 8.91%
ASW 0.37% 0.46% 0.00% 3.25% 4.73% 2.41% 6.59% 7.12% 6.78% -0.86% 7.06% 9.66% 9.93% 9.21%
CLM 2.84% 3.95% 3.25% 0.00% 0.63% 0.34% 1.33% 1.55% 1.34% -0.33% 1.41% 5.06% 5.25% 4.93%
MXL 3.88% 5.12% 4.73% 0.63% 0.00% 1.31% 2.02% 1.97% 1.98% 0.94% 2.03% 4.05% 4.25% 3.94%
PUR 2.19% 3.20% 2.41% 0.34% 1.31% 0.00% 1.43% 1.74% 1.44% -0.77% 1.47% 5.81% 5.99% 5.71%
CEU 5.85% 7.20% 6.59% 1.33% 2.02% 1.43% 0.00% 0.32% 0.03% 0.27% 0.15% 5.62% 5.81% 5.59%
FIN 6.61% 7.92% 7.12% 1.55% 1.97% 1.74% 0.32% 0.00% 0.34% 0.38% 0.60% 5.06% 5.26% 4.99%
GBR 6.19% 7.51% 6.78% 1.34% 1.98% 1.44% 0.03% 0.34% 0.00% 0.19% 0.20% 5.55% 5.75% 5.51%
IBS 0.13% 0.58% -0.86% -0.33% 0.94% -0.77% 0.27% 0.38% 0.19% 0.00% 0.15% 3.40% 3.43% 3.61%
TSI 6.68% 7.93% 7.06% 1.41% 2.03% 1.47% 0.15% 0.60% 0.20% 0.15% 0.00% 5.38% 5.59% 5.32%
CHB 8.18% 9.56% 9.66% 5.06% 4.05% 5.81% 5.62% 5.06% 5.55% 3.40% 5.38% 0.00% 0.09% 0.35%
CHS 8.54% 9.92% 9.93% 5.25% 4.25% 5.99% 5.81% 5.26% 5.75% 3.43% 5.59% 0.09% 0.00% 0.47%
JPT 7.48% 8.91% 9.21% 4.93% 3.94% 5.71% 5.59% 4.99% 5.51% 3.61% 5.32% 0.35% 0.47% 0.00%
HapMap Estimator (MAF > 5%)
LWK YRI ASW CLM MXL PUR CEU FIN GBR IBS TSI CHB CHS JPT
LWK 0.00% 0.36% 1.02% 5.84% 6.74% 5.32% 7.48% 7.71% 7.54% 3.00% 7.41% 9.24% 9.44% 9.10%
YRI 0.36% 0.00% 1.09% 6.70% 7.64% 6.17% 8.31% 8.47% 8.33% 3.77% 8.10% 10.04% 10.24% 9.99%
ASW 1.02% 1.09% 0.00% 3.64% 4.79% 3.12% 5.41% 5.60% 5.43% 1.77% 5.32% 8.14% 8.34% 8.13%
CLM 5.84% 6.70% 3.64% 0.00% 0.63% 0.32% 1.16% 1.35% 1.16% -0.07% 1.20% 4.93% 5.13% 4.92%
MXL 6.74% 7.64% 4.79% 0.63% 0.00% 1.25% 2.03% 1.96% 2.00% 1.06% 2.03% 4.03% 4.25% 4.01%
PUR 5.32% 6.17% 3.12% 0.32% 1.25% 0.00% 1.06% 1.34% 1.07% -0.35% 1.05% 5.53% 5.72% 5.57%
CEU 7.48% 8.31% 5.41% 1.16% 2.03% 1.06% 0.00% 0.33% 0.03% 0.17% 0.17% 5.87% 6.09% 5.89%
FIN 7.71% 8.47% 5.60% 1.35% 1.96% 1.34% 0.33% 0.00% 0.34% 0.32% 0.62% 5.29% 5.50% 5.26%
GBR 7.54% 8.33% 5.43% 1.16% 2.00% 1.07% 0.03% 0.34% 0.00% 0.12% 0.20% 5.82% 6.03% 5.81%
IBS 3.00% 3.77% 1.77% -0.07% 1.06% -0.35% 0.17% 0.32% 0.12% 0.00% 0.08% 3.38% 3.43% 3.67%
TSI 7.41% 8.10% 5.32% 1.20% 2.03% 1.05% 0.17% 0.62% 0.20% 0.08% 0.00% 5.66% 5.88% 5.63%
CHB 9.24% 10.04% 8.14% 4.93% 4.03% 5.53% 5.87% 5.29% 5.82% 3.38% 5.66% 0.00% 0.09% 0.34%
CHS 9.44% 10.24% 8.34% 5.13% 4.25% 5.72% 6.09% 5.50% 6.03% 3.43% 5.88% 0.09% 0.00% 0.46%
JPT 9.10% 9.99% 8.13% 4.92% 4.01% 5.57% 5.89% 5.26% 5.81% 3.67% 5.63% 0.34% 0.46% 0.00%
Hudson Definition/Estimator, Ratio of Averages
LWK YRI ASW CLM MXL PUR CEU FIN GBR IBS TSI CHB CHS JPT
LWK 0.79% 1.04% 10.30% 12.02% 9.35% 12.75% 12.92% 12.73% 12.37% 12.36% 15.13% 15.30% 15.24%
YRI 0.79% 0.92% 11.24% 12.97% 10.25% 13.79% 13.97% 13.79% 13.39% 13.41% 16.07% 16.26% 16.19%
ASW 1.04% 0.92% 6.45% 8.10% 5.65% 8.51% 8.71% 8.49% 8.23% 8.25% 11.82% 12.01% 11.94%
CLM 10.30% 11.24% 6.45% 1.05% 0.58% 1.50% 1.77% 1.49% 1.48% 1.50% 7.25% 7.52% 7.36%
MXL 12.02% 12.97% 8.10% 1.05% 2.01% 3.66% 3.57% 3.64% 3.77% 3.76% 6.42% 6.72% 6.49%
PUR 9.35% 10.25% 5.65% 0.58% 2.01% 1.05% 1.51% 1.07% 1.04% 0.95% 8.08% 8.32% 8.21%
CEU 12.75% 13.79% 8.51% 1.50% 3.66% 1.05% 0.65% 0.06% 0.42% 0.36% 10.33% 10.62% 10.51%
FIN 12.92% 13.97% 8.71% 1.77% 3.57% 1.51% 0.65% 0.68% 1.14% 1.20% 9.55% 9.84% 9.71%
GBR 12.73% 13.79% 8.49% 1.49% 3.64% 1.07% 0.06% 0.68% 0.37% 0.42% 10.30% 10.58% 10.48%
IBS 12.37% 13.39% 8.23% 1.48% 3.77% 1.04% 0.42% 1.14% 0.37% 0.40% 10.39% 10.71% 10.55%
TSI 12.36% 13.41% 8.25% 1.50% 3.76% 0.95% 0.36% 1.20% 0.42% 0.40% 10.30% 10.58% 10.49%
CHB 15.13% 16.07% 11.82% 7.25% 6.42% 8.08% 10.33% 9.55% 10.30% 10.39% 10.30% 0.17% 0.67%
CHS 15.30% 16.26% 12.01% 7.52% 6.72% 8.32% 10.62% 9.84% 10.58% 10.71% 10.58% 0.17% 0.90%
JPT 15.24% 16.19% 11.94% 7.36% 6.49% 8.21% 10.51% 9.71% 10.48% 10.55% 10.49% 0.67% 0.90%
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Table S12A    Summary of sites showing high levels of population differentiation
LEVEL POP_PAIR
# of Highly 
differentiated 
SNPs 
 % in transcribed 
regions* 
AFR ASW-LWK 258 46.8
AFR LWK-YRI 251 50.2
AFR ASW-YRI 213 45.8 LEVEL AFR=Africa; EUR=Europe; ASN=Asia; GLO=global sample 
ASN CHS-JPT 275 48.1 POP_PAIR Populations pair
ASN CHB-JPT 176 43.7 CHR Chromosome 
ASN CHB-CHS 79 38.7 POS Chromosome position  (GRCh37/hg19)
EUR FIN-TSI 343 42.6 RSID dbSNP ID (Build 135)
EUR CEU-FIN 201 40.7 AA Ancestral allele (uppercase=high confidence; lowercase=low confidence) 
EUR FIN-GBR 197 43.2 DDAF Derived allele frequencies absolute difference  
EUR GBR-TSI 100 38.9 FUNC_ANN Functional annotation(s)
EUR CEU-TSI 57 53.8 HGNC_symbol HUGO gene name 
EUR CEU-GBR 17 14.3 Ensemlb_GENE_ID Ensembl gene ID 
CON AFR-EUR 348 52.2 GENE_START_bp Gene base start 
CON AFR-ASN 317 52.6 GENE_END_bp Gene base end
CON ASN-EUR 190 53.4 GENE_PRODUCT Gene product 
* Within Gene_START-Gene_END interval
Table S12B Within-ancestry group high differentiation SNPs (top 10 shown for each comparison)
LEVEL POP_PAIR CHR POS RSID AA DDAF FUNC_ANN HGNC_symbol Ensemlb_GENE_ID GENE_START_bp GENE_END_bp GENE_PRODUCT 
AFR ASW-LWK 8 42,253,960    rs7818866 G 0.432 UTR VDAC3 ENSG00000078668 42,249,142          42,263,415       protein_coding
AFR ASW-LWK 11 4,054,405       rs6578434 t 0.421 UTR STIM1 ENSG00000167323 3,875,757             4,114,439         protein_coding
AFR ASW-LWK 1 188,792,890  rs73068734 T 0.416 - - - -                         -                      -
AFR ASW-LWK 19 56,074,189    rs34551970 T 0.399 - - - -                         -                      -
AFR ASW-LWK 13 25,919,996    rs9507502 T 0.397 TFPEAK NUPL1 ENSG00000139496 25,875,662          25,923,938       protein_coding
AFR ASW-LWK 2 227,973,892  rs73082223 T 0.397 - COL4A4 ENSG00000081052 227,867,427        228,028,829     protein_coding
AFR ASW-LWK 22 45,279,529    rs3747226 a 0.395 - PHF21B ENSG00000056487 45,277,042          45,405,880       protein_coding
AFR ASW-LWK 1 110,201,699  rs506008 t 0.394 SYNONYMOUS GSTM4 ENSG00000168765 110,198,703        110,208,118     protein_coding
AFR ASW-LWK 7 83,018,986    rs10232760 T 0.386 - SEMA3E ENSG00000170381 82,993,222          83,278,479       protein_coding
AFR ASW-YRI 2 237,044,077  rs7603279 A 0.389 - - - -                         -                      -
AFR ASW-YRI 12 22,499,621    rs7960970 C 0.381 TFPEAK ST8SIA1 ENSG00000111728 22,216,707          22,589,975       protein_coding
AFR ASW-YRI 20 59,984,746    rs6061352 G 0.376 - CDH4 ENSG00000179242 59,827,559          60,512,307       protein_coding
AFR ASW-YRI 2 227,973,892  rs73082223 T 0.371 - COL4A4 ENSG00000081052 227,867,427        228,028,829     protein_coding
AFR ASW-YRI 11 23,719,654    rs12274304 G 0.365 - - - -                         -                      -
AFR ASW-YRI 5 147,654,463  rs6887885 A 0.364 - SPINK13 ENSG00000214510 147,647,743        147,665,817     protein_coding
AFR ASW-YRI 9 125,694,610  rs1868590 C 0.359 TFPEAK - - -                         -                      -
AFR ASW-YRI 3 101,814,628  rs6441645 G 0.359 TFMOTIF - - -                         -                      -
AFR ASW-YRI 5 175,177,421  rs6556222 A 0.359 - - - -                         -                      -
AFR ASW-YRI 10 27,973,632    rs1907373 A 0.357 - MKX ENSG00000150051 27,961,803          28,034,989       protein_coding
AFR LWK-YRI 12 22,499,621    rs7960970 C 0.475 TFPEAK ST8SIA1 ENSG00000111728 22,216,707          22,589,975       protein_coding
AFR LWK-YRI 6 39,709,730    rs307491 t 0.444 - - - -                         -                      -
AFR LWK-YRI 20 14,163,707    rs62208177 A 0.424 - MACROD2 ENSG00000172264 13,976,015          16,033,842       protein_coding
AFR LWK-YRI 16 213,139          rs61420932 G 0.420 PGENE HBM ENSG00000206177 203,891                216,767             protein_coding
AFR LWK-YRI 1 143,470,807  rs7522380 a 0.419 - - - -                         -                      -
AFR LWK-YRI 2 8,209,226       rs2058754 C 0.408 - - ENSG00000235665 8,062,556             8,418,214         lincRNA
AFR LWK-YRI 6 113,191,754  rs2086502 A 0.407 - - - -                         -                      -
AFR LWK-YRI 11 34,974,109    rs10734430 G 0.397 - PDHX ENSG00000110435 34,937,376          35,042,138       protein_coding
AFR LWK-YRI 20 42,501,897    rs4812748 A 0.388 - - - -                         -                      -
AFR LWK-YRI 22 36,663,213    rs58384577 t 0.374 UTR APOL1 ENSG00000100342 36,649,056          36,663,576       protein_coding
ASN CHB-CHS 18 32,247,638    rs1240972 G 0.380 - DTNA ENSG00000134769 32,073,254          32,471,808       protein_coding
ASN CHB-CHS 6 39,709,730    rs307491 t 0.348 - - - -                         -                      -
ASN CHB-CHS 10 81,512,832    rs3964382 g 0.334 - - - -                         -                      -
ASN CHB-CHS 1 43,370,522    rs61777700 t 0.333 TFMOTIF - - -                         -                      -
ASN CHB-CHS 11 39,780,072    rs9667766 A 0.333 - - - -                         -                      -
ASN CHB-CHS 12 40,177,313    rs4385961 T 0.330 - C12orf40 ENSG00000180116 40,019,969          40,302,102       protein_coding
ASN CHB-CHS 6 79,962,805    rs4706087 G 0.329 - - - -                         -                      -
ASN CHB-CHS 9 30,999,670    rs10970027 G 0.326 - - - -                         -                      -
ASN CHB-CHS 4 48,867,222    rs12645497 t 0.325 - - - -                         -                      -
ASN CHB-CHS 6 70,154,873    rs2479987 C 0.323 - - - -                         -                      -
ASN CHB-JPT 11 133,531,655  rs11223548 C 0.423 - - - -                         -                      -
ASN CHB-JPT 8 143,764,879  rs2976398 G 0.377 TFPEAK - - -                         -                      -
ASN CHB-JPT 7 134,452,557  rs77943343 C 0.339 TFMOTIF CALD1 ENSG00000122786 134,429,003        134,655,479     protein_coding
ASN CHB-JPT 2 41,366,779    rs77703766 A 0.336 TFMOTIF - - -                         -                      -
ASN CHB-JPT 8 106,509,300  rs60855925 g 0.332 UTR ZFPM2 ENSG00000169946 106,330,920        106,816,760     protein_coding
ASN CHB-JPT 16 435,529          rs186934484 t 0.330 - TMEM8A ENSG00000129925 420,773                437,113             protein_coding
ASN CHB-JPT 19 49,092,551    rs10401347 A 0.327 ENHANCER SULT2B1 ENSG00000088002 49,055,429          49,102,683       protein_coding
ASN CHB-JPT 9 104,385,873  rs10115450 C 0.325 - GRIN3A ENSG00000198785 104,331,635        104,500,862     protein_coding
ASN CHB-JPT 8 500,785          rs12545856 A 0.314 TFPEAK - - -                         -                      -
ASN CHB-JPT 3 69,463,899    rs4428188 G 0.314 - FRMD4B ENSG00000114541 69,219,141          69,591,734       protein_coding
ASN CHS-JPT 14 106,205,022  rs12147642 g 0.543 TFPEAK IGHG1 ENSG00000211896 106,202,680        106,209,408     IG_C_gene
ASN CHS-JPT 14 106,019,779  rs28771143 g 0.406 - - - -                         -                      -
ASN CHS-JPT 4 124,549,928  rs75958653 G 0.404 - - - -                         -                      -
ASN CHS-JPT 3 69,419,614    rs34266487 C 0.390 TFPEAK FRMD4B ENSG00000114541 69,219,141          69,591,734       protein_coding
ASN CHS-JPT 2 197,586,085  rs10172319 T 0.388 TFMOTIF CCDC150 ENSG00000144395 197,504,278        197,628,214     protein_coding
ASN CHS-JPT 5 88,187,764    rs304142 C 0.387 - MEF2C ENSG00000081189 88,013,975          88,199,922       protein_coding
ASN CHS-JPT 3 83,851,186    rs4380420 C 0.387 - - - -                         -                      -
ASN CHS-JPT 11 133,541,783  rs11223554 T 0.384 - - - -                         -                      -
ASN CHS-JPT 2 41,366,779    rs77703766 A 0.380 TFMOTIF - - -                         -                      -
ASN CHS-JPT 18 76,985,839    rs12605374 G 0.380 - ATP9B ENSG00000166377 76,829,394          77,138,278       protein_coding
EUR CEU-FIN 11 39,781,515    rs9795509 A 0.404 - - - -                         -                      -
EUR CEU-FIN 8 7,281,213       rs139624327 T 0.383 - - - -                         -                      -
EUR CEU-FIN 1 17,116,355    rs151218067 G 0.378 - - - -                         -                      -
EUR CEU-FIN 2 112,190,331  rs149528480 T 0.356 TFMOTIF - ENSG00000172965 111,965,353        112,252,677     processed_transcript
EUR CEU-FIN 14 19,606,909    rs28477704 C 0.355 - - ENSG00000258314 19,606,385          19,643,377       lincRNA
EUR CEU-FIN 17 4,812,470       rs9905341 G 0.347 TFPEAK - - -                         -                      -
EUR CEU-FIN 7 153,687,489  rs144996581 A 0.346 - DPP6 ENSG00000130226 153,584,182        154,685,995     protein_coding
EUR CEU-FIN 6 166,660,967  rs9356455 c 0.343 - - - -                         -                      -
EUR CEU-FIN 15 50,612,659    rs1972701 C 0.338 - GABPB1 ENSG00000104064 50,569,389          50,647,605       protein_coding
EUR CEU-FIN 12 8,131,189       rs7300229 C 0.326 - NECAP1 ENSG00000089818 7,926,148             8,250,367         protein_coding
EUR CEU-GBR 12 22,499,621    rs7960970 C 0.316 TFPEAK ST8SIA1 ENSG00000111728 22,216,707          22,589,975       protein_coding
EUR CEU-GBR 14 19,606,909    rs28477704 C 0.309 - - ENSG00000258314 19,606,385          19,643,377       lincRNA
EUR CEU-GBR 1 17,116,355    rs151218067 G 0.290 - - - -                         -                      -
EUR CEU-GBR 1 149,583,516  rs141282873 T 0.283 - - ENSG00000232151 149,575,482        149,651,107     processed_transcript
EUR CEU-GBR 11 39,780,083    rs189303654 G 0.280 - - - -                         -                      -
EUR CEU-GBR 9 41,909,186    rs140215685 C 0.279 - - - -                         -                      -
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EUR CEU-GBR 12 9,648,921       rs11051289 a 0.276 - - ENSG00000214776 9,620,148             9,728,864         pseudogene
EUR CEU-GBR 2 87,929,798    rs56324656 A 0.276 ENHANCER - - -                         -                      -
EUR CEU-GBR 6 10,229,201    rs9465613 c 0.275 - - - -                         -                      -
EUR CEU-GBR 7 4,441,248       rs10155898 G 0.269 - - - -                         -                      -
EUR CEU-TSI 2 136,608,646  rs4988235 G 0.610 TFPEAK MCM6 ENSG00000076003 136,597,196        136,633,996     protein_coding
EUR CEU-TSI 2 135,837,906  rs7570971 A 0.597 TFMOTIF RAB3GAP1 ENSG00000115839 135,809,835        135,933,964     protein_coding
EUR CEU-TSI 15 28,365,618    rs12913832 A 0.336 - HERC2 ENSG00000128731 28,356,186          28,567,298       protein_coding
EUR CEU-TSI 2 137,622,347  rs1649569 C 0.321 - THSD7B ENSG00000144229 137,523,115        138,435,287     protein_coding
EUR CEU-TSI 3 166,540,488  rs6779741 t 0.320 - - - -                         -                      -
EUR CEU-TSI 13 98,264,304    rs4349012 T 0.286 - - - -                         -                      -
EUR CEU-TSI 16 88,727,519    rs4782395 T 0.284 - MVD ENSG00000167508 88,718,343          88,729,569       protein_coding
EUR CEU-TSI 8 27,418,443    rs2640722 G 0.280 TFMOTIF GULOP ENSG00000234770 27,417,791          27,446,590       pseudogene
EUR CEU-TSI 7 126,107,032  rs7807889 T 0.279 - GRM8 ENSG00000179603 126,078,652        126,893,348     protein_coding
EUR CEU-TSI 15 56,879,880    rs12898998 C 0.279 - - ENSG00000260392 56,835,150          56,921,790       sense_overlapping
EUR FIN-GBR 13 103,855,868  rs9518951 C 0.358 - - - -                         -                      -
EUR FIN-GBR 12 32,349,938    rs4931618 T 0.352 TFMOTIF BICD1 ENSG00000151746 32,259,769          32,536,567       protein_coding
EUR FIN-GBR 20 9,021,020       rs6118441 C 0.351 - - - -                         -                      -
EUR FIN-GBR 2 54,738,392    rs17045941 C 0.341 - SPTBN1 ENSG00000115306 54,683,422          54,896,812       protein_coding
EUR FIN-GBR 7 76,505,546    rs7789280 A 0.338 - UPK3B ENSG00000243566 76,139,745          76,648,340       protein_coding
EUR FIN-GBR 20 5,493,842       rs6038189 C 0.330 - - - -                         -                      -
EUR FIN-GBR 5 79,416,511    rs6867810 G 0.328 - SERINC5 ENSG00000164300 79,407,050          79,551,898       protein_coding
EUR FIN-GBR 21 28,721,810    rs7280320 C 0.327 TFMOTIF - - -                         -                      -
EUR FIN-GBR 9 803,158          rs10976679 A 0.327 - - - -                         -                      -
EUR FIN-GBR 2 68,349,118    rs11126179 T 0.326 - - - -                         -                      -
EUR FIN-TSI 2 136,138,627  rs3940549 a 0.505 - ZRANB3 ENSG00000121988 135,894,486        136,288,806     protein_coding
EUR FIN-TSI 2 136,608,646  rs4988235 G 0.484 TFPEAK MCM6 ENSG00000076003 136,597,196        136,633,996     protein_coding
EUR FIN-TSI 15 28,365,618    rs12913832 A 0.475 - HERC2 ENSG00000128731 28,356,186          28,567,298       protein_coding
EUR FIN-TSI 1 17,116,355    rs151218067 G 0.451 - - - -                         -                      -
EUR FIN-TSI 10 5,063,728       rs28375324 A 0.423 TFMOTIF - - -                         -                      -
EUR FIN-TSI 2 98,557,575    rs142238274 G 0.420 - TMEM131 ENSG00000075568 98,372,799          98,612,388       protein_coding
EUR FIN-TSI 2 98,342,323    rs34149969 C 0.416 - ZAP70 ENSG00000115085 98,330,023          98,356,325       protein_coding
EUR FIN-TSI 6 86,047,899    rs7764454 T 0.403 - - - -                         -                      -
EUR FIN-TSI 20 48,501,606    rs645544 G 0.394 TFPEAK SLC9A8 ENSG00000197818 48,429,250          48,508,779       protein_coding
EUR FIN-TSI 8 7,280,445       rs3958991 G 0.394 TFMOTIF - - -                         -                      -
EUR GBR-TSI 2 136,608,646  rs4988235 G 0.634 TFPEAK MCM6 ENSG00000076003 136,597,196        136,633,996     protein_coding
EUR GBR-TSI 2 135,755,629  rs1530559 G 0.476 - YSK4 ENSG00000176601 135,722,061        135,805,038     protein_coding
EUR GBR-TSI 2 136,991,517  rs12986776 C 0.412 - - - -                         -                      -
EUR GBR-TSI 15 28,365,618    rs12913832 A 0.397 - HERC2 ENSG00000128731 28,356,186          28,567,298       protein_coding
EUR GBR-TSI 11 39,780,083    rs189303654 G 0.395 - - - -                         -                      -
EUR GBR-TSI 6 99,536,850    rs6918521 T 0.378 - - - -                         -                      -
EUR GBR-TSI 10 5,063,728       rs28375324 A 0.366 TFMOTIF - - -                         -                      -
EUR GBR-TSI 1 17,116,355    rs151218067 G 0.364 - - - -                         -                      -
EUR GBR-TSI 8 7,764,420       rs142721326 G 0.329 - - - -                         -                      -
EUR GBR-TSI 1 167,582,966  rs146150591 a 0.327 - - - -                         -                      -
Note IBS excluded due to small sample size
Table S12C Between-continental group sites shown high differentiation (top 10 shown for each comparison)
LEVEL POP_PAIR CHR POS RSID AA DDAF FUNC_ANN HGNC_symbol Ensemlb_GENE_ID GENE_START_bp GENE_END_bp GENE_PRODUCT 
CON AFR-ASN 20 53,252,640    rs6014096 A 0.951 - DOK5 ENSG00000101134 53,092,136          53,267,710       protein_coding
CON AFR-ASN 2 72,826,665    rs1596930 A 0.944 - EXOC6B ENSG00000144036 72,403,113          73,053,177       protein_coding
CON AFR-ASN 15 55,936,935    rs12903208 G 0.944 - PRTG ENSG00000166450 55,903,744          56,035,288       protein_coding
CON AFR-ASN 1 159,174,683  rs2814778 T 0.943 TFPEAK,TFMOTIF DARC ENSG00000213088 159,173,097        159,176,290     protein_coding
CON AFR-ASN 2 72,501,137    rs2192015 T 0.941 - EXOC6B ENSG00000144036 72,403,113          73,053,177       protein_coding
CON AFR-ASN 22 46,500,164    rs11702897 C 0.931 TFPEAK - ENSG00000197182 46,449,749          46,509,808       protein_coding
CON AFR-ASN 5 119,745,984  rs6862601 C 0.928 - - - -                         -                      -
CON AFR-ASN 20 62,175,996    rs10854170 T 0.927 TFPEAK SRMS ENSG00000125508 62,172,163          62,178,857       protein_coding
CON AFR-ASN 6 105,883,147  rs9486092 G 0.926 - - - -                         -                      -
CON AFR-ASN 16 87,404,088    rs889603 C 0.922 TFPEAK FBXO31 ENSG00000103264 87,362,942          87,425,748       protein_coding
CON AFR-EUR 1 159,174,683  rs2814778 T 0.940 TFPEAK,TFMOTIF DARC ENSG00000213088 159,173,097        159,176,290     protein_coding
CON AFR-EUR 15 48,392,165    rs1834640 G 0.920 - - - -                         -                      -
CON AFR-EUR 5 33,951,693    rs16891982 C 0.919 NON_SYNONYMOUS SLC45A2 ENSG00000164175 33,944,721          33,984,835       protein_coding
CON AFR-EUR 1 116,935,068  rs10924081 G 0.901 TFPEAK ATP1A1 ENSG00000163399 116,915,290        116,952,883     protein_coding
CON AFR-EUR 4 3,666,494       rs58827274 C 0.896 - - - -                         -                      -
CON AFR-EUR 8 145,639,681  rs1871534 G 0.884 NON_SYNONYMOUS SLC39A4 ENSG00000147804 145,635,126        145,642,279     protein_coding
CON AFR-EUR 11 19,620,227    rs11025189 C 0.880 TFPEAK NAV2 ENSG00000166833 19,372,271          20,143,144       protein_coding
CON AFR-EUR 15 54,976,332    rs2414360 G 0.867 - - - -                         -                      -
CON AFR-EUR 17 58,610,478    rs1197095 C 0.867 - - ENSG00000259349 58,603,654          58,628,159       antisense
CON AFR-EUR 9 4,859,106       rs172447 T 0.864 - RCL1 ENSG00000120158 4,792,869             4,861,064         protein_coding
CON ASN-EUR 15 48,426,484    rs1426654 G 0.982 NON_SYNONYMOUS SLC24A5 ENSG00000188467 48,413,169          48,434,869       protein_coding
CON ASN-EUR 5 33,951,693    rs16891982 C 0.963 NON_SYNONYMOUS SLC45A2 ENSG00000164175 33,944,721          33,984,835       protein_coding
CON ASN-EUR 6 2,745,352       rs6927195 G 0.926 TFPEAK MYLK4 ENSG00000145949 2,663,863             2,751,200         protein_coding
CON ASN-EUR 2 109,543,883  rs922452 C 0.902 - EDAR ENSG00000135960 109,510,927        109,605,828     protein_coding
CON ASN-EUR 20 568,696          rs6053171 G 0.890 - - - -                         -                      -
CON ASN-EUR 3 108,192,751  rs4365635 T 0.846 - MYH15 ENSG00000144821 108,099,216        108,248,169     protein_coding
CON ASN-EUR 10 78,894,351    rs2574799 T 0.846 - KCNMA1 ENSG00000156113 78,637,355          79,398,353       protein_coding
CON ASN-EUR 2 26,113,913    rs78404020 A 0.844 - - - -                         -                      -
CON ASN-EUR 15 28,187,772    rs1545397 A 0.843 - OCA2 ENSG00000104044 28,000,021          28,344,504       protein_coding
CON ASN-EUR 17 4,400,392       rs11657785 C 0.842 TFMOTIF - - -                         -                      -




Table S13    Conservation and polymorphism in KEGG pathways
KEGG Category Number of Genes GERP / bp
% SNPs with 
MAF < 0.5%
% Syn SNPs with 
MAF < 0.5%
% NonSyn SNPs with 
MAF < 0.5%
SNPs / kb LOF / kb
Excess NonSyn / kb 
with MAF < 0.5%
Graft-versus-host disease 41 -0.0201 52.41% 50.00% 53.65% 6.8976 0.2540 0.3322
Asthma 30 0.0270 53.04% 52.58% 53.27% 11.1484 0.5273 0.1089
Metabolism of xenobiotics by cytochrome P450 69 0.0336 66.65% 61.00% 69.56% 6.8326 0.2911 0.9890
Ribosome 87 0.0872 72.67% 71.89% 73.62% 2.2008 0.0512 0.0617
Drug metabolism - cytochrome P450 71 0.1228 66.35% 63.46% 67.85% 7.5365 0.3359 0.5966
Steroid hormone biosynthesis 54 0.1850 65.88% 57.86% 70.37% 7.0934 0.2496 1.3494
Glycosphingolipid biosynthesis - globo series 14 0.1922 68.28% 62.26% 72.22% 4.0304 0.2707 0.6429
Linoleic acid metabolism 29 0.2121 71.48% 67.02% 73.96% 7.2881 0.3233 0.9860
Allograft rejection 37 0.2504 54.43% 54.62% 54.30% 7.1729 0.1881 -0.0309
Autoimmune thyroid disease 52 0.2705 64.15% 60.45% 66.13% 10.1083 0.2240 0.9452
Other glycan degradation 16 0.3221 72.13% 71.89% 72.29% 7.3826 0.2213 0.0642
alpha-Linolenic acid metabolism 19 0.3371 76.77% 71.59% 80.23% 5.3494 0.2437 0.9743
Primary immunodeficiency 35 0.3829 71.20% 67.66% 73.95% 6.4307 0.0926 0.7039
Intestinal immune network for IgA production 48 0.3878 65.57% 67.06% 64.57% 5.7722 0.1543 -0.2616
Arachidonic acid metabolism 53 0.4022 72.58% 67.10% 75.89% 7.7552 0.2632 1.2917
Glutathione metabolism 44 0.4045 68.09% 64.33% 71.02% 4.9126 0.1181 0.5180
Hematopoietic cell lineage 87 0.4295 71.98% 68.98% 73.95% 6.8845 0.1866 0.6658
Drug metabolism - other enzymes 51 0.4304 66.96% 63.89% 68.74% 8.1855 0.3098 0.6956
Retinol metabolism 64 0.4461 67.51% 65.28% 68.72% 8.2191 0.3381 0.5277
Complement and coagulation cascades 68 0.4541 73.16% 68.10% 76.28% 8.4874 0.1874 1.3453
Ascorbate and aldarate metabolism 25 0.4616 64.75% 58.62% 68.20% 8.7159 0.2977 1.2914
Folate biosynthesis 11 0.4975 63.24% 56.79% 68.27% 5.5394 0.0599 0.8273
Tyrosine metabolism 41 0.5052 74.67% 69.71% 77.85% 6.6317 0.1431 1.0860
Glycosaminoglycan degradation 21 0.5269 70.86% 70.43% 71.16% 5.6035 0.2245 0.0799
One carbon pool by folate 17 0.5403 75.84% 76.64% 75.31% 5.3992 0.0803 -0.1847
Oxidative phosphorylation 129 0.5446 74.37% 70.30% 77.03% 4.3440 0.1240 0.5949
Steroid biosynthesis 17 0.5475 73.40% 67.57% 79.06% 5.7648 0.1533 1.0375
Cytosolic DNA-sensing pathway 56 0.5589 73.08% 70.74% 74.64% 6.4460 0.1976 0.5158
Histidine metabolism 28 0.5673 73.15% 68.80% 75.72% 6.3994 0.2059 0.8921
Cytokine-cytokine receptor interaction 265 0.5791 73.33% 70.38% 75.42% 5.7901 0.1324 0.5767
Glycerolipid metabolism 49 0.5870 74.18% 67.70% 79.11% 4.6746 0.1179 0.9373
Glycosphingolipid biosynthesis - ganglio series 15 0.5895 71.65% 64.81% 76.47% 3.2585 0.0999 0.6328
Butanoate metabolism 34 0.5936 72.31% 70.72% 73.27% 5.7034 0.1692 0.3084
Biosynthesis of unsaturated fatty acids 22 0.5984 75.83% 73.68% 77.48% 3.6264 0.0738 0.2953
Pentose and glucuronate interconversions 28 0.6001 64.25% 57.08% 68.61% 8.0256 0.3033 1.3406
Parkinson's disease 126 0.6272 75.26% 70.99% 78.07% 4.5324 0.1070 0.6659
Glycosphingolipid biosynthesis - lacto and neolacto series 26 0.6298 75.35% 70.44% 78.67% 4.6232 0.1287 0.7672
Primary bile acid biosynthesis 16 0.6348 71.71% 70.99% 72.12% 5.8184 0.1467 0.1437
Fatty acid metabolism 42 0.6457 76.09% 71.36% 78.98% 6.2898 0.1983 1.0393
Sulfur metabolism 13 0.6577 69.23% 68.97% 69.39% 4.9102 0.1469 0.0420
Porphyrin and chlorophyll metabolism 41 0.6585 68.82% 63.87% 71.82% 7.6972 0.1709 1.0545
Nicotinate and nicotinamide metabolism 24 0.6835 75.98% 70.93% 79.40% 4.6301 0.2060 0.8048
PPAR signaling pathway 69 0.6868 77.43% 72.36% 81.00% 5.7948 0.1937 1.0637
Tryptophan metabolism 40 0.6961 74.86% 72.10% 76.70% 7.0455 0.2072 0.6955
Amino sugar and nucleotide sugar metabolism 44 0.6964 74.83% 70.84% 78.03% 4.4905 0.1165 0.6144
Antigen processing and presentation 85 0.6991 62.13% 62.47% 61.89% 5.8430 0.1661 -0.0526
Glycerophospholipid metabolism 77 0.6995 74.50% 69.78% 78.07% 4.3266 0.0984 0.6760
Lysosome 121 0.7024 73.87% 71.41% 75.66% 5.6914 0.1150 0.4910
NOD-like receptor signaling pathway 62 0.7255 75.66% 71.24% 78.87% 5.1817 0.1153 0.7965
Fructose and mannose metabolism 34 0.7261 73.80% 67.26% 79.72% 5.8778 0.1315 1.1738
Phenylalanine metabolism 17 0.7403 70.47% 67.22% 72.80% 8.1204 0.0755 0.8034
RIG-I-like receptor signaling pathway 71 0.7558 74.13% 73.11% 74.83% 4.6367 0.1284 0.1752
Glycolysis / Gluconeogenesis 61 0.7708 75.39% 70.27% 79.19% 6.7050 0.1603 1.1562
Type I diabetes mellitus 43 0.7716 63.55% 58.60% 67.11% 6.6060 0.1288 0.7888
Pyrimidine metabolism 95 0.7720 74.81% 70.47% 78.50% 4.8542 0.1140 0.7146
Valine, leucine and isoleucine degradation 44 0.7738 76.05% 71.71% 78.90% 5.1769 0.1626 0.7948
Pentose phosphate pathway 27 0.7792 75.39% 66.97% 82.97% 7.3695 0.1887 1.8794
SNARE interactions in vesicular transport 37 0.7861 75.66% 74.14% 76.60% 3.0855 0.0812 0.1813
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis 25 0.7917 73.86% 69.67% 76.79% 5.5284 0.1305 0.7637
Riboflavin metabolism 16 0.7967 71.85% 62.16% 77.43% 6.6554 0.1808 1.7043
beta-Alanine metabolism 22 0.8052 75.70% 70.89% 78.48% 6.1797 0.1626 1.0211
Terpenoid backbone biosynthesis 15 0.8059 73.73% 68.38% 78.26% 4.2603 0.1002 0.7207
Regulation of autophagy 34 0.8105 72.47% 67.00% 76.19% 4.2222 0.0769 0.6998
Pantothenate and CoA biosynthesis 16 0.8115 74.34% 71.08% 76.22% 5.2944 0.2577 0.5954
O-Glycan biosynthesis 30 0.8121 75.40% 70.83% 78.67% 4.7068 0.1259 0.7371
Pyruvate metabolism 40 0.8181 75.02% 70.06% 78.89% 6.1095 0.1254 1.0124
Apoptosis 87 0.8227 75.16% 71.65% 77.79% 4.5141 0.0748 0.5578
Toll-like receptor signaling pathway 102 0.8251 73.02% 69.32% 75.99% 4.8741 0.1043 0.5885
Leishmania Infection 72 0.8435 70.24% 66.56% 73.44% 5.2868 0.1259 0.5815
Base excision repair 33 0.8530 73.31% 68.70% 76.12% 7.7649 0.2543 1.1442
Sphingolipid metabolism 39 0.8560 72.85% 69.19% 75.69% 5.6615 0.1187 0.6718
Limonene and pinene degradation 10 0.8635 77.27% 78.26% 76.74% 6.4597 0.1468 -0.2936
Peroxisome 78 0.8692 76.86% 72.66% 79.64% 6.0333 0.1452 0.9265
Propanoate metabolism 32 0.8853 75.48% 71.61% 78.18% 5.5815 0.1076 0.7604
Systemic lupus erythematosus 135 0.8868 68.77% 65.31% 71.83% 5.6810 0.1569 0.5664
Renin-angiotensin system 17 0.8880 76.55% 72.29% 79.52% 7.4264 0.1715 1.1418
Nitrogen metabolism 23 0.8999 73.38% 70.33% 75.74% 4.5559 0.1420 0.4686
Selenoamino acid metabolism 25 0.9014 76.06% 72.77% 78.80% 4.2893 0.0745 0.5191
Glycine, serine and threonine metabolism 31 0.9054 74.05% 67.07% 78.52% 7.9198 0.1603 1.6775
Natural killer cell mediated cytotoxicity 133 0.9093 71.40% 66.72% 75.12% 5.2649 0.1137 0.7390
Glyoxylate and dicarboxylate metabolism 16 0.9284 74.74% 71.95% 76.75% 5.6202 0.1147 0.5598
Ether lipid metabolism 33 0.9306 75.10% 66.67% 80.38% 5.0831 0.1599 1.2858
Homologous recombination 28 0.9369 76.78% 71.65% 79.72% 6.5608 0.0802 1.1874
p53 signaling pathway 68 0.9386 73.23% 69.06% 76.50% 3.9781 0.0669 0.5363
Nucleotide excision repair 44 0.9485 78.96% 72.61% 83.46% 6.0749 0.1176 1.4084
Jak-STAT signaling pathway 155 0.9627 75.28% 73.44% 76.72% 5.2934 0.0948 0.3669
Cysteine and methionine metabolism 34 0.9661 73.67% 68.59% 78.24% 4.9437 0.1079 0.7998
Purine metabolism 158 0.9758 75.15% 70.39% 78.99% 5.2612 0.1086 0.8452
Starch and sucrose metabolism 52 0.9784 69.77% 67.25% 71.47% 7.4653 0.2496 0.5750
RNA polymerase 29 0.9798 73.28% 71.93% 74.80% 4.7201 0.1138 0.2277
DNA replication 35 0.9828 79.21% 72.18% 84.19% 7.0908 0.1106 1.7917
Glycosaminoglycan biosynthesis - keratan sulfate 15 0.9845 77.02% 75.81% 78.38% 3.4780 0.0740 0.1746
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Glycosaminoglycan biosynthesis - chondroitin sulfate 22 0.9866 69.11% 65.15% 72.36% 5.4593 0.0652 0.6205
Adipocytokine signaling pathway 67 1.0085 77.17% 71.09% 82.63% 4.5105 0.0709 0.9479
Cell adhesion molecules (CAMs) 132 1.0274 72.29% 68.14% 75.79% 6.2160 0.0964 0.8085
Valine, leucine and isoleucine biosynthesis 11 1.0365 78.60% 67.29% 85.39% 6.5327 0.1605 2.2581
Alanine, aspartate and glutamate metabolism 32 1.0465 72.45% 68.45% 75.78% 5.0135 0.0791 0.6360
Glycosaminoglycan biosynthesis - heparan sulfate 26 1.0501 73.30% 65.17% 80.17% 4.0657 0.0385 0.9490
Arginine and proline metabolism 54 1.0515 72.59% 67.90% 76.39% 6.1549 0.1361 0.8992
Vibrio cholerae infection 54 1.0572 73.45% 69.23% 77.39% 5.6519 0.0972 0.7755
Galactose metabolism 26 1.0600 74.30% 71.50% 76.94% 7.2196 0.1750 0.7101
Epithelial cell signaling in Helicobacter pylori infection 68 1.0623 75.32% 71.00% 78.97% 4.3264 0.0946 0.6450
Fc epsilon RI signaling pathway 79 1.0665 73.93% 68.01% 80.18% 3.9882 0.0750 0.7387
Bladder cancer 42 1.0806 75.29% 71.26% 79.53% 4.5657 0.0806 0.6402
N-Glycan biosynthesis 46 1.0841 73.29% 69.37% 76.42% 4.8872 0.0926 0.6245
Neuroactive ligand-receptor interaction 271 1.0877 73.35% 68.18% 77.52% 6.3871 0.1260 1.0363
Olfactory transduction 382 1.0905 61.95% 61.41% 62.18% 16.9448 0.5508 0.2341
Aminoacyl-tRNA biosynthesis 41 1.1020 76.40% 70.91% 80.20% 6.4340 0.0743 1.2150
VEGF signaling pathway 76 1.1127 75.28% 69.48% 80.75% 4.2553 0.0894 0.8086
Taurine and hypotaurine metabolism 10 1.1166 71.19% 64.21% 75.89% 5.5573 0.0235 1.0832
Progesterone-mediated oocyte maturation 85 1.1167 75.50% 68.64% 83.16% 3.9256 0.0534 0.8590
Chemokine signaling pathway 189 1.1259 75.89% 70.01% 81.42% 4.5618 0.0650 0.8956
Alzheimer's disease 163 1.1469 74.75% 69.58% 79.63% 4.8773 0.0858 0.8286
Citrate cycle (TCA cycle) 30 1.1529 71.80% 67.49% 75.40% 7.0320 0.1498 0.9326
Non-small cell lung cancer 54 1.1557 73.87% 69.64% 78.53% 3.4838 0.0296 0.4854
Protein export 23 1.1611 73.48% 71.32% 75.33% 3.1403 0.0338 0.2364
Endocytosis 181 1.1739 74.89% 70.04% 79.24% 5.0552 0.0744 0.8181
mTOR signaling pathway 52 1.1829 76.77% 71.91% 82.90% 3.6746 0.0448 0.6357
Pancreatic cancer 70 1.1879 76.29% 72.61% 79.97% 3.6996 0.0645 0.4974
Leukocyte transendothelial migration 115 1.1906 74.47% 68.91% 79.77% 5.0713 0.0840 0.9073
Circadian rhythm - mammal 13 1.1934 75.83% 72.51% 78.44% 5.9257 0.0247 0.7160
Huntington's disease 177 1.2018 76.07% 73.96% 77.83% 4.9509 0.0855 0.4017
ABC transporters 44 1.2030 75.51% 70.83% 78.52% 9.8768 0.3322 1.5848
Fc gamma R-mediated phagocytosis 96 1.2233 74.30% 69.37% 78.89% 4.7385 0.0727 0.7625
Vascular smooth muscle contraction 115 1.2399 74.67% 70.05% 79.10% 5.0336 0.0831 0.7755
B cell receptor signaling pathway 75 1.2490 73.00% 66.82% 79.25% 4.2512 0.0503 0.7921
Prion diseases 35 1.2599 74.67% 70.71% 78.02% 6.4623 0.1411 0.8734
Mismatch repair 23 1.2617 74.48% 70.30% 76.94% 7.9493 0.2107 1.1178
Chronic myeloid leukemia 73 1.2625 75.41% 71.31% 79.69% 3.5633 0.0467 0.5091
Lysine degradation 44 1.2651 75.30% 72.21% 77.67% 5.7411 0.1106 0.6374
Melanoma 70 1.2677 75.69% 69.53% 82.32% 3.3856 0.0597 0.6848
Proximal tubule bicarbonate reclamation 22 1.2683 74.91% 73.36% 76.51% 6.2701 0.1320 0.3662
Non-homologous end-joining 13 1.2691 78.91% 81.01% 77.55% 5.9237 0.1029 -0.6566
GnRH signaling pathway 101 1.2747 74.35% 68.16% 80.73% 4.8717 0.0805 0.9478
Proteasome 44 1.2819 72.09% 66.29% 78.17% 3.3977 0.0329 0.5851
Dorso-ventral axis formation 24 1.2917 71.91% 65.53% 78.10% 5.8588 0.1105 1.0837
Glioma 65 1.2943 74.06% 68.48% 80.48% 3.6480 0.0459 0.6455
Insulin signaling pathway 137 1.2999 75.55% 71.07% 79.94% 4.8142 0.0677 0.7459
Aldosterone-regulated sodium reabsorption 42 1.3044 73.31% 68.16% 78.98% 4.5925 0.0516 0.7438
T cell receptor signaling pathway 108 1.3076 74.76% 69.27% 80.51% 4.0328 0.0448 0.7198
Neurotrophin signaling pathway 126 1.3087 74.39% 69.10% 79.80% 3.7210 0.0482 0.6367
Thyroid cancer 29 1.3094 76.99% 73.68% 80.50% 4.0868 0.0369 0.5138
Oocyte meiosis 112 1.3109 74.08% 68.84% 79.86% 3.9404 0.0478 0.6622
Small cell lung cancer 84 1.3144 75.63% 70.84% 79.39% 6.8443 0.0692 1.1232
Taste transduction 51 1.3236 72.67% 68.91% 75.71% 8.8760 0.2274 1.0715
Amyotrophic lateral sclerosis (ALS) 51 1.3290 74.44% 67.90% 80.39% 4.4108 0.0858 0.8994
Regulation of actin cytoskeleton 211 1.3379 76.14% 70.87% 81.07% 5.3839 0.0870 0.9740
Maturity onset diabetes of the young 25 1.3509 71.96% 69.23% 74.49% 3.9900 0.1056 0.3536
Phosphatidylinositol signaling system 76 1.3514 74.70% 66.62% 82.36% 5.1850 0.0814 1.2553
Calcium signaling pathway 177 1.3536 74.17% 69.12% 79.34% 6.0295 0.0844 0.9859
Pathways in cancer 324 1.3568 75.73% 71.86% 79.22% 5.4476 0.0689 0.7484
Basal transcription factors 35 1.3641 72.30% 67.72% 76.22% 5.2090 0.1063 0.7394
Pathogenic Escherichia coli infection 54 1.3658 72.41% 69.82% 75.62% 4.6576 0.0797 0.3995
Cell cycle 124 1.3745 76.86% 73.33% 79.85% 4.3522 0.0570 0.5763
Melanogenesis 101 1.3761 77.29% 73.17% 81.73% 4.2687 0.0475 0.6545
ECM-receptor interaction 84 1.3930 74.32% 68.19% 78.84% 10.0136 0.1393 1.9306
Acute myeloid leukemia 57 1.4002 76.24% 73.74% 79.20% 3.5782 0.0474 0.3408
Colorectal cancer 62 1.4035 75.32% 69.82% 80.69% 4.0290 0.0574 0.7352
MAPK signaling pathway 266 1.4086 75.41% 70.11% 80.91% 4.4701 0.0571 0.7932
Cardiac muscle contraction 77 1.4167 73.26% 69.66% 77.51% 5.2025 0.0938 0.6178
ErbB signaling pathway 87 1.4172 74.54% 71.40% 78.06% 3.9630 0.0674 0.4346
Tight junction 131 1.4200 75.50% 69.86% 80.45% 5.9718 0.0928 1.1170
Endometrial cancer 52 1.4222 74.36% 68.26% 80.62% 4.2673 0.0503 0.8197
Prostate cancer 88 1.4256 77.45% 73.46% 81.73% 4.1382 0.0527 0.6226
Notch signaling pathway 47 1.4403 73.23% 67.93% 78.40% 6.0744 0.0551 1.0041
Gap junction 89 1.4459 74.99% 68.81% 82.40% 4.9384 0.0579 0.9779
Focal adhesion 199 1.4481 74.99% 69.60% 79.73% 7.0446 0.0945 1.2483
RNA degradation 56 1.4499 75.70% 73.06% 77.91% 3.7303 0.0556 0.3652
Inositol phosphate metabolism 54 1.4548 75.45% 67.00% 82.65% 5.7267 0.1008 1.4663
Long-term depression 70 1.4718 74.67% 68.19% 82.33% 5.1857 0.0923 1.0563
Renal cell carcinoma 70 1.4865 76.25% 73.49% 79.66% 3.5419 0.0369 0.3685
Type II diabetes mellitus 47 1.4881 73.88% 68.74% 80.08% 4.9770 0.0408 0.8180
Ubiquitin mediated proteolysis 134 1.4933 75.98% 71.71% 80.48% 4.2878 0.0610 0.6472
Adherens junction 73 1.5145 76.36% 71.45% 81.44% 5.1530 0.0674 0.8853
Viral myocarditis 70 1.5208 73.23% 69.24% 76.50% 9.3327 0.2142 1.2103
Long-term potentiation 70 1.5580 75.30% 70.45% 81.75% 4.0585 0.0552 0.6662
Wnt signaling pathway 150 1.5742 75.54% 71.16% 80.11% 4.0333 0.0402 0.6122
Basal cell carcinoma 55 1.5831 76.21% 72.84% 79.47% 5.7745 0.0471 0.7174
Vasopressin-regulated water reabsorption 44 1.6037 77.58% 74.37% 80.89% 4.8000 0.0615 0.6023
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 74 1.6068 75.98% 69.94% 81.28% 6.6280 0.1140 1.3319
Axon guidance 129 1.6074 74.87% 69.18% 80.24% 5.3155 0.0620 0.9819
Hedgehog signaling pathway 56 1.6267 74.05% 70.55% 77.15% 5.8334 0.0637 0.6942
Spliceosome 124 1.6316 72.76% 69.76% 77.38% 3.5500 0.0665 0.3523
TGF-beta signaling pathway 85 1.6711 76.47% 73.67% 79.10% 4.2332 0.0410 0.4502
Dilated cardiomyopathy 90 1.7720 75.36% 69.47% 80.14% 6.7394 0.0954 1.3019
Hypertrophic cardiomyopathy (HCM) 83 1.8657 74.90% 68.57% 79.79% 6.8656 0.1022 1.3815
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Table S14    Average numbers of potentially functional variants per individual in each population
ASW LWK YRI CEU FIN GBR IBS TSI CHB CHS JPT CLM MXL PUR Min Max
synonymous DAF <0.5% 97 117 103 34 30 33 28 40 41 43 47 42 37 44 28 117
DAF 0.5-5% 337 399 418 102 103 102 103 104 85 82 86 125 108 139 82 418
DAF >5% 1312 1274 1255 1393 1394 1390 1390 1394 1401 1399 1400 1405 1402 1394 1255 1405
nonsynonymous DAF <0.5% 326 404 351 175 162 165 131 193 204 212 221 189 184 202 131 404
DAF 0.5-5% 747 874 905 318 321 320 318 312 251 236 248 361 320 377 236 905
DAF >5% 2470 2383 2329 2739 2737 2739 2711 2748 2732 2719 2728 2744 2740 2715 2329 2748
Stop-loss DAF <0.5% 1.1 1.2 1.0 1.0 1.1 1.0 1.0 1.0 1.1 1.2 1.1 1.0 1.0 1.0 1.0 1.2
DAF 0.5-5% 1.5 1.9 1.8 1.1 1.0 1.2 1.0 1.1 1.0 1.2 1.0 1.1 1.0 1.2 1.0 1.9
DAF >5% 2.5 2.7 2.7 2.6 2.7 2.6 2.8 2.6 2.2 2.1 2.1 2.3 2.2 2.5 2.1 2.8
HGMD DM DAF <0.5% 3.8 3.3 3.9 4.8 3.9 4.5 3.4 5.1 2.5 2.5 2.8 3.8 3.1 4.3 2.5 5.1
DAF 0.5-5% 14 15 17 8.1 8.5 7.6 9.1 7.4 4.8 4.9 4.9 8.5 8.0 8.7 4.8 17
DAF >5% 16 18 15 11 12 12 12 11 16 16 16 13 13 13 11 18
COSMIC DAF <0.5% 1.6 2.0 1.7 1.4 1.3 1.5 1.3 1.5 1.4 1.3 1.8 1.5 1.5 1.5 1.3 2.0
DAF 0.5-5% 4.2 5.1 4.5 1.9 2.1 1.9 1.9 1.8 1.8 2.2 1.9 2.1 1.9 2.2 1.8 5.1
DAF >5% 9.0 10 9.1 5.6 5.2 5.6 6.1 6.0 6.4 6.7 6.9 5.9 6.2 6.0 5.2 10
UTR DAF <0.5% 341 122 144 157 158 123 122 121 169 430 140 166 134 367 121 430
DAF 0.5-5% 1175 403 317 304 484 409 402 417 314 1355 423 527 397 1421 304 1355
DAF >5% 3701 3968 3937 3927 3973 3977 3973 3956 3924 3530 3950 3951 3971 3492 3530 3977
Non-coding RNA DAF <0.5% 13 17 14 4.0 4.1 3.9 4.2 4.3 5.1 5.9 6.2 5.4 5.0 5.5 3.9 17.4
DAF 0.5-5% 58 65 70 18 18 18 17 18 15 14 15 22 19 24 13.7 69.8
DAF >5% 187 185 179 194 195 192 190 191 191 193 191 196 193 194 178.6 196
Motif_gain_in_TF_peak DAF <0.5% 11 14 12 5.1 4.7 5.0 5.0 5.4 4.9 4.9 5.8 5.9 5.3 6.6 4.7 14
DAF 0.5-5% 51 58 59 25 25 25 27 24 23 24 24 28 26 29 23 59
DAF >5% 174 173 173 171 172 172 168 171 170 169 166 174 167 173 166 174
Motif_loss_in_TF_peak DAF <0.5% 54 69 59 18 19 18 22 22 21 22 27 24 21 26 18 69
DAF 0.5-5% 244 281 301 84 84 86 80 81 71 72 73 101 87 109 71 301
DAF >5% 615 589 584 650 650 650 647 654 637 643 636 649 637 651 584 654
Other conserved DAF <0.5% 7,641         9,936         8,057         2,026         2,200         2,152         2,510         2,217         2,479         2,821         3,066         3,003         2,600         3,256         2,026         9,936         
DAF 0.5-5% 32,196       37,221       39,359       8,567         8,625         8,620         9,015         8,673         7,162         7,096         7,123         11,048       9,584         12,565       7,096         39,359       
DAF >5% 128,100    124,101    122,904    133,200    133,978    133,431    133,045    133,363    133,341    133,059    132,769    134,155    133,981    133,941    122,904    134,155    
Total conserved DAF <0.5% 8,391         10,871       8,861         2,337         2,500         2,453         2,783         2,564         2,844         3,209         3,483         3,377         2,942         3,652         2,337         10,871       
DAF 0.5-5% 34,543       39,946       42,216       9,399         9,465         9,454         9,862         9,496         7,829         7,739         7,788         12,040       10,453       13,630       7,739         42,216       
DAF >5% 139,994    135,684    134,371    145,666    146,481    145,905    145,475    145,843    145,779    145,468    145,164    146,657    146,442    146,378    134,371    146,657    
ASW LWK YRI CEU FIN GBR IBS TSI CHB CHS JPT CLM MXL PUR Min Max
synonymous DAF <0.5% 506 642 547 175 166 167 139 203 218 226 240 215 194 237 139 642
DAF 0.5-5% 2005 2359 2468 594 594 591 586 592 497 478 500 740 641 810 478 2468
DAF >5% 12650 12309 12190 13237 13243 13216 13196 13232 13077 13058 13067 13284 13246 13232 12190 13284
nonsynonymous DAF <0.5% 645 806 697 298 279 280 224 331 355 365 387 340 320 357 224 806
DAF 0.5-5% 1954 2278 2377 709 717 711 715 703 563 540 571 833 740 892 540 2377
DAF >5% 10496 10195 10056 11173 11170 11183 11130 11198 11026 11008 11012 11171 11104 11124 10056 11198
Indel-non-frameshift DAF <0.5% 1.1 1.0 1.0 1.1 1.0 1.0 1.0 1.1 1.1 1.0 1.1 1.0 1.3 1.1 1.0 1.3
DAF 0.5-5% 19 22 23 6.4 7.1 6.6 6.3 5.6 5.3 5.1 5.1 8.3 7.0 8.4 5.1 23
DAF >5% 79 73 74 88 88 89 88 87 84 83 84 85 84 86 73 89
Stop-loss DAF <0.5% 1.5 1.7 1.3 1.1 1.1 1.2 1.3 1.1 1.2 1.3 1.3 1.1 1.1 1.1 1.1 1.7
DAF 0.5-5% 3.2 3.9 4.3 1.5 1.4 1.4 1.3 1.4 1.1 1.2 1.1 1.5 1.3 1.7 1.1 4.3
DAF >5% 38 37 37 38 38 39 37 38 38 38 38 39 40 39 37 40
Stop-gain DAF <0.5% 8.8 10 9.6 5.0 4.7 4.6 3.9 5.5 5.7 5.8 5.5 5.8 4.8 5.8 3.9 10
DAF 0.5-5% 16 19 18 6.4 6.5 6.3 6.5 6.6 5.8 5.3 5.8 7.5 7.2 7.2 5.3 19
DAF >5% 25 27 25 26 27 27 24 26 27 27 27 28 28 26 24 28
Indel-frameshift DAF <0.5% 1.0 1.0 1.0 1.0 1.1 1.1 0.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 0.0 1.1
DAF 0.5-5% 15 18 19 5.6 5.8 6.5 7.0 6.0 5.5 5.8 5.8 5.7 5.2 7.3 5.2 19
DAF >5% 26 25 25 28 28 29 28 29 26 26 26 27 26 29 25 29
Splice site donor DAF <0.5% 2.9 3.6 3.0 2.1 1.7 1.8 1.7 2.3 2.0 2.4 2.3 1.9 1.9 2.1 1.7 3.6
DAF 0.5-5% 5.6 7.2 6.6 2.9 2.7 2.8 3.0 2.5 2.4 2.5 2.4 3.5 3.6 3.4 2.4 7.2
DAF >5% 3.4 3.3 2.6 4.2 4.4 3.9 3.1 4.4 5.1 4.9 5.2 4.3 4.3 4.4 2.6 5.2
Splice site acceptor DAF <0.5% 2.2 2.9 2.5 1.7 1.7 1.8 1.5 1.9 1.8 1.8 1.6 1.5 1.7 2.0 1.5 2.9
DAF 0.5-5% 3.6 3.8 4.0 1.7 1.5 1.5 1.8 1.7 1.7 1.5 1.7 1.8 1.6 1.8 1.5 4.0
DAF >5% 2.2 2.7 2.1 3.3 3.3 3.4 3.4 3.3 4.6 4.3 4.6 3.9 3.6 3.2 2.1 4.6
HGMD-DM DAF <0.5% 6.2 5.7 6.3 7.2 6.6 7.2 5.0 7.7 3.7 3.8 4.5 5.3 4.6 6.3 3.7 7.7
DAF 0.5-5% 28 32 33 15 16 16 17 15 11 10 11 16 15 17 10 33
DAF >5% 39 43 40 28 29 29 30 29 34 34 34 31 30 31 28 43
COSMIC DAF <0.5% 2.9 3.8 2.9 1.8 1.8 1.7 1.6 1.8 2.0 2.1 3.0 2.2 1.8 2.2 1.6 3.8
DAF 0.5-5% 12 15 14 4.3 3.8 3.8 4.0 3.8 3.7 3.9 4.2 4.6 3.7 4.9 3.7 15
DAF >5% 32 32 31 28 28 28 29 28 29 29 30 28 29 29 28 32
UTR DAF <0.5% 1612 2099 1740 493 498 487 514 559 584 635 715 674 586 714 487 2099
DAF 0.5-5% 7277 8472 8889 2087 2132 2099 2184 2097 1701 1665 1721 2642 2323 2953 1665 8889
DAF >5% 42816 41488 41139 44839 44905 44854 44824 44873 44201 44141 44152 44898 44746 44895 41139 44905
Non-coding_RNA DAF <0.5% 160 210 173 44 46 44 47 51 52 57 65 61 54 64 44 210
DAF 0.5-5% 770 898 934 207 210 212 225 212 166 159 170 269 236 313 159 934
DAF >5% 5007 4880 4826 5208 5222 5229 5227 5217 5143 5152 5136 5240 5183 5240 4826 5240
Motif_gain_in_TF_peak DAF <0.5% 132 148 136 91 91 90 91 93 92 93 98 96 93 99 90 148
DAF 0.5-5% 592 650 657 382 389 384 388 383 371 371 374 404 394 419 371 657
DAF >5% 3779 3829 3823 3329 3333 3331 3330 3350 3342 3341 3336 3429 3389 3471 3329 3829
Motif_loss_in_TF_peak DAF <0.5% 328 421 349 125 127 124 134 142 136 146 162 157 139 163 124 421
DAF 0.5-5% 1674 1944 2028 539 557 544 555 533 455 459 465 656 596 732 455 2028
DAF >5% 5160 5042 4989 5179 5189 5173 5165 5199 5120 5116 5111 5234 5197 5265 4989 5234
all_nonfunction_sites DAF <0.5% 113,190    148,364    119,718    29,023       31,919       30,960       35,173       32,271       34,875       39,689       43,686       43,872       37,491       47,501       29,023       148,364    
DAF 0.5-5% 545,984    634,101    667,345    140,160    142,839    142,951    151,307    142,224    116,542    115,084    116,942    184,452    159,504    209,087    115,084    667,345    
DAF >5% 3,652,026 3,545,318 3,519,625 3,774,613 3,794,886 3,783,796 3,775,778 3,776,575 3,733,106 3,724,728 3,717,790 3,789,739 3,776,944 3,787,751 3,519,625 3,794,886 
all_sites DAF <0.5% 116,216    152,267    122,978    30,034       32,918       31,944       36,129       33,425       36,081       40,974       45,107       45,184       38,654       48,892       30,034       152,267    
DAF 0.5-5% 558,996    649,303    683,239    143,987    146,737    146,802    155,270    146,066    119,668    118,137    120,115    189,257    163,737    214,430    118,137    683,239    
DAF >5% 3,728,104 3,619,039 3,592,643 3,854,212 3,874,781 3,863,507 3,855,295 3,856,263 3,811,719 3,803,199 3,796,180 3,869,561 3,856,439 3,867,461 3,592,643 3,874,781 
Functional annotations for variants can be found at
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/functional_annotation/annotated_vcfs/
Conservation scores for variants can be found at
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/supporting/variant_gerp_scores/
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Table S15    Number of variants in linkage disequilibrium (LD) with the SNPs in GWAS catalog
HapMap Pilot Phase 1
r2 ш ͘ϱ ŝŶ ĨƌŝĐĂŶƐ ;ŶсϭϴϱͿ 8.3 18 22.6 4.7
r2 ш ͘ϱ ŝŶ ŵĞƌŝĐĂŶƐ ;ŶсϮϰϮͿ 13.3 28.6 35.7 4.7
r2 ш ͘ϱ ŝŶ ƐŝĂŶƐ ;ŶсϮϴϲͿ 21.3 46.2 58 4.7
r2 ш ͘ϱ ŝŶ ƵƌŽƉĞĂŶƐ ;ŶсϯϳϵͿ 20.5 44.7 55.8 4.6
r2 ш ͘ϱ ŝŶ Ăůů ŝŶĚŝǀŝĚƵĂůƐ ;Ŷсϭ͕ϬϵϮͿ 14 29.4 36.2 4.8
r2 ш ͘ϱ ŝŶ ĞĂĐŚ ĐŽŶƚŝŶĞŶƚĂů ƉŽƉƵůĂƚŝŽŶ 5.9 11.8 14.4 4.7
|D’|=1 in each continental population 10.9 36.3 73 4.7
LD Criteria Avg. # Variants in LD й'ZWшϮ
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Figure S1. Overview of data generation, processing and analysis 
Flowchart summarising steps involved in generating the 1000 Genomes Project Phase 1 release.  
Boxes indicate steps in the process and numbers indicate the corresponding section(s) within the 
supplementary material.   
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Figure S2. 1000 Genomes Project Phase I populations 
Populations collected as part of the HapMap Project (blue) and the 1000 Genomes Project (green) 
include: Europe (IBS (Iberian Populations in Spain), GBR (British from England and Scotland ), CEU 
(Utah residents with ancestry from northern and western Europe), FIN (Finnish in Finland), TSI 
(Toscani in Italia)); East Asia (JPT (Japanese in Tokyo, Japan), CHB (Han Chinese in Beijing, China), 
CHS (Han Chinese South)); Africa (ASW (African Ancestry in SW USA), YRI (Yoruba in Ibadan, 
Nigeria), LWK (Luhya in Webuye, Kenya)); Americas (MXL (Mexican Ancestry in Los Angeles, CA, 
USA), PUR (Puerto Ricans in Puerto Rico), CLM (Colombians in Medellín, Colombia)). A – Total 
number of samples sequenced; B – Source of DNA (blood (bld) or LCL); C – Gender composition  
(Male/Female); D – Number that are part of mother-father-child trios (t), parent-child duos (d) or 



































































































Figure S3.  Sequencing depth and genotyping accuracy 
The relationship between average sequencing depth (low-coverage data) and genotype 
discordance between Phase 1 release genotypes and estimates from the OMNI SNP array 




Figure S4.  Geography and technology stratify patterns of genetic variation. 
PCA plots (1st and 2nd components: estimated from release genotypes, see Methods) for all 
samples (left hand side) and those within EUR (right hand side).  In the top row individuals are 
coloured by population of origin.  In the bottom row samples are coloured by primary technology 
from which low-coverage data have been generated.  At the continental level, the PCA plots mirror 
previous observations regarding to the relationships between groups.  Within Europe, however, 
technology is an important component driving differentiation between the release haplotypes. 
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Figure S5.  Errors in haplotype estimation. 
Distributions of median distance between phase ‘switch errors’ at common SNPs in Phase 1 
haplotypes as estimated from comparison to SNP array genotypes (OMNI) genotyped in trios, 
where haplotypes can be determined by transmission. Trio genotypes were available for 97 
individuals from AFR (24 ASW, 73 YRI), 169 individuals from AMR (60 CLM, 54 MXL, 55 PUR), 100 
individuals from EAS (100 CHS), and 16 individuals from EUR (2 CEU, 14 IBS). 
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Figure S6.  Geographical differentiation of rare variants. 
a, Excess within-population (compared to wider ancestry-based grouping – see Figure 2a for a 
definition of which populations are in which group) allele sharing as a function of variant frequency 
within the group.  Metric defined as the ratio of the probability of picking (without replacement) two 
chromosomes that share a variant within a population (weighted by the number of pairs within each 
population) compared to the same probability across the wider group (see Supplement).  Dotted line 
indicates the excess within-continent (ancestry-group) sharing. b, As for part a, but the excess within-
population sharing metric is calculated separately for each population within its ancestry-based 
group.  The statistic for MXL samples drops below 1 for variants between 0.5% and 5%, indicating a 





Figure S7.  The length of shared haplotypes around variants of different frequencies. 
a, Median genetic length of shared haplotype identity for pairs of chromosomes carrying variants of 
different frequency in each population (removing cryptically-related samples, singleton variants and 
allowing for up to two genotyping errors). The inset shows the expectation from a model of explosive 
recent population growth (Nelson et al. 2012) in which an effective population size of 10,000 has 
grown to 4 million in  the last 10,000 years (assuming a generation time of 25 years).  b, The 
distribution of physical (left) and genetic (right) shared haplotype lengths for variants of frequency 2% 
in the GBR population.  c, The fraction of shared haplotypes that extend over 1Mb as a function of 





Figure S8.  Shared haplotype length around f2 variants shared within and between populations. 
Summary of median physical length of haplotypes around variants present exactly twice across the 
sample, broken down by the population origin of the chromosomes sharing the variant.  Bar 
heights are normalised to the maximum across the graph (within FIN; 140 kb). 
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Figures S9.  Properties of genetic variation in regions of different inferred ancestry within the 
populations sampled from the Americas. 
a, Estimated ancestry proportions for individuals in the ASW, MXL, CLM and PUR populations (blue: 
European, light-brown: African, red: Native American, black: unassigned regions). b, Average per 
base heterozygosity.  c, Ratio of nonsynonymous to synonymous variants within the same regions.  





Figure S10.  Conservation and variation by sequence annotation and variant type. 
a, The fraction of sites at each codon position (C1-C3), and at sites showing different types of variant, 
where the evolutionary conservation (GERP) score is greater than 2. b, Boxplots showing the 
distribution of GERP scores within part A.  Note that GERP scores are a function of the site, not the 
variant type. c, The fraction of sites within noncoding features of different types at all sites (white) 
and sites showing variation (grey). d,.  Boxplots showing the distribution of scores for part c. Apart 
from pseudogenes, those sites at which variation is observed show a consistently lower level of 






Figure S11.  Excess rare nonsynonymous variants by KEGG pathway. 
a, The relationship between evolutionary conservation and load of rare NonSyn variants in KEGG 
pathways estimated from , where N and S are the number of NonSyn and Syn variants across a 
ƉĂƚŚǁĂǇ ƌĞƐƉĞĐƚŝǀĞůǇ ĂŶĚ Z ĂŶĚ  ƌĞƉƌĞƐĞŶƚ ƌĂƌĞ ;фϬ͘ϱйͿ ĂŶĚ ĐŽŵŵŽŶ ;шϬ͘ϱйͿ ǀĂƌŝĂŶƚƐ ƌĞƐƉĞĐƚŝǀĞůǇ͘  
Negative values arise from a higher NonSyn:Syn ratio among common than rare variants.  Dot area is 
proportional to the number of genes in the KEGG pathway.  b, Excess rare nonsynonymous mutations 
in KEGG gene pathways for each ancestry-based group of populations (defined as in Figure 2A). 
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Figure S12.  Analysis of SNP density and allele frequency around CTCF motifs. 
SNP density and allele frequencies around the CTCF-binding motifs shown in Figure 4c.  a, SNP density 





Figure S13. Difference between nonsynonymous and synonymous variants in population 
differentiation. 
The fraction of pairwise population comparisons where nonsynonymous variants show greater 
differentiation, as measured by FST, than synonymous variants, at each allele frequency.  The red line 
shows a smoothed estimate to highlight the trend. 
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Figure S14 Accuracy of variant imputation. 
a, Accuracy of imputation into 3 individuals from AMR (MXL), 4 individuals of European ancestry (3 
CEU and 1 TSI) and 4 individuals of South Asian ancestry (Gujarati from Houston: GIH).  Lines as for 
Fig. 5b.  None of the imputed samples were sequenced in the current phase of the project. 
b, Comparison of imputation of high quality SNP genotypes from a backbone of haplotypes 
estimated using family information (a mixture of duos and trios) to imputation from the Phase 1 
release haplotypes, as a function of variant frequency.  In each population group imputation from 
the Phase 1 haplotypes is only slightly worse than from the benchmark data, indicating that variant 
frequency and haplotype structure are the primary determinants of imputation performance.  c, 
Accuracy of large deletion imputation for samples within Phase 1 arising from the fact that SV 
genotype likelihoods were only calculated for samples with Illumina sequencing data (see 





Figure S15.  SNP discovery from low-coverage and targeted exome data. 
Within the target exome consensus (24.3 Mb spanning 194,041 exons of 15,412 genes; see 
Supplementary Information), the plot shows the fraction of SNPs that were identified from both 
low-coverage and exome data (purple), exome-data only (red) and low-coverage data only (blue) as 
a function of the estimated variant count from the integrated haplotype release.  About 60% of 
singleton variants were detected only from the exome data.  At higher frequencies, about 10% of 
SNPs are discovered using only one approach, reflecting differences in the processing, analysis and 
filtering of variants from the different data sources.  These will reflect a mixture of true and false 
positives from each approach.  Details on the consensus target for the exome analysis can be found 
at: 
 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/supporting/exome_pull_down/. 
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